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SCIENTIFIC OPINION 
Scientific Opinion on Dietary Reference Values for fats, including 
saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty 
acids, trans fatty acids, and cholesterol
1
 
EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
This Opinion of the EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA) deals with the setting of 
Dietary Reference Values (DRVs) for fats. A lower bound of the reference intake range for total fat of 
20 energy % (E%) and an upper bound of 35 E% are proposed. Fat intake in infants can gradually be reduced 
from 40 E% in the 6-12 month period to 35-40 E% in the 2
nd
 and 3
rd
 year of life. For specific fatty acids the 
following is proposed: saturated fatty acid (SFA) and trans fatty acid intake should be as low as possible; not to 
set any DRV for cis-monounsaturated fatty acids; not to formulate a DRV for the intake of total cis-
polyunsaturated fatty acids (PUFA); not to set specific values for the n-3/n-6 ratio; to set an Adequate Intake (AI) 
of 4 E% for linoleic acid (LA); not to set any DRV for arachidonic acid; not to set an UL for total or any of the 
n-6 PUFA; to set an AI for alpha-linolenic acid (ALA) of 0.5 E%; not to set an UL for ALA; to set an AI of 
250 mg for eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) for adults; to set an AI of 100 mg 
DHA for infants (>6 months) and young children <24 months; to increase by 100-200 mg preformed DHA in 
addition to the AI for adults as an adequate supply of n-3 long chain PUFA during pregnancy and lactation; not 
to set any DRV for conjugated linoleic acid. For cholesterol it was decided not to propose a reference value 
beside the limitation on the intake of SFA. 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on Population Reference Intakes for the 
European population, including fat. 
Dietary fats or lipids include triacylglycerols, phosphatidylcholine and cholesterol. Along with 
proteins, carbohydrates, and alcohol, fats are a major energy source for the body. Fatty acids are also 
involved in many other vital processes in the body (e.g. structural components of cell membranes, 
precursors for bioactive molecules, regulators of enzyme activities, regulation of gene expression). 
Fatty acids can be classified according to their number of double bonds. Saturated fatty acids (SFA) 
have no double bonds, while monounsaturated fatty acids (MUFA) have one double bond and 
polyunsaturated fatty acids (PUFA) have two or more double bonds. These double bonds can have 
either the cis or trans configuration. Most unsaturated fatty acids in the diet have the cis 
configuration, but trans fatty acids (TFA) are also present as either trans-MUFA or trans-PUFA. 
Trans-PUFA have at least one trans double bond and may therefore also have double bonds in the cis 
configuration. 
In most countries, separate dietary recommendations exist for total fat intake, saturated fatty acids, 
monounsaturated fatty acids, polyunsaturated fatty acids, and trans fatty acids. For this purpose, 
polyunsaturated fatty acids are frequently subdivided into n-6 polyunsaturated fatty acids, n-3 
polyunsaturated fatty acids, and n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA). This latter 
class of fatty acids has 20 or more carbon atoms. Except for the n-3 long-chain polyunsaturated fatty 
acids, recommendations are expressed as percentage of total dietary energy (E%) or as grams per day.  
Due to its physical properties, cholesterol is also a fat. It does not provide energy, but plays a central 
role in many metabolic processes. Recommendations are expressed in milligrams per day (mg/day) or 
in milligrams per megajoule (mg/MJ). 
Total fat 
Fat is an important dense source of energy and facilitates the absorption of fat-soluble dietary 
components such as vitamins. Fats and oils are also important sources of essential fatty acids (EFA). 
High-fat diets may decrease insulin-sensitivity and are positively associated with changes in fasting 
and postprandial factor VII, which may increase cardiovascular risk. However, a precise dose-
response relationship can not be defined. There is evidence that a moderate fat intake (<35 E%) is 
accompanied by a reduced energy intake and therefore moderate weight reduction and/or prevention 
of weight gain. However, there are not sufficient data to define a Lower Threshold Intake (LTI) or 
Tolerable Upper Intake Level (UL) for total fat. The Panel concludes that only a Reference Intake 
range can be established for total fat intake, partly based on practical considerations (e.g. current 
levels of intake, achievable dietary patterns). At the lowest observed intake of total fat (20 E%) in 
European countries no overt signs of deficiencies have been observed nor adverse effects on blood 
lipids. Total fat intakes > 35 E% may be compatible with both good health and normal body weight 
depending on dietary patterns and the level of physical activity. The Panel proposes to set for adults a 
lower bound of the Reference Intake range of 20 E% and an upper bound of 35 E%. 
Fat intake in infants, which is high during the breastfeeding period, can gradually be reduced in the 
second half of the first year of life from the start of the complementary feeding period up to three 
years of age: 40 E% in the 6 to 12 month period and 35 to 40 E% in the 2
nd
 and 3
rd
 year of life. Fat 
intakes below 25 E% have been associated with low vitamin levels in some young children. 
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Saturated fatty acids 
SFA are synthesised by the body and are not required in the diet. Therefore, no Population Reference 
Intake (PRI), Average Requirement (AR), Lower Threshold Intake (LTI), or Adequate Intake (AI) is 
set. 
There is a positive, dose-dependent relationship between the intake of a mixture of saturated fatty 
acids and blood low density lipoprotein (LDL) cholesterol concentrations, when compared to 
carbohydrates. There is also evidence from dietary intervention studies that decreasing the intakes of 
products rich in saturated fatty acids by replacement with products rich in n-6 polyunsaturated fatty 
acids (without changing total fat intake) decreased the number of cardiovascular events. As the 
relationship between saturated fatty acids intake and the increase in LDL cholesterol concentrations is 
continuous, no threshold of saturated fatty acids intake can be defined below which there is no 
adverse effect. Thus, also no Tolerable Upper Intake Level can be set. 
The Panel concludes that saturated fatty acids intake should be as low as is possible within the context 
of a nutritionally adequate diet
4
. Limiting the intake of saturated fatty acids should be considered 
when establishing nutrient goals and recommendations. 
Cis-monounsaturated fatty acids (cis-MUFA) 
Cis-monounsaturated fatty acids are synthesised by the body, have no known specific role in 
preventing or promoting diet-related diseases, and are therefore not indispensable constituents of the 
diet. The Panel proposes not to set any Dietary Reference Value for cis- monounsaturated fatty acids. 
Cis-polyunsaturated fatty acids (cis-PUFA) 
In view of the different metabolic effects of the various dietary cis- polyunsaturated fatty acids, the 
Panel proposes not to formulate a Dietary Reference Value for the intake of total cis- polyunsaturated 
fatty acids. Also, the Panel proposes not to set specific values for the n-3/n-6 ratio as there are 
insufficient data on clinical and biochemical endpoints in humans to recommend a ratio independent 
of absolute levels of intake. 
n-6 polyunsaturated fatty acids (n-6 PUFA)  
Linoleic acid (LA) cannot be synthesised by the body, is required to maintain “metabolic integrity”, 
and is therefore an EFA. However, there are not sufficient scientific data to derive an Average 
Requirement, a Lower Threshold Intake or a Population Reference Intake.  
There is a negative (beneficial), dose-dependent relationship between the intake of linoleic acid and 
blood LDL cholesterol concentrations, while this relationship is positive for HDL cholesterol 
concentrations. In addition, linoleic acid (LA) lowers fasting blood triacylglycerol concentrations 
when compared to carbohydrates. There is also evidence that replacement of saturated fatty acids by 
n-6 polyunsaturated fatty acids (without changing total fat intake) decreases the number of 
cardiovascular events in the population. As the relationship between linoleic acid intake and the blood 
lipid profile is continuous, no threshold value of linoleic acid intake can be identified below which the 
risk for cardiovascular events increases.  
The Panel proposes to set an Adequate Intake for linoleic acid of 4 E%, based on the lowest estimated 
mean intakes of the various population groups from a number of European countries, where overt LA 
deficiency symptoms are not present.  
                                                     
 
4 Nutritionally adequate diets“ are the subject of food-based dietary guidelines and mean a dietary pattern which provides all essential 
nutrients in adequate amounts as well as energy delivering macronutrients in proportions that are known to maintain health 
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Arachidonic acid (ARA) is synthesised by the body from linoleic acid and is therefore not an essential 
fatty acid despite its important role in maintaining “metabolic integrity”. The Panel proposes not to 
set any Dietary Reference Value for arachidonic acid. 
Finally, there is at present no consistent evidence that the intake of any of the n-6 polyunsaturated 
fatty acids  has detrimental effects on health (e.g. in promoting diet-related diseases). The Panel 
proposes not to set a Tolerable Upper Intake Level UL for total or any of the n-6 polyunsaturated fatty 
acids. 
n-3 polyunsaturated fatty acids (n-3 PUFA) 
Alpha-linolenic acid (ALA) cannot be synthesised by the body, is required to maintain “metabolic 
integrity”, and is therefore considered to be an EFA. However, there are not sufficient scientific data 
to derive an Average Requirement, a Lower Threshold Intake or a Population Reference Intake.. The 
Panel proposes to set an Adequate Intake for alpha-linolenic acid of 0.5 E%, based on the lowest 
estimated mean intakes of the various population groups from a number of European countries, where 
overt alpha-linolenic acid deficiency symptoms are not present. There is no convincing evidence that 
the intake of alpha-linolenic acid has detrimental effects on health (e.g. in promoting diet-related 
diseases). The Panel, therefore, proposes not to set a Tolerable Upper Intake Level for alpha-linolenic 
acid. 
The human body can synthesise eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from 
alpha-linolenic acid. Intervention studies have demonstrated beneficial effects of preformed n-3 long-
chain polyunsaturated fatty acids on recognised cardiovascular risk factors, such as a reduction of 
plasma triacylglycerol concentrations, platelet aggregation, and blood pressure. These effects were 
observed at intakes 1g per day, well above levels that were associated with lower cardiovascular 
disease (CVD) risk in epidemiological studies. With respect to cardiovascular diseases, prospective 
epidemiological and dietary intervention studies indicate that oily fish consumption or dietary n-3 
long-chain polyunsaturated fatty acids supplements (equivalent to a range of 250 to 500 mg of 
eicosapentaenoic acid plus docosahexaenoic acid daily) decrease the risk of mortality from coronary 
heart disease (CHD) and sudden cardiac death. An intake of 250 mg per day of eicosapentaenoic acid 
plus docosahexaenoic acid appears to be sufficient for primary prevention in healthy subjects. 
Therefore, and taking into account that available data are insufficient to derive an Average 
Requirement, the Panel proposes to set an Adequate Intake of 250 mg for eicosapentaenoic acid plus 
docosahexaenoic acid for adults based on cardiovascular considerations.  
To this intake 100 to 200 mg of preformed docosahexaenoic acid should be added during pregnancy 
and lactation to compensate for oxidative losses of maternal dietary docosahexaenoic acid and 
accumulation of docosahexaenoic acid in body fat of the foetus/infant. 
In older infants, docosahexaenoic acid intakes at levels of 50 to 100 mg per day have been found 
effective for visual function in the complementary feeding period and are considered to be adequate 
for that period. 
The Panel proposes an Adequate Intake of 100 mg docosahexaenoic acid for older infants (>6 months 
of age) and young children below the age of 24 months. 
The currently available evidence does not permit to define an age specific quantitative estimate of an 
adequate dietary intake for eicosapentaenoic acid and docosahexaenoic acid for children aged 2 to 18 
years. However, dietary advice for children should be consistent with advice for the adult population 
(i.e., 1 to 2 fatty fish meals per week or ~250 mg of eicosapentaenoic acid plus docosahexaenoic acid 
per day).  
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Trans fatty acids (TFA) 
Trans fatty acids are not synthesised by the human body and are not required in the diet. Therefore, no 
Population Reference Intake, Average Requirement, or Adequate Intake is set. 
Consumption of diets containing trans-monounsaturated fatty acids, like diets containing mixtures of 
saturated fatty acids, increases blood total and LDL cholesterol concentrations in a dose-dependent 
manner, compared with consumption of diets containing cis-monounsaturated fatty acids  or cis-
polyunsaturated fatty acids. Consumption of diets containing trans-monounsaturated fatty acids  also 
results in reduced blood HDL cholesterol concentrations and increases the total cholesterol to HDL 
cholesterol ratio. The available evidence indicates that trans fatty acids  from ruminant sources have 
adverse effects on blood lipids and lipoproteins similar to those from industrial sources when 
consumed in equal amounts. Prospective cohort studies show a consistent relationship between higher 
intakes of trans fatty acids  and increased risk of coronary heart disease. The available evidence is 
insufficient to establish whether there is a difference between ruminant and industrial trans fatty acids  
consumed in equivalent amounts on the risk of coronary heart disease. 
Dietary trans fatty acids  are provided by several fats and oils that are also important sources of 
essential fatty acids and other nutrients. Thus, there is a limit to which the intake of trans fatty acids  
can be lowered without compromising adequacy of intake of essential nutrients. Therefore, the Panel 
concludes that trans fatty acids  intake should be as low as is possible within the context of a 
nutritionally adequate diet. Limiting the intake of trans fatty acids  should be considered when 
establishing nutrient goals and recommendations. 
Conjugated linoleic acids (CLA) 
There is no convincing evidence that any of the conjugated linoleic acids isomers in the diet play a 
role in prevention or promotion of diet-related diseases. The Panel therefore proposes not to set any 
Dietary Reference Value for conjugated linoleic acids. 
Cholesterol 
Cholesterol is synthesised by the body and is not required in the diet. Therefore, no Population 
Reference Intake, Average Requirement, or Adequate Intake is set. 
Although there is a positive dose-dependent relationship between the intake of dietary cholesterol 
with blood LDL cholesterol concentrations, the main dietary determinant of blood LDL cholesterol 
concentrations is saturated fat intake. Furthermore, most dietary cholesterol is obtained from foods 
which are also significant sources of dietary saturated fatty acids, e.g. dairy and meat products. 
Therefore the Panel decided not to propose a reference on cholesterol intake beside its conclusion on 
the intake of saturated fatty acids. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The scientific advice on nutrient intakes is important as the basis of Community action in the field of 
nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The 
Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European 
Community dates from 1993. There is a need to review and if necessary to update these earlier 
recommendations to ensure that the Community action in the area of nutrition is underpinned by the 
latest scientific advice.  
In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European 
Community
5
. The report provided reference intakes for energy, certain macronutrients and 
micronutrients, but it did not include certain substances of physiological importance, for example 
dietary fibre. 
Since then new scientific data have become available for some of the nutrients, and scientific advisory 
bodies in many EU member states and in the US have reported on recommended dietary intakes. For a 
number of nutrients these newly established (national) recommendations differ from the reference 
intakes in the SCF (1993) report. Although there is considerable consensus between these newly 
derived (national) recommendations, differing opinions remain on some of the recommendations. 
Therefore, there is a need to review the existing EU reference intakes in the light of new scientific 
evidence, and taking into account the more recently reported national recommendations. There is also 
a need to include dietary components that were not covered in the SCF opinion of 1993, such as 
dietary fibre, and to consider whether it might be appropriate to establish reference intakes for other 
(essential) substances with a physiological effect. 
In this context the EFSA is requested to consider the existing population reference intakes for energy, 
micro- and macronutrients and certain other dietary components, to review and complete the SCF 
recommendations, in the light of new evidence, and in addition advise on a population reference 
intake for dietary fibre.  
For communication of nutrition and healthy eating messages to the public it is generally more 
appropriate to express recommendations for the intake of individual nutrients or substances in food-
based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient 
based recommendations for a healthy diet into food based recommendations intended for the 
population as a whole. 
TERMS OF REFERENCE AS PROVIDED BY EUROPEAN COMMISSION 
In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/2002, the 
Commission requests EFSA to review the existing advice of the Scientific Committee for Food on 
population reference intakes for energy, nutrients and other substances with a nutritional or 
physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, 
contribute to good health through optimal nutrition.  
In the first instance the EFSA is asked to provide advice on energy, macronutrients and dietary fibre. 
Specifically advice is requested on the following dietary components:  
 Carbohydrates, including sugars; 
                                                     
 
5 Scientific Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientific 
Committee for Food 31st series, Office for Official Publication of the European Communities, Luxembourg, 1993. 
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 Fats, including saturated fatty acids, poly-unsaturated fatty acids and mono-unsaturated fatty 
acids, trans fatty acids; 
 Protein; 
 Dietary fibre. 
Following on from the first part of the task, the EFSA is asked to advise on population reference 
intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a 
nutritional or physiological effect in the context of a balanced diet which, when part of an overall 
healthy lifestyle, contribute to good health through optimal nutrition. 
Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice into 
guidance, intended for the European population as a whole, on the contribution of different foods or 
categories of foods to an overall diet that would help to maintain good health through optimal 
nutrition (food-based dietary guidelines). 
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ASSESSMENT 
A draft of this Opinion, agreed by the NDA Panel on 2 July 2009, was published on the EFSA 
website
6
 for public consultation between 5 August and 15 October 2009. The draft Opinion was also 
discussed at a National Expert Meeting with Member States on Dietary Reference Values held in 
Barcelona on 7 and 8 September 2009. All the public comments received and comments from 
Member States that related to the remit of EFSA were assessed and the Opinion has been revised 
taking relevant comments into consideration. The comments received, a report on the outcome of the 
public consultation, and the minutes of the meeting with Member States have been published on the 
EFSA website. 
1. Introduction 
Dietary fats or lipids mainly consist of triacylglycerol, which are molecules composed of three fatty 
acids and glycerol, but phosphatidylcholine and cholesterol are also included. Along with proteins, 
carbohydrates, and alcohol, fats are a major energy source for the body. The energy produced by one 
gram of the most common triacylglycerols in the diet is approximately 37 kilojoules (kJ) (9 
kilocalories (kcal)) per gram. Fatty acids, however, are also involved in many other vital processes. 
Fatty acids can be classified according to their number of double bonds. Saturated fatty acids (SFA) 
have no double bonds, while monounsaturated fatty acids (MUFA) have one double bond and 
polyunsaturated fatty acids (PUFA) have two or more double bonds. The position of the double bond 
can vary along the carbon chain and its position can be indicated in several ways. When counted from 
the carboxyl-end (-COOH) of the molecule, the so-called “∆x”-nomenclature is applied, while the “n-
x” or “ x” classification is used when counting starts from the methyl-end (-CH3). Thus, “n-9” or 
“ 9” means that the double bond is located at the ninth carbon atom from the methyl-end. These 
double bonds can have either the cis or trans configuration. Cis means that the two carbon (C)-atoms 
(or hydrogen (H)-atoms) adjacent to the double bound point into the same direction, while in the trans 
configuration the two carbon atoms point into opposite directions. As an example, elaidic acid [trans-
C18:1(n-9)] and oleic acid [cis-C18:1(n-9)] are shown in Figure 1. These two molecules are so-called 
geometrical isomers. 
 
 
 
Figure 1:  Structure of oleic acid and elaidic acid 
                                                     
 
6 http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902045161.htm 
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Most unsaturated fatty acids in the diet have the cis configuration, but trans fatty acids (TFA) are also 
present. Both trans-MUFA and trans-PUFA exist. Trans-PUFA have at least one trans double bond 
and may therefore also have double bonds in the cis configuration. 
In most countries, separate dietary recommendations exist for total fat intake, SFA, MUFA, PUFA, 
and TFA. For this purpose, PUFA are frequently subdivided into n-6 PUFA, n-3 PUFA, and n-3 long-
chain polyunsaturated fatty acids (n-3 LCPUFA). This latter class of fatty acids has 20 or more carbon 
atoms. Except for the n-3 LCPUFA, recommendations are expressed as percentage of total dietary 
energy (E%) or as milligrams (mg) per day.  
Due to its physical properties, cholesterol, a steroid, is also included in dietary fats. It does not 
provide energy, but plays a central role in many metabolic processes. Recommendations are expressed 
in mg/day or in mg/megajoule (MJ). 
2. Categories, structure and function 
In foods, fats are represented by several components such as fatty acids and sterols. Fatty acids are 
generally esterified on the glycerol backbone as triacylglycerols (also referred to as triglycerides, see 
below), but are also part of the phospholipid molecule. Phospholipids, which generally represent less 
than 1% of total dietary lipids, are found in cell membranes, milk fat globules, and eggs. A major 
phospholipid is phosphatidylcholine. Structurally, there are no differences between a fat and oil. Fats, 
however, are usually solid at room temperature, while oils are liquid. 
Triacylglycerols and fatty acids facilitate the absorption of other fat-soluble components such as 
vitamins. In the body, fatty acids are not only a major source of energy for the body, but also serve 
many vital functions (e.g. structural components of cell membranes, precursors for bioactive 
molecules, regulators of enzyme activities (e.g. protein myristoylation), regulation of gene 
expression). 
2.1. Triacylglycerols and fatty acids 
Triacylglycerols represent the major dietary form of fatty acids. The term “fatty acid” designates any 
of the aliphatic monocarboxylic acids that can be liberated by hydrolysis of triacylglycerols from fats 
and oils. In general, fatty acids represent more than 90% by weight of triacylglycerols. Three fatty 
acids are esterified to a glycerol backbone. Due to the asymmetric structure of substituted glycerol, 
the esterified fatty acids are distinguished by their position, namely sn-1, sn-2 and sn-3 position. 
Considering their metabolic fate (action of lipases) in the digestive tract, sn-1 and sn-3-esterified fatty 
acids are considered as esterified at “external” positions, whereas the sn-2 position is named 
“internal”.  
Pancreatic lipase has a high specificity for the sn-1 and sn-3 position of dietary triacylglycerols so that 
free fatty acids from the sn-1 and sn-3 position and 2-monoacylglycerol are released and absorbed into 
the enterocyte where they are reassembled into triacylglycerols thereby conserving the fatty acid at 
the sn-2 position. Whilst the absorption of saturated fatty acids decreases with increasing chain length 
because of slow solubilisation into mixed micelles in the intestinal lumen and because of the 
formation of insoluble soaps with divalent cations like calcium, it can be enhanced by positioning the 
saturated fatty acid at sn-2 (Carnielli et al., 1996). Mixtures of saturated and unsaturated fatty acids in 
dietary fat, however, are almost completely absorbed (Bonanome and Grundy, 1989).  
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Figure 2:  Structure of a triacylglycerol 
The most common fatty acids in the diet are listed in Table 1. 
Table 1:  Main fatty acids in the diet. 
Systematic nomenclature Common name Abbreviation 
Saturated fatty acids (SFA) 
 Butanoic acid Butyric acid 4:0 
 Hexanoic acid Caproic acid 6:0 
 Octanoic acid Caprylic acid 8:0 
 Decanoic acid Capric acid 10:0 
 Dodecanoic acid Lauric acid 12:0 
 Tetradecanoic acid Myristic acid 14:0 
 Pentadecanoic acid Pentadecilic acid 15:0 
 Hexadecanoic acid Palmitic acid 16:0 
 Heptadecanoic acid Margaric acid 17:0 
 Octadecanoic acid Stearic acid 18:0 
   
Cis-monounsaturated fatty acids (cis-MUFA) 
 Hexadecenoic acid Palmitoleic acid 16:1Δ9c 
 Octadecenoic acid Oleic acid 18:1Δ9c (n-9; ω9) 
 Eicosenoic acid Gadoleic acid 20:1Δ9c 
   
Trans-monounsaturated fatty acids (trans-MUFA) 
 Octadecenoic acid Elaidic acid 18:1Δ9t (n-9; ω9) 
 Octadecenoic acid Trans-vaccenic acid 18:1Δ11t (n-7; ω7) 
   
Polyunsaturated fatty acids (PUFA) 
 n-6 Polyunsaturated fatty acids (n-6 PUFA)  
.Octadecadienoic acid Linoleic acid 18:2Δ9c,12c (n-6; ω6) 
.Octadecatrienoic acid γ-Linolenic acid 18:3Δ6c,9c,12c (n-6; ω6) 
.Eicosatetraenoic acid Arachidonic acid 20:4Δ5c,8c,11c,14c (n-6; ω6) 
   
 n-3 Polyunsaturated fatty acids (n-3 PUFA) 
.Octadecatrienoic acid α-Linolenic 18:3Δ9c,12c,15c (n-3; ω3) 
.Eicosapentaenoic acid EPA 20:5Δ5c,8c,11c,14c,17c (n-3; ω3) 
.Docosapentaenoic acid DPA 22:5Δ7c,10c,13c,16c,19c (n-3; ω3) 
.Docosahexaenoic acid DHA 22:6Δ4c,7c,10c,13c,16c,19c (n-3; ω3) 
   
Conjugated linoleic acid (CLA)  
 Octadecadienoic acid Rumenic acid 18:2Δ9c,11t 
 Octadecadienoic acid  18:2Δ10t,12c 
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2.1.1. Saturated fatty acids (SFA) 
Although exceptions exist, SFA consist - like all fatty acids - of an even number of carbon atoms. This 
number usually ranges between 4 and 20. Depending on the number of carbon atoms, SFA are divided 
into short chain saturated fatty acids (SCFA: less than 6 carbon atoms), medium chain fatty acids 
(MCFA: 6-10 carbon atoms), or long chain saturated fatty acids (12 to 18 carbon atoms). It should be 
noted, however, that this division is not stringent, and – that for example lauric acid with 12 carbon 
atoms is sometimes also denoted as a MCFA. In this Opinion, however, lauric acid is considered as a 
long chain saturated fatty acid. 
The most prevailing SFA in the diet are lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), 
and stearic acid (18:0). The human body can synthesise SFA, although to a very low extent. 
2.1.2. Monounsaturated fatty acids (MUFA) 
MUFA have one double bond in the fatty-acid chain. The quantitatively most important representative 
in the diet and in tissue lipids is oleic acid (18:1, n-9) with a double bond at the n-9 (ω9) position. 
Like other fatty acids, MUFA are almost completely absorbed from the intestine and are oxidised (for 
energy production), converted into other fatty acids, or incorporated into tissue lipids. Humans can 
synthesise MUFA and MUFA are therefore not required as such from the diet. 
2.1.3. Polyunsaturated fatty acids (PUFA) 
PUFA have 2 to 6 double bonds. Humans lack the enzymes Δ12- and Δ15-desaturase that can 
introduce double bonds in the n-6 and n-3 positions, respectively. Two PUFA with methylene-
interrupted cis-double bonds of the omega-3 (alpha-linolenic acid, 18:3, n-3) and omega-6 series 
(linoleic acid, 18:2, n-6) are thus essential to humans and must be provided by the diet. They are also 
the most abundant PUFA in the diet. The n-6 and n-3 PUFA are metabolised (desaturated and 
elongated) further by the same enzyme systems. PUFA with 20 or more carbon atoms are usually 
referred to as LCPUFA. Important n-6 and n-3 PUFA occurring in foods are mentioned in Table 1.  
The essential PUFA and LCPUFA serve important physiological functions in the organism. 
Arachidonic acid (ARA) and eicosapentaenoic acid (EPA) can be further transformed to eicosanoids, 
a group of biologically active substances including prostaglandins, prostacyclins and leukotrienes, 
which participate in the regulation of blood pressure, renal function, blood coagulation, inflammatory 
and immunological reactions and other functions in tissues. Furthermore, n-6 and n-3 PUFA, 
particularly the LCPUFA, are important structural components of cell membranes. They are essential 
for various membrane functions such as fluidity, permeability, activity of membrane-bound enzymes 
and receptors, and signal transduction. 
Other non-essential cis-PUFA can be formed from saturated and monounsaturated fatty acids, e.g. in 
the n-7 and n-9 series. These are generally found in small amounts in foods. 
2.1.3.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
n-6 PUFA mainly include linoleic acid (LA), and to a lesser extent ARA. Strictly speaking, only 
linoleic acid is essential, as the body can synthesise arachidonic acid from linoleic acid at intakes 
below 3.8 E% (Angela Liou and Innis, 2009). ARA is the precursor for series 2 prostanoids and series 
4 leukotrienes (Kinsella et al., 1990). 
Linoleic acid, when incorporated into skin ceramides, is essential for maintaining the water-
permeability barrier of the skin thereby avoiding excessive trans-epidermal water loss and the 
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accompanying energy loss from water evaporation. Linoleic acid is metabolised to, for example, 
gamma-linolenic acid (18:3, n-6), dihomo-gamma-linolenic acid (20:3, n-6; DHGLA) and arachidonic 
acid (20:4, n-6; ARA). The conversion of linoleic acid is limited. Emken et al. (1994), for example, 
estimated that less than 1% of deuterated LA was converted into ARA, possibly due to a low ∆5 
desaturase activity (El Boustani et al., 1989), which may be even further decreased in elderly women 
(Babin et al., 1999). Also the activity of ∆-6 desaturase decreases with age (Angela Liou and Innis, 
2009). 
2.1.3.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
n-3 PUFA are polyunsaturated fatty acids with one of the double bonds located at three carbon atoms 
from the methyl end. The quantitatively most important n-3 PUFA in the diet are: 18:3 (alpha-
linolenic acid, ALA), 20:5 (eicosapentaenoic acid, EPA), 22:5 (docosapentaenoic acid, DPA), and 
22:6 (docosahexaenoic acid, DHA). EPA is the precursor for series 3 prostanoids and series 5 
leukotrienes (Kinsella et al., 1990). 
ALA is essential in human nutrition as precursor for the n-3 LCPUFA. EPA, DPA and to a lesser 
degree DHA are synthesised from ALA through the sequential action of various desaturases and 
elongases in animal tissues, but not in plants. Estimates for the conversion of ALA into EPA are 
around 8 to 12%, while the conversion into DHA may be less than 1% (Goyens et al., 2006). Due to 
this low conversion and the fact that ALA, and EPA and DHA may have different biological function, 
many authorities have separate recommendations for ALA on the one hand, and for EPA and DHA on 
the other hand (see section 4). 
DHA is a component of membrane structural lipids, especially of phospholipids in nervous tissue and 
the retina. The developing brain accumulates large amounts of DHA both pre- and postnatally, 
particularly during the first two years of life, which is predominantly acquired from the mother via 
placental transfer and breast milk, although the capacity of the brain to synthesise DHA increases with 
gestational age (Clandinin, 1999; Salem et al., 1996). 
Linoleic acid and ALA are converted into their respective LCPUFA by the same enzymes. In fact, the 
conversion of ALA into EPA and DHA is decreased when the amount of linoleic acid in the diet 
increases (and vice versa). For this, reason, some dietary recommendations also include guidelines for 
the n-3/n-6 ratio in the diet. Whilst the proportion of dietary ALA converted into n-3 LCPUFA is not 
influenced by the dietary n-3/n-6 ratio, the amounts of n-3 LCPUFA formed depends on the amount of 
ALA consumed (Goyens et al., 2006). The ability to convert ALA into n-3 LCPUFA and the levels of 
n-3 LCPUFA in plasma phospholipids and red blood cells are, moreover, individually related to 
polymorphisms in the human ∆-5 and ∆-6 desaturase genes FADS1 and FADS2 (Schaeffer et al., 
2006). 
2.1.4. Trans fatty acids (TFA) 
Most unsaturated fatty acids in the diet have the cis configuration, but TFA are also present. These 
fatty acids originate from several sources and trans-MUFA are the most common TFA in the diet. 
Trans-PUFA, however, are also present. Trans-PUFA have at least one trans double bond and may 
therefore also have double bonds in the cis configuration. TFA do not serve any vital functions. 
2.1.5. Conjugated linoleic acid (CLA) 
CLA refers to a mixture of positional and geometric natural isomers of linoleic acid, whose double 
bounds can be in either trans or cis configuration. They differ from most natural PUFA in that the 
double bonds are not separated by a methylene carbon, but are conjugated. 
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2.2. Sterols 
Sterols are mainly represented by cholesterol from animal fat, while phytosterols (sitosterol, 
campesterol, and stigmasterol) are present in vegetable-derived food items and supplemented 
products. 
Cholesterol is a sterol found in the cell membranes of all body tissues. It is not only derived from the 
diet, but it is also synthesised by the body. Cholesterol plays a central role in many biochemical 
processes. For example, cholesterol is a precursor for the synthesis of steroid hormones. In animal fat, 
sterols are mainly represented by cholesterol, while phytosterols are present in vegetable-derived food 
items and supplemented products. Trace amounts of cholesterol are also found in plant membranes. 
Due to too limited data available at habitual intakes, phytosterols will not be considered further in this 
Opinion. 
3. Dietary sources and intake data 
3.1. Dietary sources  
Examples of typical fat and fatty acid compositions of some common edible fats and oils are provided 
in Table 2, while Table 3 presents examples of the composition of some animal-derived food 
products. 
Table 2:  Typical fatty acid (g/100 g) and cholesterol (mg/100 g) profiles of some edible oils and 
fats. 
 Milk fat Coconut 
oil 
Palm 
kernel oil 
Palm 
oil 
Cocoa 
butter 
Olive 
oil 
Low-
erucic 
rapeseed 
oil 
High-
linoleic 
acid 
sunflower 
oil 
Corn 
oil 
Soybean  
oil 
SFA 63.4 86.5 81.5 49.3 59.7 13.8 7.4 10.3 12.9 15.3 
<12:0 11.0 14.1 7.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 12:0 3.2 44.6 47.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 
 14:0 9.1 16.8 16.4 1.0 0.1 0.0 0.0 0.0 0.0 0.0 
 16:0 26.8 8.2 8.1 43.5 25.4 11.3 4.3 5.9 10.6 10.7 
 18:0 12.3 2.8 2.8 4.3 33.2 2.0 2.1 4.5 1.8 4.0 
           
MUFA 25.9 5.8 11.4 37.0 32.9 73.0 63.3 19.5 27.6 22.7 
 Cis-18:1(n-9) 21.0 5.8 11.4 36.6 32.6 71.3 61.7 19.5 27.3 22.6 
 Trans-C18:1 3.7          
           
PUFA 3.7 1.8 1.6 9.3 3.0 10.5 28.1 65.7 54.7 57.3 
 18:2, n-6 3.3 1.8 1.6 9.1 2.8 9.8 18.6 65.7 53.2 50.1 
 18:3, n-3 0.4 0.0 0.0 0.2 0.1 0.8 9.1 NA 1.2 6.5 
 CLA 0.4 NA NA NA NA NA NA NA NA NA 
Cholesterol 265 0 0 0 0 0 0 0 0 0 
 
Values are derived from the U.S. Department of Agriculture, Agricultural Research Service. USDA Nutrient Database for 
Standard Reference, Release 20. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/nutrientdata, accessed on 
August 26, 2008. 
NA: not available  
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Table 3:  Typical fat and fatty acid (g/100 g food) and cholesterol (mg/100 g food) of some animal-
derived food products. 
 
 Milk 
 
Butter 
 
Lean Pork 
(<5 g 
fat/100 g) 
 
Lean Beef 
(<5 g 
fat/100 g) 
 
Lean Lamb 
(<5 g 
fat/100 g) 
 
Chicken 
(white 
meat) 
Fatty Fish 
(>10 g 
fat/100 g) 
Lean Fish 
(<2 g 
fat/100 g) 
Total fat 3.2 81.1 3.8 4.0 4.4 1.6 11.1 1.3 
         
SFA  1.86 51.37 1.26 1.46 1.88 0.37 2.42 0.38 
<12:0  0.30 8.95 <0.01 0.00 0.01 0.00 0.00 0.00 
 12:0 0.80 2.95 <0.01 <0.01 0.01 0.00 <0.01 0.00 
 14:0 0.30 7.44 0.04 0.10 0.09 0.01 0.54 0.03 
 16:0 0.83 21.70 0.79 0.89 0.90 0.26 1.71 0.26 
 18:0 0.36 10.0 0.41 0.47 0.73 0.10 0.91 0.09 
         
MUFA 0.81 21.01 1.57 1.66 1.69 0.48 4.60 0.35 
 Cis 18:1 0.81 16.98 1.36 1.52* 1.60* 0.40* 1.98* 0.23* 
 Trans-
C18:1 
NA 2.98 0.02  .  .   
         
PUFA 0.20 3.04 0.45 0.17 0.22 0.40 2.41 0.42 
 18:2, n-6 0.12 2.17 0.37 0.20 0.13 0.24 0.27 0.06 
 18:3, n-3 0.08 0.32 0.01 0.01 0.07 0.01 0.25 0.01 
 20:5, n-3 0.00 0.00 0.00 0.0 NA 0.00 0.57 0.07 
 22:6, n-3 0.00 0.00 0.00 0.0 NA 0.02 0.86 0.20 
 CLA NA  0.27 NA  NA NA NA NA NA 
Cholesterol 10 215 57 45 74 57 78 48 
 
Values are from the U.S. Department of Agriculture, Agricultural Research Service. USDA Nutrient Database for Standard 
Reference, Release 20. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/nutrientdata, accessed on February 
26, 2009. 
NA: not available 
* undifferentiated 
3.1.1. Saturated fatty acids (SFA) 
SFA are present in animal- and plant-derived foods. Dairy fat is relatively rich in MCFA. Coconut oil 
and palm kernel oil also contain appreciable amounts of MCFA. The latter fat sources are also rich in 
lauric and myristic acids. Palm oil and meat are characterised by high amounts of palmitic (16:0) and 
stearic acid (18:0), while cocoa butter is relatively rich in stearic acid (18:0). 
3.1.2. Monounsaturated fatty acids (MUFA) 
Like SFA, MUFA originate from both plant and animal-derived foods. Especially olive, high oleic 
acid sunflower and rapeseed oils are rich sources. Besides, seeds and nuts contain significant 
amounts. Although the SFA content is in general higher, products rich in SFA are also a source of 
MUFA. Finally, fish may contain significant amounts of MUFA. 
3.1.3. Polyunsaturated fatty acids (PUFA) 
Vegetable oils and fish oils are important sources of PUFA. In many cereals and vegetables, the 
proportion of PUFA in the fat can also be high, although the total fat content of these products is 
relatively low. 
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3.1.3.1. n-6 polyunsaturated fatty acids (n-6 PUFA)  
Foods rich in n-6 PUFA include vegetable oils such as corn oil, soybean oil, and sunflower seed oil. 
Medium-high levels are found in rapeseed oil. Also dressings and fat spreads containing these oils 
have moderate levels of n-6 PUFA. Linoleic acid is the predominating PUFA in many vegetable oils. 
Oils derived from bacteria and microalgae and, to a lesser extent, egg yolk and lean meat contain 
ARA. 
3.1.3.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
Alpha-Linolenic acid (18:3, n-3), a plant-derived n-3 PUFA, is found in some vegetable foods, e.g. 
linseeds, rapeseed oil and walnuts. Fish is a unique rich source of n-3 LCPUFA (EPA and DHA). 
Other natural sources are human milk and cultivated marine algae (single cell oils). EPA and DHA 
may also be provided by foods and supplements enriched with the LCPUFA.  
3.1.4. Trans fatty acids (TFA) 
A large number of TFA isomers of MUFA and PUFA, including positional isomers of individual fatty 
acids, occurs in foods. These TFA originate from several sources: 
 Bacterial transformation of unsaturated fatty acids in the rumen of ruminant animals. 
 Industrial hydrogenation (used to produce semi-liquid and solid fats that can be used for the 
production of foods such as margarine, shortenings and biscuits). 
 Deodorisation (a necessary step in refining) of unsaturated vegetable oils (or occasionally fish 
oils) high in polyunsaturated fatty acids. 
 Heating and frying of oils at too high temperatures (> 220°C). These modifications are time-
dependent with about 5% of isomerisation of n-3 18:3 after 2 hours and 25% after 12 hours of 
heating (Henon et al., 1999).  
Dairy and beef fat typically contain around 3 to 6% TFA (as % weight (wt%) of total fatty acids), 
while levels in lamb and mutton can be somewhat higher. In fat of milk and meat products from 
ruminant animals the main TFA are isomers of the monounsaturated fatty acid oleic acid, with trans-
vaccenic acid (18:1t, n-7) predominating (about 30 to 50% of total trans-18:1 isomers in milk fat). 
The TFA content in margarine and fat spreads may vary, depending on the proportion of partially 
hydrogenated oils used. In foods containing partially hydrogenated vegetable oil, the main TFA are 
also isomers of oleic acid with elaidic acid (18:1t n-9) accounting for 20 to 30% of total trans-18:1 
isomers. The TFA profiles of ruminant fat and hydrogenated vegetable oil show considerable overlap 
for many TFA isomers, although present in different proportions (Table 4). Except for trans-C18:1 
isomers, trans isomers of other MUFA (e.g. 14:1 and 16:1) as well as of polyunsaturated fatty acids 
also occur. Partially hydrogenated fish oil also contains trans 20:1 and 22:1 isomers. Dietary TFA are 
secreted into human milk. 
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Table 4:  Typical proportions (% of total trans 18:1 isomers) of positional 18:1 trans-isomers in 
ruminant and industrially hydrogenated fats from conventional foods 
Trans 18:1 isomer 
n-x position of double bond 
-position 
of double 
bond 
Milk fat, 
goat 
Milk fat, 
ewe 
Milk fat, 
cow 
Industrially 
hydrogenated fats 
n-2 16 10 8 6-8 1 
n-3 15 6 6 4-6 2 
n-4 14 9 8 8 
a 
n-5 13 8 7 6-7 9-12
a
 
n-6 12 9 7 6-10 8-13 
n-7 (vaccenic acid) 11 37 47 30-50 10-20 
n-8 10 10 9 6-13 10-20 
n-9 (elaidic acid) 9 6 5 5-10 20-30 
n-10 to n-12 6-8 3 2 2-9 14-18 
n-13 5 < 1 < 1 < 1 2 
n-14 4 < 1 < 1 < 1 1 
Data compiled from Precht et al., 2001; Wolff et al., 2000; and Seppänen-Laakso et al., 1996. 
a Sum of n-4 and n-5 isomers 
3.1.5. Conjugated linoleic acid (CLA) 
Cis-9, trans-11 CLA (rumenic acid) is present in small amounts in ruminant fats and produced by 
bacteria. Mammals can also synthesise rumenic acid from trans-vaccenic acid (trans-18:1, n-7) 
through the action of ∆9 desaturases. Trans-10, cis-12 CLA in combination with rumenic acid (50/50) 
is found in supplements and produced by industrial processing. Human milk contains small quantities 
of rumenic acid and trans-10, cis-12 CLA. 
3.1.6. Cholesterol 
Cholesterol is present in animal-derived food items. Eggs in particular are a rich source of cholesterol. 
However, also dairy products and meats substantially contribute to the intake of cholesterol.  
3.2. Intake data 
Typical intakes of total fat and fatty acids are presented for children and adolescents in 15 countries 
(Annexes 1a and 1b) and adults in 22 countries in Europe (Annexes 2a and 2b). The data refer to 
individual based food consumption surveys, conducted from 1994 onwards. Most studies comprise 
national representative population samples. The data were derived from national reports and from a 
recently published overview (Elmadfa, 2009). 
As demonstrated in the Annexes there is a large diversity in the methodology used to assess the 
individual intakes of children, adolescents and adults. Because the different methods apply to 
different time frames, this inevitably resulted in variance in both the quality and quantity of available 
data, which make direct comparisons difficult. Moreover, age classifications are in general not 
uniform. Comparability might also be hampered by differences in food composition tables used for 
the conversion of food consumption data to estimated nutrient intakes. For fat, fatty acids and 
cholesterol, however, values might be considered as reasonably comparable (Deharveng et al., 1999). 
It should also be kept in mind that food consumption data is prone to reporting errors and there might 
be a varying degree of underreporting in different surveys. 
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Although these differences may have an impact on the acccuracy of between-country comparisons and 
the results should be interpreted with caution, the presented data still give a good overview of the fat 
intake in a number of European countries. Most studies reported mean intakes and standard deviations 
(SD) or mean intakes and intake distributions. The number of studies that assessed the intake of n-3 
and n-6 polyunsaturated fatty acids and trans fatty acids appeared to be small. Dietary supplements 
were generally not taken into account in the calculation of intake estimates.  
3.2.1. Total fat 
Apart from infants till 18 months of age, available data show that average total fat intakes in children 
and adolescents in European countries varied between 28 and 42 E%, with 60% of the average intakes 
between 31 and 35 E%. Within population ranges varied from 22 to29 E% (5 percentile) to 38 to46% 
E% (95
th
 percentile). In infants in the second half of the first year of life average intakes varied 
between approximately 26 and 29 E%.  
In adults average total fat intakes ranged from less than 30 E% to 47 E%. With the exception of adults 
aged 19 to 34 years, about one third of the reported average data were between 30 and 35 E%; 
approximately 15% were 40 E% or higher. In young adults these proportions were 50% and 8%, 
respectively. Within population ranges varied between 22 and 25 E% at the lower (5
th
 percentile) and 
38 to48 E% at the upper end (95
th
 percentile) of the distributions. 
In general, mean intakes were lowest in Norway and Portugal and highest in Latvia, Lithuania and 
Greece. 
3.2.2. Saturated fatty acids (SFA) 
In infants average intakes were between 11 and 13 E%. In Italian and Hungarian children mean SFA 
intakes of 10 to 11 E% were found. In other countries most average intakes ranged between 13 and 
15 E%, whereas in some age groups in Belgium, Denmark and the UK mean intakes were 15 E% and 
higher. The lower (5
th
 percentile) and upper (95
th
 percentile) end of the intake distributions varied 
between 8 and 9 E% and between 15 and 19 E%. 
In adults average SFA intakes varied between less than 9 and 26 E%, with lowest values mostly in 
South European countries and highest values in Romania. In adults aged 35 to 64 years and 65 and 
over approximately 35% of the reported average intakes were 15 E% or higher (7% in individuals 
aged 19 to 35 years). Within population ranges varied between 7 and 11 E% at the lowest 
(5
th 
percentile) and between 17 and 22 E% at the highest (95
th
) percentile. 
3.2.3. Monounsaturated fatty acids (MUFA) 
Average MUFA intakes ranged between 8 and 11 E% in infants and in children and adolescents 
mostly between 10 and 13 E% (range approximately 9 and 18 E%). In Portugal and Spain the highest 
average intakes were observed. Intake distributions varied between 6 and 9 E% (5
th
 percentile) and 
between 13 and 17 E% (95
th
 percentile). 
In adults the highest mean intake was found in Greece (22 to 23 E%); in other European countries 
average intakes varied between 11 and 18 E%. When intake distributions were available, within 
population ranges varied between 6 and 8 E% and between 14 and 17 E% at the 5
th
 and 
95
th
 percentiles, respectively. 
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3.2.4. Polyunsaturated fatty acids (PUFA) 
In infants PUFA contributed on average 4 to5% to total energy intake. In children and adolescents this 
contribution ranged from approximately 4% to 9%, with the highest intake in Hungary. Intake 
distributions ranged between 2.4 and 4.7 E% (5
th
 percentile) and between 5.7 and 12.9 E% 
(95
th 
percentile). 
In adult populations average PUFA intakes varied between 4 and 8 E%, with highest intakes in 
Lithuania and Hungary. The lower and upper end of the intake distributions varied between 2.7 and 
4.1 E% (5
th
 percentile) and between 4.7 and 11 E% (95
th
 percentile). 
3.2.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
Some countries reported data for cis n-6 PUFA and/or linoleic acid. For children, average cis n-6 
PUFA intakes in absolute amounts varied between approximately 5 and 17 g per day and as 
percentage of energy between 2.9 E% (Sweden) and 6.9 E% (the Netherlands). Within population 
ranges varied between 2.7 to 7.7 g per day and 4.2 to 11.6 g per day and between 1.8 to 3.7 E% and 
4.2 to 11.6 E% at the 5
th
 and 95
th
 percentiles, respectively.  
For adults, average intake of cis n-6 PUFA ranged between 3.8 E% and nearly 6 E%. Distribution of 
intakes were only available for the Netherlands, ranging from 2.6 to 9.8 E% at the 5
th
 and the 
95
th 
percentile respectively, and for the UK, ranging from 1.9 to 10.5 E% at the 2.5
th
 and 97.5
th
 
percentile, respectively. 
3.2.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
Some countries reported data for cis n-3 PUFA and/or ALA, EPA and DHA. 
For children average cis n-3 PUFA varied between 1.1 and 2.2g per day (0.6 E% and 1.4 E%). At the 
5th percentile average intakes ranged from 0.5 to 0.8 g per day (0.3 to 0.5 E%); at the 95th percentile 
average intakes ranged from 1.9 to 3.8 g/day (0.6 to 1.7 E%). Mean ALA intake was around 0.8 g per 
day (0.5 E%) for young children and 0.5 to 1.1 g per day (0.5 to 0.6 E%) for children and for 
adolescents. The intake of EPA and DHA varied between 0.02 and 0.04 g per day (0.01 to 0.02 E%) 
and less than 0.1 to 0.13 g per day (0.03 to 0.06 E%), respectively. 
In adults average intakes of cis n-3 PUFA ranged from approximately 1.5 to 2.6 g/day (0.7 to 1.3 E%). 
Distribution of intakes ranged in the Netherlands from 0.4 to 4.2 g per day (0.3 to 1.3 E%) at the 5
th
 
and the 95
th
 percentile, and in the UK from 0.4 to 5.2 g per day (0.3 to 1.8 E%) at the 2.5
th
 and 97.5
th
 
percentile, respectively. For ALA mean intakes varied between 0.7 g per day and approximately 2.3 
g per day (~0.4 to 0.8 E%). For EPA and DHA the mean intakes were between 0.03 and 0.15 g/d 
(0.01 and 0.06 E%) and between 0.05 and 0.27 g per day (0.02 and 0.12 E%), respectively. 
3.2.5. Trans fatty acids (TFA) 
Data of the intake of TFA in children were available for Denmark, the Netherlands, Sweden and the 
UK. Average intakes varied between 0.6 and 1.7 E%. Within population ranges varied between 0.2 
and 0.4 E% and 0.8 to3.3 E% (5
th
 and 95
th
 percentiles, respectively). 
TFA intake data for adults referred to Denmark, Finland, the Netherlands and the UK. Average 
intakes varied between 0.5 and 1.6 E%. Distribution of intakes ranged 0.2 to 0.7 E% (5
th
 percentile) 
and from 0.9 to 1.7 E% (95
th
 percentile). 
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Evidence from a number of countries indicates that the intake of TFA in the EU has decreased 
considerably over recent years, owing to reformulation of food products, e.g. fat spreads, sweet 
bakery products and fast food. More recent reported intakes in some EU Member States are close to 
1 to 2 E% (EFSA, 2004). For example, in the UK the average intake of TFA has been halved to less 
than 1 E% (SACN, 2007). In France, intake data from 4079 individuals 3 to 79 years of age collected 
with 7-day food diaries and calculated with tables of TFA content of foods from 2008 show that TFA 
intakes have decreased by 40 % and are, on average, 1 E% in adults (1.4 E% at the 95th percentile), 
including 0.6 % for TFA from ruminant sources and 0.4 % for TFA from other sources (AFSSA, 
2009). Average intakes of TFA in Denmark, Finland, Norway and Sweden have decreased to around 
0.5 to 0.6 E% (Johansson et al., 2006; Lyhne et al., 2005; Männistö et al., 2003; Becker et al., 2005).  
3.2.6. Cholesterol 
In children below 15 years of age average intakes of cholesterol varied between approximately 
100 mg per day and more than 400 mg per day. In adolescents aged 15 to 18 years average intakes 
were between nearly 180 and 600 mg per day. At the 95th percentile the highest values were observed 
in Germany.  
Except for Romania, average intakes in adults ranged from nearly 200 mg per day to 550 mg per day. 
Mean daily intakes of about 800 and 700 mg per day were reported for Romanian men and women. 
4. Overview of Dietary Reference Values and recommendations 
Several national and international organisations and authorities have formulated Dietary Reference 
Values or recommendations for the intakes of total fat, fatty acids, and cholesterol. The German 
Society for Nutrition has published in 2006 a guideline on fat consumption based on an assessment of 
the strength for the evidence for the relationship between fat in the diet and certain dietary-related 
diseases (DGE, 2006). 
In general, recommendations are expressed as E%. For the long chain n-3 PUFA and cholesterol, 
recommendations may be expressed in mg. An overview of some dietary recommendations as set by 
different organisations is presented in Annex III and summarised in this paragraph. 
Most organisations have formulated a lower consumption level for total fat, because it was reasoned 
that at too low intakes adequate consumption of fat-soluble vitamins and essential fatty acids (EFA) 
could not be ensured. Upper limits for total fat intake have also been formulated because of possible 
relationships between total fat intake with energy intake and the risk to develop type 2 diabetes 
mellitus. In view of in particular their detrimental effects on dyslipoproteinaemia and cardiovascular 
risk, upper consumption levels for SFA and TFA were formulated. For linoleic acid and alpha-
linolenic acid lower consumption levels were formulated to prevent essential fatty acid deficiency. In 
addition, it was acknowledged that PUFA intake might protect against cardiovascular disease. 
However, upper limits were also formulated, mainly because of lack of data of extreme life-long high 
PUFA intakes on human health. Finally, only a limited number of organisations have formulated 
guidelines for dietary cholesterol. For those who did not, it was generally reasoned that guidelines for 
total fat and SFAwould already result in adecreased intake of cholesterol. 
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4.1. Adults 
4.1.1. Total fat 
Based on epidemiological and intervention studies in humans indicating a reduction in the risk of 
cardiovascular disease and obesity if a balanced diet with a maximum of 30 E% of fat is consumed in 
conjunction with physical activity, the German-Austrian-Swiss recommendations (D-A-CH, 2008) set 
a reference value for fat intake of 30 E%. During pregnancy and lactation this can be increased to 
35 E%. 
The Nordic Nutrition Recommendations (NNR, 2004) recommend a total fat intake of 25 to 35 E% 
calculated as triglycerides from the age of 2 years onwards with a population goal of 30 E% of total 
fat for planning purposes. It is stated that a reduction of fat intake below 25 E% does not provide any 
additional benefits, since very low fat diets tend to reduce HDL cholesterol and increase triglycerides 
in blood and impair glucose tolerance in susceptible individuals. 
The UK Committee on Medical Aspects of Food Policy (COMA) (DoH, 1991) concludes that DRVs 
for fat should be calculated from the summation of reference values for individual classes of fatty 
acids (saturated fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, trans fatty acids) 
and glycerol. Total fatty acid intake should therefore average 30 E% and total fat including glycerol 
33 E% including alcohol or 35 E% excluding alcohol. 
The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend limiting 
total fat intake to 30–35 % of energy intake given the increasing prevalence of obesity, despite the 
empirical nature of this value. In addition, below 30 E%, a well-balanced intake of various fatty acids, 
especially polyunsaturated fatty acids, is more difficult to reach using the current food supply. 
The Health Council of the Netherlands (GR, 2001) recommends an amount of fat equivalent to 20 to 
40 E% for individuals with an ideal bodyweight. Overweight individuals or individuals with 
undesirable weight gain should limit their fat intake to 20–35 E%. The lower level of 20 E% was set 
as a diet with a fat content of less than 20 E% has an adverse effect on HDL cholesterol and 
triglycerides concentrations. An amount of 20 E% was also considered to be sufficient for an 
adequate linoleic acid intake. The upper bound of 40 E% was chosen because higher intakes could 
have adverse effects on the postprandial concentration of lipids in the blood and on the concentration 
of blood coagulation factor VII. It also reflects the average fat consumption in the Netherlands. 
The US Institute of Medicine (IoM, 2005) did not set an AI, an estimated average requirement (EAR) 
or a recommended dietary allowance (RDA) for adults as insufficient data were available to identify a 
defined intake level for fat based on maintaining fat balance or on the prevention of chronic diseases. 
The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend keeping fat intake between 20 
E% and 35 E% 
The WHO/FAO (2003) recommendations for total fat are formulated to include countries where the 
usual fat intake is typically above 30 E% as well as those where the usual intake may be very low, for 
example less than 15 E%. The WHO considers that total fat energy of at least 20 E% is consistent 
with good health. For countries where the usual fat intake is between 15 E% and 20 E%, there is no 
direct evidence that raising fat intake to 20 E% will be beneficial for men. WHO/FAO therefore sets a 
population nutrient intake goal of 15-30 E%. For women of reproductive age at least 20 E% has been 
recommended by the Joint FAO/WHO Expert Consultation on Fats and Oils in Human Nutrition that 
met in 1993 (FAO/WHO, 1994). 
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4.1.2. Saturated fatty acids (SFA) 
The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend a maximum saturated 
fatty acid intake of 10 E% in order to prevent a rise in blood cholesterol concentrations. 
The Nordic Nutrition Recommendations (NNR, 2004) set a maximum intake of 10 E% of saturated 
fatty acids and trans fatty acids (calculated as fatty acids) based on the assumption that a reduction in 
the intake of SFA and TFA would reduce the risk of coronary heart disease (CHD). 
The UK COMA Committee (DoH, 1991) recommends that saturated fatty acids should provide an 
average of 10% of total dietary energy (including alcohol). A reduction of SFA in the diet to 10 E% in 
the UK would be expected to result in a decrease of blood cholesterol concentrations of about 
0.4 mmol/L. 
The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend limiting the 
intake of saturated fatty acids to about 8 E% or 25 % of total fatty acids based on epidemiological 
data which associate excess intake of SFA with coronary heart disease as well as on the knowledge of 
the effect of different SFA. It is also recommended to consider the different SFA independently. 
The Health Council of the Netherlands (GR, 2001) states that SFA increase the risk of coronary heart 
disease. Therefore, SFA intake should be as low as possible. A UL for SFA has been set at 10 E% for 
adults and children of 4 years and older and is based on the lowest percentage of intakes currently 
observed in the Netherlands. 
The US Institute of Medicine (IoM, 2005) did not set an AI, EAR or RDA as there was no evidence to 
indicate that saturated fatty acids are essential in the diet or have a beneficial role in the prevention of 
chronic diseases. The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend consuming 
less than 10 E% of saturated fatty acids. 
The WHO/FAO (2003) set population nutrient intake goals for SFA at <10 E%.  
4.1.3. Monounsaturated fatty acids (MUFA)  
The German-Austrian-Swiss recommendations (D-A-CH, 2008) state that monounsaturated fatty acids 
can be consumed up to 10 E%. With higher fat intakes >10 E% of MUFA are acceptable. 
The Nordic Nutrition Recommendations (NNR, 2004) state that the intake of cis-unsaturated fatty 
acids of adults and children from 2 years of age should be at about 20 E% with MUFA making up 
around 10 to 15 E% of it and PUFA around 5 to 10 E%.  
The UK COMA Committee (DoH, 1991) recommends that cis monounsaturated fatty acids 
(principally oleic acid) should provide an average of 12% of total dietary energy (including alcohol) 
for the population. 
The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend an intake of 
monounsaturated fatty acids of 20 E% in adults including pregnant and lactating women. It was 
concluded that the neutrality of oleic acid was an advantage and that its consumption was justified. 
The Health Council of the Netherlands (GR, 2001) did not formulate AI for monounsaturated fatty 
acids alone but formulated AI ranges for monounsaturated fatty acids together with polyunsaturated 
fatty acids. They have been calculated on the basis of DRVs for fats, saturated fatty acids and trans 
fatty acids. Given a total fat consumption of 20 E%, the intake of monounsaturated fatty acids plus 
polyunsaturated fatty acids equals not less than 8 E% and no more than 19 E%. At a fat consumption 
of 35 E%, the optimum intake of monounsaturated fatty acids plus polyunsaturated fatty acids is 
Dietary reference values for fats 
 
 
25 EFSA Journal 2010; 8(3):1461 
between 22 E% and 33 E%. Since the intake of polyunsaturated fatty acids should be between 3 E% 
and 12 E%, it is also possible to calculate upper and lower bounds for the intake of monounsaturated 
fatty acids. When total fat consumption is 35 E% and there is low intake of polyunsaturated fatty 
acids (3 E%), the optimum intake of monounsaturated fatty acids varies from 19–30 E%. Where there 
is a high intake of polyunsaturated fatty acids (12 E%), the optimum intake of monounsaturated fatty 
acids varies from 10 to 21 E%. 
The US Institute of Medicine (IoM, 2005) did not set an AI, EAR or RDA as there was no evidence to 
indicate that monosaturated fatty acids are essential in the diet and they have no known role in 
preventing chronic diseases. 
The WHO/FAO (2003) calculated the population nutrient intake goals for MUFA as “total fat minus 
(saturated fatty acids + polyunsaturated fatty acids + trans fatty acids)” and did not set a definitive 
value. 
4.1.4. Polyunsaturated fatty acids (PUFA) 
4.1.4.1. n-6 Polyunsaturated fatty acids (n-6 PUFA) 
The German-Austrian-Swiss recommendations (DGE, 2006; D-A-CH, 2008) advise that both n-6 and 
n-3 fatty acids should contribute between 7 and 10% of total energy intake. Recommended intakes for 
LA are based on the mean LA requirement of young adults (2 E%, CV of 15%) and are set at 2.5 E% 
for adults and children of 4 years and older. 
The Nordic Nutrition Recommendations (NNR, 2004) recommend an intake of cis-unsaturated fatty 
acids of about 20 E% for adults and children from 2 years of age with MUFA making up around 10 to 
15 E% and PUFA around 5 to 10 E% including 1 E% n-3 PUFA. Minimum requirements on which 
the recommendations are based are derived from threshold intake data from children. A ratio of n-6 to 
n-3 PUFA between 3 and 9 is considered to be adequate.  
The SCF (1992) calculated a PRI of 2 E% of linoleic acid based on rough estimations from infant 
feeding studies. It is recommended that total PUFA intake should not exceed 15 E%. The same PRI is 
applied for pregnant or lactating women. 
The UK COMA (DoH, 1991) recommends that cis ployunsaturated fatty acids should provide an 
average of 6% of total dietary energy (including alcohol) for the population. They should be derived 
from a mixture of n-6 and n-3 fatty acids. Dietary intake of total PUFA should not exceed 10 E%. For 
infants, children and adults, linoleic acid should provide at least 1 E%. 
The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend an intake of 
linoleic acid of 4 E% in adults and 4.4 E% in pregnant and lactating women with a n-6/n-3 ratio of 
5:1. This recommendation is based on outcomes of studies of the effect of PUFA on cardiovascular 
disease and cancer. Concerning long-chain PUFAs, values are proposed after observation of usual 
consumption in dietary surveys around 500 mg per day corresponding to 0.2 E%. The 
recommendation is doubled to 0.4 E% for long-chain PUFA in pregnant and lactating women. 
The Health Council of the Netherlands (GR, 2001) has set an AI for linoleic acid of 2 E% in adults 
which is considered to be sufficient to prevent deficiency and reach a triene/tetraene ratio in plasma 
(eicosatrienoic acid:arachidonic acid) ratio below 0.2. Adults having a triene/tetraene ratio of less than 
0.2 are considered to have an adequate fatty acid status. In pregnancy and lactation the 
recommendation is raised to 2.5 E%. In pregnancy an average amount of 525 g of linoleic acid is 
deposited in the foetus. Breastfeeding women secrete on average 3.2 g per day of linoleic acid. 
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The US Institute of Medicine (IoM, 2005) states that studies in adult patients receiving total parental 
nutrition have shown to reverse n-6 fatty acid deficiency symptoms with as little as 7.4 to 8 g per day 
of linoleic acid. However, these data were considered insufficient to set an EAR and the AI is 
calculated based on the median intake of linoleic acid in the United States in the respective age group. 
In the US, the presence of an n-6 fatty acid deficiency is basically nonexistent in the free-living 
population. The AI for the age groups of 19 to 30 years and 31 to 50 years is 17g per day of linoleic 
acid for men and 12 g per day for women. From 51 years onwards the AI for linoleic acid is reduced 
to 14 g per day in men and 11 g per day in women due to the lower energy expenditure in comparison 
to the younger age groups. The AI for pregnant and lactating women has been set at 13 g per day 
using the same calculation method as for non-pregnant and non-lactating women. 
The WHO/FAO (2003) set the population nutrient intake goals for n-6 PUFA at 5 to 8 E% with a total 
intake of PUFA of 6 to 10 E%. 
4.1.4.2. n-3 Polyunsaturated fatty acids (n-3 PUFA) 
The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend that n-6 and n-3 fatty 
acids together should contribute 7 to 10% of total energy intake with a ratio of linoleic acid (n-6) to 
alpha-linolenic acid (n-3) of 5:1. The estimated value for n-3 fatty acid intake is 0.5 E% for all age 
groups including infants, children, pregnant and lactating women and is based on the 
recommendations for n-6 PUFA taking into account the desirable ratio. For primary and secondary 
prevention of coronary heart disease 0.25 and 1 g per day of n-3 LCPUFA, respectively, are deemed 
to be adequate, whilst up to 3 g per day are considered to be safe. DHA intake during pregnancy and 
lactation is to be at least 200 mg per day. 
The Nordic Nutrition Recommendations (NNR, 2004) recommend an intake of cis-unsaturated fatty 
acids of about 20 E% for adults and children from 2 years of age with MUFA making up around 10 to 
15 E% of it and PUFA around 5 to 10 E% including 1 E% n-3 PUFA. Minimum requirements on 
which the recommendations are based were derived from threshold intake data from children. A ratio 
of n-6 to n-3 PUFA between 3 and 9 is considered to be adequate.  
The SCF (1992) calculated a PRI of 0.5 E% of n-3 PUFA based on data from current dietary habits in 
Europe. It is recommended that habitual intakes of total PUFA should not exceed 15 E% and total n-3 
PUFA intake should not exceed 5 E%. The same PRI is applied for pregnant or lactating women. 
The UK COMA (DoH, 1991) recommends that cis-polyunsaturated fatty acids should provide an 
average of 6% of total dietary energy (including alcohol) for the population. They should be derived 
from a mixture of n-6 and n-3 fatty acids. Dietary intake of PUFA should not exceed 10 E%. For 
infants, children and adults alpha-linolenic acid should provide at least 0.2 E%. The Scientific 
Advisory Committee on Nutrition (SACN) recommended an intake of 450 mg of n-3 LCPUFA for the 
population including pregnant women (SACN, 2004). 
The Nutritional Recommendations for the French Population (AFSSA, 2001) recommend an intake of 
alpha-linolenic acid of 0.8 E% in adults and 0.9 E% in pregnant and lactating women with a n-6/n-3 
ratio of 5:1. This recommendation is based on the outcome of studies of the effect of PUFA on 
cardiovascular disease and cancer. Concerning LCPUFAs, values are proposed after observation of 
usual consumption in dietary surveys around 500 mg per day corresponding to 0.2 E%, including 
120 mg per day DHA, corresponding to 0.05 E%. The recommendation is doubled to 0.4 E% for 
LCPUFA and 0.1 E% for DHA in pregnant and lactating women. 
The Health Council of the Netherlands (GR, 2001) has set an AI for alpha-linolenic acid of 1 E% in 
adults, which is based on the protective effect of alpha-linolenic acid in relation to CHD. In pregnancy 
an average amount of 75 g of alpha-linolenic acid is deposited in the foetus. Breastfeeding women 
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secrete on average 0.5 g per day of alpha-linolenic acid. The recommendations are the same for 
pregnant and lactating women (GR, 2001). An AI for n-3 fatty acids from fish has been set at 0.45 g 
per day for adults and pregnant and lactating women (GR, 2006). 
The US Institute of Medicine (IoM, 2005) states that studies in adult patients who were fed by gastric 
tube showed a alpha-linolenic acid deficiency with intakes ranging from 0.015 to 0.095 g per day 
whereas intakes of 0.3 g per day prevented symptoms of deficiency. However, these data were 
considered insufficient to set an EAR and the AI is calculated based on the median intake of alpha-
linolenic acid in the United States where the presence of n-3 fatty acid deficiency is basically 
nonexistent in the free-living population. Small amounts of EPA and DHA can contribute towards 
reversing an n-3 fatty acid deficiency and can therefore contribute towards the AI for alpha-linolenic 
acid. For men the AI of alpha-linolenic acid has been set at 1.6 g per day and for women at 1.1 g per 
day. The AI for pregnant (1.4 g per day) and lactating women (1.3 g per day) has been set using the 
same calculation method as for non-pregnant and non-lactating women.  
The WHO/FAO (2003) set the population nutrient intake goals for n-3 PUFA at 1 to 2 E% with a total 
intake of PUFA of 6 to 10 E%. 
4.1.5. Trans fatty acids (TFA) 
The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend limiting the intake of 
trans fatty acids to <1 E% based on the fact that trans fatty acids increase LDL and decrease HDL 
cholesterol concentrations and increase the risk for coronary heart disease. 
The Nordic Nutrition Recommendations (NNR, 2004) recommend a maximum intake of 10 E% of 
saturated fatty acids and trans fatty acids (calculated as fatty acids) from the age of 12 months 
onwards based on the assumption that a reduction in the intake of SFA and TFA would reduce the risk 
of CHD. 
The UK COMA (DoH, 1991) states that trans fatty acid intake in the population should not increase 
further than the current estimated average of 5 g per day or 2 % of dietary energy (including alcohol). 
In 2007, the UK SACN endorsed the recommendation set by COMA, that the average trans fatty acid 
intake should not exceed 2 E%. It states that there is consistent evidence to support a moderate effect 
of trans fatty acids on increasing the risk of CHD. The primary mechanism for this effect appears to 
be via changes in the blood lipoprotein profile, although inflammatory responses and endothelial 
function may also be negatively affected by dietary trans fatty acids (SACN, 2007). 
In its report on health risks and benefits of trans fatty acids in food the French AFSSA states that 
daily consumption of total trans fatty acids higher than 2 E% gives rise to a significant increase in the 
risk of cardiovascular disease. Therefore it is recommended to consider this value a consumption level 
that should not be exceeded (AFSSA, 2005). 
The Health Council of the Netherlands (GR, 2001) states that trans fatty acids increase the risk of 
coronary heart disease and may have adverse effects on the metabolism of EFA. The Health Council 
of the Netherlands therefore recommends keeping intake levels as low as possible. 
The Dietary Guidelines for Americans (HHS/USDA, 2005) recommend keeping trans fatty acid 
intake as low as possible. 
The WHO/FAO (2003) set the population nutrient intake goals for trans fatty acids at below 1 E%. 
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4.1.6. Cholesterol 
Only the German-Austrian-Swiss recommendations (D-A-CH, 2008) and the WHO/FAO (2003) have 
set recommendations for a maximum intake of cholesterol. Both recommend not exceeding a 
cholesterol intake of 300 mg per day in the adult population.  
4.2. Infants and children 
4.2.1. Total fat 
The German-Austrian-Swiss recommendations (D-A-CH, 2008) for total fat intake are 35 to 45 E% 
for infants from 4 to <12 months old. For children from 1 to <4 years old 30 to 40 E% are 
recommended, thereafter up to the age of 15 years 30 to 35 E%. 
The Nordic Nutrition Recommendations (NNR, 2004) do not set recommendations for total fat intake 
for infants aged 0 to 6 months. For infants between 6 and 11 months of age the proportion of total fat 
should be kept between 30 and 45 E% and between 30 and 35 E% in infants between 12 and 23 
months of age. 
The Health Council of the Netherlands (GR, 2001) has set an AI for total fat for infants from 0 to 
5 months at the average fat content of human milk (40 to 45 E%). For infants aged 6 to 11 months it 
has endorsed the recommendation of the European Society of Paediatric Gastroenterology, which sets 
an AI at 40 E%. 
The recommended intakes of the US Institute of Medicine (IoM, 2005) for total fat for infants from 
0 to 6 months are based on an AI that reflects the observed mean intake of infants fed human milk. 
This corresponds to 31 g fat per day and 55% of total energy intake of infants from 0 to 6 months, 
assuming that the energy requirements of the infants are being met. The proportion of energy from 
dietary fat decreases during the second 6 months of life. The AI for older infants aged 7 to 12 months 
is based on the average intake of fat ingested from human milk and complementary foods. This 
corresponds to 30 g fat per day and 40% of total energy. No AI, EAR or RDA has been set by IoM for 
children and adolescents aged 1 to 18 years, as data generally show that there is no effect of fat intake 
on growth when consumed at levels as low as 21 E% and insufficient evidence exists to identify a 
defined intake level of fat to prevent obesity and chronic disease. The Dietary Guidelines for 
Americans (HHS/USDA, 2005) recommend a total fat intake of 30 to 35 E% for children 2 to 3 years 
of age and between 25 E% and 30 E% for children and adolescents 4 to 18 years of age.  
4.2.2. Saturated fatty acids (SFA) 
The German-Austrian-Swiss recommendations (D-A-CH, 2008) for SFA intake in children are less 
than 10 E%. 
The Health Council of the Netherlands (GR, 2001) set an AI for SFA for infants at 25 E% based on 
SFA equivalents in human milk. The maximum intake for children of 6–11 months should be 20 E% 
and 15 E% for children of 1–3 years of age. 
4.2.3. Monounsaturated fatty acids (MUFA)  
No recommendations for children were set. 
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4.2.4. Polyunsaturated fatty acids (PUFA) 
4.2.4.1. n-6 Polyunsaturated fatty acids (n-6 PUFA) 
The German-Austrian-Swiss recommendations (D-A-CH, 2008) recommend a linoleic acid intake of 
4 E% for children 0 to 4 months, 3.5 E% in children aged 4–12 months, 3 E% in children from 1–3 
years, decreasing to 2.5 E% thereafter. 
The Nordic Nutrition Recommendations (NNR, 2004) recommend that from 6–23 months of age the 
total amount of PUFA should constitute 5–10% of the total energy intake, including at least 1% of n-3 
fatty acids. From 6 to 11 months of age it is recommended that the initial n-6/n-3 ratio of 5 to 15:1 (in 
infant and follow-on formulae) should gradually approach the ratio for adults 3 to 9:1. 
The SCF (1992) defined for n-6 PUFA a PRI of 4.5 E% of for infants 6–11 months and of 3 E% for 
infants 1–3 years. PRIs for children above 4 years should be the same as those for adults. 
The Health Council of the Netherlands (GR, 2001) concluded that the AI for linoleic acid for infants 
from 0 to 5 months is 0.6 g/kg bodyweight per day based on breast milk composition. An AI for 
arachidonic acid for children from 0 to 5 months has been set at 0.04 g/kg bodyweight per day. 
The US Institute of Medicine (IoM, 2005) based the AI for n-6 PUFA for infants from 0 to 6 months 
on the observed mean intakes of infants fed human milk. This corresponds to 4.4 g per day of n-6 
PUFA and around 8% of daily energy intake. The AI for older infants aged 7 to 12 months is based on 
the average intake of n-6 PUFA ingested from human milk and complementary foods. This 
corresponds to 4.6 g per day of n-6 PUFA and around 6% of daily energy intake. For children and 
adolescents an AI for linoleic acid is set based on the median intake of linoleic acid consumed in the 
United States where the presence of an n-6 fatty acid deficiency is basically nonexistent in the free-
living population. For children aged 1 to 3 years the AI is set at 7g per day of linoleic acid, for 
children from 4 to 8 years of age the AI is 10 g per day. For 9 to 13 year old boys it is 12 g per day 
and for girls 10 g per day of linoleic acid. In the age group of 14 to 18 years the AI for boys is 16 g 
per day and for girls 11 g per day of linoleic acid. 
4.2.4.2. n-3 Polyunsaturated fatty acids (n-3 PUFA) 
The recommendations from Germany, Austria and Switzerland (D-A-CH, 2000) for alpha-linolenic 
acid intake for children do not differ from the recommendations for adults (0.5 E%). 
The Nordic Nutrition Recommendations (NNR, 2004) recommend that from 6–23 months of age the 
total amount of PUFA should constitute 5–10% of the total energy intake, including at least 1% of n-3 
fatty acids. From 6 to 11 months of age it is recommended that the n-6/n-3 ratio of 5 to 15:1 (in infant 
and follow-on formula) should gradually approach the ratio for adults of 3 to 9:1. 
The SCF (1992) defined a PRI of 0.5 E% of n-3 PUFA for infants 6 months to 3 years of age. 
The Health Council of the Netherlands (GR, 2001) concluded that the AI for alpha-linolenic acid for 
infants from 0 to 5 months is 0.08 g/kg bodyweight per day based on breast milk composition. The AI 
for n-3 fatty acids from fish has been set for children and adolescence from 6 months to 18 years at 
0.15 to 0.2 g per day. An AI for DHA has been set for children from 0 to 5 months at 0.02 g/kg per 
day. 
The US Institute of Medicine (IoM, 2005) based the AI for n-3 PUFA for infants aged 0 to 6 months 
on the amount of n-3 fatty acids, total fat, and energy provided by human milk. This results in an AI 
of 0.5 g per day and 1% of energy intake. The AI for older infants aged 7 to 12 months is based on the 
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average intake of n-3 PUFA ingested from human milk and complementary foods. This corresponds to 
0.5 g per day of n-3 PUFA and around 0.67% of daily energy intake. For children and adolescents an 
AI for alpha-linolenic acid is set based on the median intake of alpha-linolenic acid consumed in the 
United States where the presence of n-3 fatty acid deficiency is basically nonexistent in the free-living 
population. Small amounts of EPA and DHA can contribute towards reversing n-3 fatty acid 
deficiency and can therefore contribute towards the AI for alpha-linolenic acid. The AI is set at 0.7 g 
per day for children between 1 and 3 years and for children between 4 and 8 years at 0.9 g per day. 
For boys between the age of 9 and 13 years the AI is 1.2 g per day of alpha-linolenic acid and for girls 
1.0 g per day. This is increased in the age group of boys from 14 to 18 years to 1.6 g per day and in 
girls to 1.1 g per day of alpha-linolenic acid. 
4.2.5. Cholesterol 
Only the German-Austrian-Swiss recommendations (D-A-CH, 2000) and Eurodiet (2000) have set 
guidance values for children. Cholesterol intake in children should not exceed 80 mg/1000 kcal. 
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Table 5:  Overview of dietary recommendations for the intakes of total fat and fatty acids intakes for adults as set by different organisations. 
 
Countries / 
Organisation 
Year Total fat SFA TFA cis-MUFA PUFA Cholesterol 
United 
Kingdom 
1991 33 E% <10 E% < 2 E% 12 E% 6 E% with at least 1 E% LA and 
0.2 E% ALA  
 
Germany, 
Austria, 
Switzerland 
2000 30 E% <10 E% < 1 E%  Total PUFA: 7-10 E%, n-6 
PUFA 2.5 E%, n-3 PUFA: 0.5 
E% 
< 300 mg 
per day 
France 
 
 
2001 
2005 
30-35 E% <8 E% < 2 E% 
 
 
20 E% 4 E% of which 4 % LA, 0.8 E% 
ALA, 0.20 E% LCPUFA, and 
0.05 E% DHA 
 
The 
Netherlands 
 
 
2001 
2006 
 
20-40 E% < 10 E% alap  <12 E% of which at least 2 E% 
LA, 1.0 E% ALA, 450 mg EPA 
+ DHA 
 
USA 
 
 
2002 
2005 
20-35 E% < 10 E% alap  5-10 E% LA, 0.6-1.2 E% ALA  
WHO/FAO 
 
2003 15-30 E% < 10 E% < 1 E%  6-10 E%, of which 5-8 E% n-6 
PUFA and 1-2 E% n-3 PUFA  
< 300 mg 
per day 
Nordic 
Countries 
 
2004 25-35 E% <10 E% (includes TFA) 10-15 E% 5-10%, of which 1 E% n-3 fatty 
acids 
 
SFA: Saturated fatty acids; TFA: Trans fatty acids; cis-MUFA: cis-monounsaturated fatty acids; PUFA: Polyunsaturated fatty acids; LA: Linoleic acid; ALA: alpha-linolenic acid; EPA: 
eicosapentaenoic acid; DHA: docosahexaenoic acid; alap = as low as possible; E%: percent of energy. 
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5. Criteria (endpoints) on which to base Dietary Reference Values 
The amount and type of fat in the diet affects a wide variety of metabolic responses. As fat provides 
energy, changes in fat intake will usually be accompanied by changes in the intake of other energy 
providing food constituents, namely carbohydrates and/or protein. Therefore, these effects cannot be 
discussed in isolation. In general, responses are discussed relative to those of another nutrient that 
delivers energy. This can complicate comparisons between studies, as in one study – for example – 
carbohydrates are taken as point of reference, while in another study oleic acid is the point of 
reference. It is also possible that studies have been carried out under non-isocaloric conditions. These 
latter studies will however not be considered, except for the outcome of body weight control. In 
addition, in view of the large number of studies in this field, emphasis will be on recent meta-analyses 
of data from randomised intervention trials or prospective cohort studies.  
5.1. Dietary requirements 
There are insufficient data to determine the absolute amounts of fat and individual fatty acids which 
are needed for metabolic integrity and human health. Observed intakes in healthy population groups 
in combination with observed intakes associated with deficiency symptoms and amounts needed to 
alleviate such symptoms are useful to provide estimates of nutritionally sufficient and, therefore, 
desirable intake levels. 
During pregnancy and lactation an estimate of the additional needs for both the increase in maternal 
body tissues and the growth and development of the foetus and the production of breast milk need to 
be taken to into account. 
For infants in the first half of the first year of life requirements are assumed to be covered by the 
nutrients provided with exclusive breastfeeding by a well nourished mother. 
5.1.1. Total fat 
Fat is an important source of energy and facilitates the absorption of fat soluble vitamins and 
carotenoids. Despite this important role of fat and despite the indispensability of the two fatty acids 
LA and ALA, it is not possible to define a quantitative requirement for total fat. 
5.1.1.1. Adults 
Within the European adult population, intake ranges varied from 22 to 26 E% at the lower end (2.5 to 
10
th 
percentile) to 38 to 48 E% at the upper end (90 to 97.5
th
 percentile) of the distributions. Very low 
fat diets may increase the risk of an insufficient intake of PUFA, can impair the absorption of fat-
soluble vitamins and be associated with insufficiency of other essential nutrients like zinc and 
B vitamins. The addition of 5 g fat to a diet providing only 5 g fat per day (total of 10g fat per day) 
was shown to significantly improve blood vitamin A concentrations and improve vitamin K 
availability (Jayarajan et al., 1980; Uematsu et al., 1996). Such low fat intakes are highly unlikely in 
European countries and no signs of deficiency have been observed at the lowest observed intakes in 
the European population including pregnant and lactating women.  
5.1.1.2. Pregnancy 
Pregnancy leads to an additional energy requirement of 375, 1200, 1950 kJ per day during the first, 
second and third trimesters, respectively (Prentice and Goldberg, 2000; Butte and King, 2005). There 
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are no data which would suggest that the fat intake as percentage of the total energy should differ 
from that of the diet in non-pregnant women. 
5.1.1.3. Lactation 
Lactating women have an increase in energy expenditure consistent with the energy cost of milk 
synthesis. Part of this energy can be mobilised from subcutaneous fat particularly but the major part 
has to be provided by the diet. An additional energy requirement of 1380 to 1900 kJ per day has been 
estimated (Butte and King, 2005; IoM, 2005). There are no data which would suggest that the fat 
intake as percentage of the total energy should differ from that of the diet in non-lactating women. 
5.1.1.4. Infants and children 
The observed mean intake of fat of infants from 0 to 6 months fed human milk averages 50 to 55% of 
total energy intake. Fat intake usually decreases thereafter to reach adult values by the end of the third 
year of life (Aggett et al., 1994; Agostoni et al., 2008). Within the European child and adolescent 
population, fat intake ranges varied from 22 to 29 E% (5 to 10
th
 percentile) to 38 to 46 E% (90 to 
97.5
th
 percentile).  
If the diet provides an adequate supply of energy and essential nutrients, there is no evidence that a 
dietary fat intake of 30 E% adversely affects the growth and development of healthy children in 
European countries. A review of studies from Europe and North America found little evidence of 
adverse effects of low dietary fat on growth of young children aged 6 to 36 months. The percentage of 
dietary fat was not correlated with growth velocity or energy density of the diet between ages 6 and 
12 months, whereas energy density of the diet was positively associated with energy intake and 
weight gain (Fjeld et al., 1989, Butte, 1996, Nicklas et al., 1992, Shea et al., 1993). No association 
between fat intake and growth was detected in infants aged 7 to 13 months or children aged 2 to 5 
years or 3 to 5 years (Friedman and Goldberg, 1976; Lapinleimu et al., 1995, Michaelsen and 
Jorgensen, 1995). 
In the Special Turku Coronary Risk Factor Intervention Project (STRIP) trial, a moderately restricted 
fat intake (25 to 30E%) was not associated with compromised growth or impaired neurological 
development in 1062 infants between 7 and 36 months and followed-up until the age of 18 years 
(Niinikoski et al., 1996). A similar intervention with a dietary fat intake of 30 to 35 E% in Danish 
infants also did not result in impaired growth between ages 7 and 13 months (Michaelsen, 1997). 
Some investigators have reported lower vitamin and mineral intakes in association with low-fat diets 
(Jayarajan et al., 1980). A cohort of 500 Canadian preschoolers was stratified according to fat intake: 
<30%, 30 to 40% or >40% of energy from fat between the ages of 3 and 6 years. Low-fat intake was 
associated with inadequate intake of fat-soluble vitamins. For children habitually on low-fat diets, the 
odds ratio for underweight for the age of 6 years was 2.3 (Gibson et al., 1993). The effect of dietary 
fat intake on growth of 140 children in New Zealand was examined at the age of 2, 4, 6 and 8 years 
(Boulton and Magarey, 1995).The median dietary fat intake (in percent of energy) fell from 44% at 3 
months to 36% at 6 months at which level it remained until 8 years. At each age interval no 
differences were observed in height, weight or skinfold thickness among children consuming <30%, 
30 to 34.9% and >34.9% of dietary energy as fat. 
In conclusion, older infants and children can grow normally with total fat intakes as low as about 
25 E% provided the energy intake and the intake of micronutrients is appropriate. Because of the 
higher energy requirement of infants and children per kilogram of body weight, such a low-fat diet 
may bear an increased risk of an overall too low energy intake. 
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5.1.2. cis-Polyunsaturated fatty acids (PUFA) 
There are only two fatty acids that are essential to maintain metabolic integrity: linoleic acid and 
alpha-linolenic acid (see sections 2.1.3.1 and 2.1.3.2). Case reports of deficiency of the n-6 fatty acid 
linoleic acid and of the n-3 fatty acid alpha-linolenic acid do not allow defining the precise 
requirements for these essential fatty acids (Bjerve et al., 1987; 1989; Bjerve, 1989; Holman et al., 
1982). 
Mean dietary PUFA intakes in Europe range between 3.6 and 8 to 9 E% in both children and adults 
(see Annex 1a and b). 
At the lowest observed intake of cis n-3 PUFA and cis n-6 PUFA in children, adolescents and adults 
in Europe (see section 3.2.4.1 and 3.2.4.2), no overt sign of deficiencies were observed. There are also 
no indications of overt deficiencies in pregnant and lactating women. 
Human milk supplies 10 to 18% of fats as PUFA depending on maternal dietary habits. Therefore, at 
early ages up to 10 E% may be represented by polyunsaturated fatty acids, possibly decreasing to 5 to 
10 E% once total fat intake is reduced to 30 E%.  
5.1.2.1. cis n-6 Polyunsaturated fatty acids (n-6 PUFA) 
Cases of LA deficiency were reported in patients on (total) parenteral nutrition (e.g. Jeppesen et al., 
1998) and in infants fed skim-milk formula providing between 10 and 800 mg of LA/kg bodyweight 
per day. A LA intake of less than 0.1 E% resulted in dry squamous skin laesions, susceptibility to 
staphylococcal infections and retarded growth. Symptoms disappeared with a LA intake of 1 E% and 
did not occur in infants consuming 1.3 to 7.3 E% in the form of LA (Hansen et al., 1963). LA 
deficiency was associated with an elevated ratio of eicosatrienoic acid to arachidonic acid (>0.4 to 
0.2) (Holman, 1960; Jeppesen et al., 1998). 
No data are available to establish desirable tissue LA levels or to conclude on the LA requirement of 
healthy individuals.  
The habitual dietary intake in European countries varies considerably (see Section 3.2.4.1 and 
Annex 1) and does not lead to signs of LA deficiency. There is no indication for the necessity of an 
increase of LA intake during pregnancy and lactation, because the absolute amount consumed will 
increase in proportion to the increased energy intake.  
Human milk supplies 10 to 18%of total fatty acids as n-6 PUFA, mostly LA, depending on maternal 
dietary habits. Therefore, at early ages up to 5 to 8 E% may be represented by n-6 PUFA, later to 
decrease to 3 to 6 E% once total fat intake is reduced to 30 E%.  
The synthesis of long-chain n-6 derivatives, whose main compound in the n-6 series is arachidonic 
acid (ARA, 20:4, n-6), seems in conjunction with dietary intake to cover the needsof healthy (non-
vegetarian) subjects, given the present lifestyle and dietary habits, and no requirement for preformed 
arachidonic acid can be defined for infants, adults and children, despite a low rate of conversion of 
LA into ARA in LA-deficient subjects (Plourde and Cunnane, 2007) and in infants (Demmelmair et 
al., 2001).  
Pregnant women with an adequate intake of LA do provide sufficient ARA for the foetus. The ARA 
content in human milk is similar over the world (0.35 to 0.7 weight % of total fatty acids) (Yuhas et 
al., 2006). 
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5.1.2.2.  cis n-3 Polyunsaturated fatty acids (n-3 PUFA) 
The essentiality of ALA consists of its role as a precursor for EPA and DHA. From the few cases of 
n-3 PUFA deficiency reported in the literature it was concluded that 0.2 E% of ALA were sufficient 
to increase deficient plasma levels of EPA, DPA and DHA, but not of ALA, and that this intake 
stimulated growth in growth-deficient children. From the same case reports “minimal” and “optimal” 
intakes of n-3 LCPUFA were calculated, 100 to 200 mg per day and 350 to 400 mg per day, 
respectively (Bjerve et al., 1987 and 1989). However, the plasma and tissue levels of DHA below 
which visual or neural functions are impaired are not known. 
Mean ALA intakes in the European population of 0.7 to 0.9 g per day (0.5 E%) of young children, 1.0 
to 1.2 g per day (0.4 to 0.6 E%) in children and adolescents and 0.7 to 2.3 g per day (0.4 to 0.8 E%) in 
adults have been reported and were not associated with signs of deficiency. Human milk supplies 0.5 
to 1%of total fatty acids as n-3 PUFA depending on maternal dietary habits. The same content is 
requested by European law in infant formulae intended for non-breastfed infants. 
Studies in normal healthy adults consuming western diets, which are rich in linoleic acid (LA), show 
that supplemental ALA raises EPA and DPA status in the blood and in breast milk (Brenna et al., 
2009).The conversion of the essential fatty acid ALA to LCPUFA, particularly to DHA is low in 
humans and is estimated to be approximately 5% to EPA and <0.5% to DHA both in studies 
performed with stable isotopes and in supplementation studies where the increase of EPA and/or 
DHA in blood lipids in response to physiological and supraphysiological amounts of ALA was 
measured (Plourde and Cunnane, 2007). Whilst EPA increased significantly in most instances, the 
response of DHA was much smaller or not measurable and not related to the dose of ALA, except in 
vegetarians or in ALA deficiency. Possible explanations for this non-response are low endogenous 
synthesis, homoeostatic regulation of DHA levels in tissues and influences of the individual diet. 
However, women convert twice as much ALA to DHA than men (Burdge and Wootton, 2002) and 
this conversion is increased by estrogens, which may explain the increase in maternal DHA status 
measured as DHA content in plasma and red blood cell phospholipids during pregnancy (Otto et al., 
1997 and 2001). Maternal DHA status, more than maternal ALA status or actual dietary intake, has a 
positive effect on placental DHA transfer to the foetus and on DHA content in human milk. 
The foetal brain is rich in fat, especially in DHA and ARA. First ARA and later DHA accumulate 
rapidly during the third trimester of pregnancy and after birth (Clandinin et al., 1980a and b). The 
growth spurt of the brain starts in the 28
th
 week of gestation and continues to 1 year whilst the demand 
for DHA and ARA continues to 2 years of age (Martinez, 1992; 1994) and DHA content of the brain 
continues to increase in adolescence (Carver et al., 2001). In the normal term infant total DHA 
content of the body is about 3.8 g (Cunnane et al., 2000) and n-3 PUFA accretion during the last 
trimester has been estimated to be 34.1 mg/kg body weight per day of which most is DHA (Lapillonne 
and Jensen, 2009). Whole body and brain DHA accumulation may be limited by DHA availability due 
to a low maternal DHA status. In addition, recent data indicate that there is inter-individual variation 
in the ability to convert the precursor ALA to n-3 LCPUFA and, particularly to DHA, which is related 
to common polymorphisms in the human ∆-5 and ∆-6 desaturase genes FADS1 and FADS2 
(Schaeffer et al., 2006). DHA is preferentially transferred across the human placenta to the foetus 
mediated by specific transfer proteins (Larque et al., 2003 and 2006). 
Estimates of the DHA amount a woman needs to accumulate to accommodate the needs of her infant 
for deposition of DHA in the brain and retina during the last trimester of pregnancy (about 10 g) and 
during six months of lactation (12 to 14 g) add up to an additional requirement of 22 to 25 g 
equivalent to 90 to 100 mg per day over her basic DHA requirement (SACN, 2004) satisfied by 
limited endogenous synthesis from ALA and her habitual dietary DHA intake which may be low in 
many women in Europe who do not regularly consume fatty fish (or fish oil). Oxidative losses of 
maternal dietary DHA and accumulation of DHA in body fat of the foetus/infant should be taken into 
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account when estimating adequate dietary DHA intakes for pregnant women (SACN, 2004). A recent 
consensus among several research projects and scientific societies recommends a dietary intake of at 
least 200 mg of DHA per day for both pregnant and lactating women (Koletzko et al., 2007 and 2008). 
Intakes of fish, fish oils or n-3 LCPUFA from other sources during pregnancy are positively 
associated with slightly longer gestation, slightly higher birth weight and a reduced risk of preterm 
delivery (Koletzko et al., 2008). Moreover, a higher intake predicted a lower prevalence of 
postpartum depression (Hibbeln, 2002).  
The main n-3 compound supplied by human milk is docosahexaenoic acid, DHA, 22:6n-3, averaging 
7 to 8 mg/dL (means of DHA range from 0.17% to 1.0% of total fatty acids (Yuhas et al., 2006)). The 
DHA content of human milk is mainly a reflection of the variability in maternal DHA intake. 
However, even in the milk of vegans who consume no DHA containing food, some DHA (0.05 % of 
total fatty acids) (Sanders et al., 1978) is present. A dose dependent relationship between habitual 
maternal DHA consumption and DHA levels in human milk was demonstrated (Gibson et al., 1997). 
However, ALA or EPA dietary supplements have little effect on blood or breast milk DHA levels 
(Brenna et al., 2009). 
The DHA amount contained in breast milk can be considered to provide an estimate of the amount of 
DHA which is added to infant formulae since it has been shown that 2 to 6 months old infants who 
were fed a formula which contained ALA only and no EPA and DHA accumulated less DHA in brain 
than breast-fed infants (Farquharson et al., 1992; Makrides et al., 1994): 2.5 mg per day compared to 
5.0 mg per day (Cunnane et al., 2000). Addition of ALA to the diets of formula-fed infants does raise 
DHA, but no level of ALA tested raises DHA to levels achievable with preformed DHA at intakes 
similar to typical human milk DHA supply (Brenna et al., 2009). Hoffman et al. (2004) investigated 
the effects of solid baby food supplementation with DHA on visual maturation at one year of age in 
term infants exclusively breastfed from birth until four months and likely to have breast milk as the 
only source of milk until one year of age. Infants were randomly assigned at six months of age to 
consume daily one jar of either standard commercial solid baby foods (controls, n = 26) or baby foods 
containing DHA-enriched egg yolk (intervention, n = 25) until the age of one year. Breast-feeding 
continued in both groups up to an age of about nine months. Thus, for the entire 6-months trial period, 
the intervention group received an average of 108 mg DHA per day (13 mg/kg body weight per day) 
from baby foods and breast milk compared with 38 mg DHA per day (4.5 mg/kg body weight per day) 
in control infants from breast milk only. In DHA-supplemented infants, visual evoked potential (VEP) 
acuity was significantly more mature at 12 months of age than in controls. Both red blood cell-DHA 
levels and DHA intake were significantly correlated with VEP acuity at 12 months. 
Such small amounts of DHA may be needed for optimal growth and development of infants and 
children: approximately 20 to 50 mg per day of DHA in the 0 to 6 months period (estimated from the 
DHA content and the daily breast milk volume: 7 to 8 mg/dL and 500 to 750 mL) and 100 mg per day 
in the 6 to 24 months period (estimated from RCT with DHA) (e.g. Hoffman et al., 2004). 
5.2. Blood lipids and lipoproteins 
Numerous studies have dealt with the effects of fatty acids on blood lipid and lipoprotein 
concentrations. In addition to the many individual studies, also several meta-analyses have been 
published (Gardner and Kraemer, 1995; Clarke et al., 1997; Howell et al., 1997; Kris-Etherton and 
Yu, 1997; Mensink et al., 2003; Mozaffarian et al., 2006). Although quantitative estimates of the 
effects varied slightly, conclusions were essentially similar. 
Although certain genetic dispositions have been shown to influence the levels of blood lipid levels 
and explain part of the variability in the effects of nutrient consumption on risk factors for example 
cardiovascular diseases, the Panel considers that the present knowledge on interactions between 
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environment and human genome is at present insufficient to determine Dietary Reference Values with 
a view on preventive dietary measures early in life (Ordovas, 2009). 
5.2.1. Total fat 
When SFA are kept constant, varying total fat has no significant effects on LDL cholesterol (IoM, 
2005). Data from intervention studies consistently show that, at low intakes of SFA (<10%E), 
decreasing total fat intake increases the total/HDL cholesterol ratio and TG concentrations and 
decreases blood concentrations of HDL cholesterol, particularly in sedentary populations which are 
overweight or obese. This is supported by observational studies and provides a basis to set a lower 
bound (about 20 E%) for total fat intake (IoM, 2005).  
5.2.2. Saturated fatty acids (SFA) 
There is wide consensus that a mixture of SFA increases blood total, LDL and HDL cholesterol 
concentrations (Annex IV) relative to carbohydrates. As a consequence, the total to HDL cholesterol 
ratio does not change. A mixture of dietary SFA also decreased fasting triacylglycerol concentrations. 
SFA, however, differ in their potency to change blood lipid and lipoprotein concentrations. While 
lauric, myristic and palmitic acid raise blood total and LDL cholesterol concentrations, effects of 
stearic acid are more similar to those of carbohydrates. Effects of SFA on blood HDL cholesterol 
concentrations are in the opposite direction: lauric acid strongly increases blood HDL cholesterol 
concentrations, an effect that decreases with increasing chain length. Thus, stearic acid had the 
smallest effects on blood HDL cholesterol concentrations. For the total to HDL cholesterol ratio, 
effects of lauric acid are more favourable than carbohydrates. Stearic acid also slightly decreased this 
ratio, but effects did not differ significantly from those of carbohydrates. Effects of myristic and 
palmitic acids were very similar to those of carbohydrates. No differences between the effects of the 
different SFA on fasting blood triacylglycerol concentrations were detected. 
5.2.3. Cis-monounsaturated fatty acids (cis-MUFA) 
Cis-MUFA had a modest blood total and LDL cholesterol-lowering effect relative to carbohydrates. 
HDL cholesterol concentrations increased and consequently the blood total to HDL cholesterol ratio 
decreased. Fasting blood triacylglycerol concentrations also decreased. This effect was comparable to 
that of SFA. In these studies, cis-MUFA was mainly provided by oleic acid. 
Palmitoleic acid (C16:1(n-7)) is a minor cis-MUFA in the human diet and in blood plasma. One well-
controlled study in slightly hypercholesterolaemic men showed that the effects of palmitoleic acid on 
blood LDL cholesterol concentrations are comparable to those of palmitic acid (16:0). HDL 
cholesterol concentrations were significantly lower with palmitoleic than with palmitic acid. In view 
of the low levels of palmitoleic acid in the diet, the practical relevance of these findings is however 
limited (Nestel et al., 1994). 
5.2.4. cis-Polyunsaturated fatty acids (cis-PUFA) 
5.2.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
cis n-6 PUFA lowered blood total and LDL cholesterol concentrations relative to carbohydrates. 
These effects were slightly stronger than those for cis-MUFA. Blood HDL cholesterol concentrations 
also increased, but this effect was slightly less than with SFA and cis-MUFA. Consequently, the 
blood total to HDL cholesterol ratio decreased. Changes in blood triacylglycerol were comparable to 
those of SFA and cis-MUFA. In these analyses, cis n-6 PUFA refers to linoleic acid. Increasing the 
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daily intake of ARA (20:4, n-6) from 210 mg to 1700 mg for 50 days did not influence the blood lipid 
and lipoprotein levels (Nelson et al., 1997). 
5.2.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
Effects of alpha-linolenic acid on the blood lipoprotein profile are comparable to those of linoleic 
acid. EPA and DHA, on the other hand, lower blood triacylglycerol concentrations compared to 
carbohydrates and other fatty acids. This effect is in particular evident in patients with increased 
blood triacylglycerol levels. In addition, these fatty acids may slightly increase blood LDL and HDL 
cholesterol concentrations. However, it should be noted that at daily intakes below <1 g, effects of n-3 
LCPUFA on the blood lipoprotein profile are small (Balk et al., 2006). 
5.2.5. Trans fatty acids (TFA) 
Evidence from many controlled human intervention studies indicates that consumption of diets 
containing trans-MUFA, like diets containing mixtures of SFA, consistently results in increased blood 
total and LDL cholesterol concentrations, compared with consumption of diets containing cis-MUFA 
or cis-PUFA (EFSA, 2004; Mozaffarian and Clarke 2009). The effect shows a linear dose response 
relationship with blood LDL cholesterol concentrations, indicating that effects are proportional to the 
amounts of TFA consumed. While the blood LDL cholesterol concentration increasing effect of trans-
MUFA was very similar to that of palmitic acid (C16:0) and slightly less than that of myristic acid 
(C14:0), the available evidence does not provide a definitive answer to the question of whether TFA 
have an effect on blood LDL cholesterol concentrations different from that of SFA on a gram-for-
gram basis. Consumption of diets containing trans-MUFA also results in reduced blood HDL 
cholesterol concentrations compared with consumption of diets containing SFA, cis-MUFA or cis-
PUFA. Therefore, trans-MUFA, in comparison with other fatty acids, increase the total cholesterol to 
HDL cholesterol ratio. 
Evidence from controlled human intervention studies also indicates that, relative to diets containing 
SFA, cis-MUFA or cis-PUFA, consumption of diets containing TFA results in increased 
concentrations of fasting TG. The relationship shows a linear dose response.  
In most of the human intervention studies reviewed above, the effects of trans-MUFA from 
hydrogenated vegetable oils were assessed. Two recent studies have evaluated effects of trans-MUFA 
from ruminants on the blood lipoprotein profile. A controlled human intervention study indicates that, 
compared with a low total TFA diet (0.8% of energy), a diet with 3.7% of energy from TFA, whether 
from ruminant or industrial sources, had similar adverse effects on blood lipids and lipoproteins, 
including increases in blood LDL cholesterol concentrations, decreases in blood HDL cholesterol 
concentrations, and increases in the ratio of total to HDL cholesterol (Motard-Bélanger et al., 2008). 
The outcome from a second study was equivocal - compared with a diet containing ~5% TFA from 
dairy products, a diet containing industrially produced TFA lowered blood LDL cholesterol and HDL 
cholesterol concentrations in women but not in men while the ratio of total to HDL cholesterol was 
not affected (Chardigny et al., 2008). 
In conclusion, available evidence indicates that consumption of diets containing trans-MUFA, like 
diets containing mixtures of SFA, increases blood total and LDL cholesterol concentrations in a dose-
dependent manner compared with consumption of diets containing cis-MUFA or cis-PUFA. 
Consumption of diets containing trans-MUFA also results in reduced blood HDL cholesterol 
concentrations and increased total cholesterol to HDL cholesterol ratio. The available evidence 
indicates that TFA from ruminant sources have similar adverse effects on blood lipids and 
lipoproteins to those from industrial sources. 
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5.2.6. Conjugated linoleic acid (CLA) 
From an extensive review of the literature, it was concluded that a mixture of CLA isomers has no 
major effects on plasma lipids (Terpstra, 2004; Salas-Salvadó et al., 2006). Studies have also been 
carried out to address the specific effects of the two major CLA isomers on the plasma lipoprotein 
profile. Tricon et al. (2004) found in healthy humans that cis-9, trans-11 CLA decreased blood LDL 
cholesterol and triacylglycerol concentrations, and the LDL to HDL cholesterol ratio as compared 
with trans-10, cis-12 CLA. The isomers were studied at three different daily intakes: approximately 
0.6 g, 1.2 g, and 2.4 g. A dose-response relationship was however not evident. In contrast, Naumann 
et al. (2006) did not observe in humans with LDL phenotype B differential effects of a daily 
consumption of 3 g of cis-9, trans-11 CLA or trans-10, cis-12 CLA on the blood lipoprotein profile. 
Thus, these intervention studies do not provide evidence that a mixture of CLA isomers, cis-9, trans-
11 CLA, or trans-10, cis-12 CLA have a clinically significant impact on the blood lipoprotein profile. 
5.2.7. Cholesterol 
Weggemans et al. (2001) have reviewed the effects of dietary cholesterol on blood lipids and 
lipoproteins. Based on the results of 17 well-controlled studies involving 556 subjects, it was found 
that the addition of 100 mg dietary cholesterol per day increased total cholesterol concentrations by 
0.056 mmol/L (95% CI: 0.046, 0.065 mmol/L), LDL cholesterol concentrations by 0.050 mmol/L 
(95% CI: 0.042, 0.058 mmol/L), and HDL cholesterol concentrations by 0.008 mmol/L (95% CI: 
0.005, 0.010 mmol/L). The ratio of total to HDL cholesterol increased by 0.020 units (95% CI: 0.010, 
0.030). When studies were divided into two groups based on the polyunsaturated-to-saturated fat ratio 
(P/S-ratio), the response in LDL cholesterol was 0.036 mmol/L for studies with a background diet 
characterised by a low P/S ratio (<0.7) and 0.061 mmol/L for studies with a high P/S ratio (>0.7). The 
fatty acid composition of the background diet did not affect responses of blood HDL cholesterol 
concentrations or the ratios of total to HDL cholesterol. 
5.2.8. Conclusion 
Under iso-energetic conditions, the most favourable lipoprotein profile to lower atherosclerotic risk is 
achieved when a mixture of SFA and TFA is replaced by a mixture of oleic acid, linoleic acid and n-3 
LCPUFA. These effects are dose-dependent. The various SFA may also differ in their effects on the 
blood lipoprotein profile. In particular, the effects of stearic acid may be less disadvantageous than 
those of myristic and palmitic acids. However the available data are insufficient to set different DRVs 
for different SFA. 
5.3. Haemostatic function 
Haemostatic function is a complex interplay of many processes such as endothelial function, platelet 
aggregation, coagulation and fibrinolysis. Each of these processes is determined by many different 
factors. This complex interplay illustrates that haemostatic function cannot be described by one single 
factor, which complicates dietary studies in this area. A further complication is that many different 
approaches exist to measure these factors and no single method exists to evaluate all aspects of 
haemostatic function.  
5.3.1. Total fat 
The effects of total fat intake on haemostatic profiles are conflicting. Overall, however, it appears that 
high-fat diets increase factor VII activity or levels, which are positively related to cardiovascular risk 
(Vorster et al., 1997; Thijssen and Mensink, 2005). Due to the different methods to measure factor 
VII, it is not possible to quantify these effects. 
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5.3.2. Saturated fatty acids (SFA) 
From an extensive review of the literature, it was concluded that SFA with 12 to 16 carbon atoms 
might increase factor VII levels as compared to stearic acid. It was emphasised however that studies 
were far from consistent. For other factors involved in the coagulation or fibrinolytic pathway, or in 
platelet aggregation, no consistent patterns have emerged (Miller, 2005; Thijssen and Mensink, 2005). 
5.3.3. Cis-monounsaturated fatty acids (cis-MUFA) 
In two studies, Berry et al. (2007a, 2007b) compared the acute effects of a sunflower oil high in oleic 
acid with those of palm oil and shea butter - rich in the SFA stearic acid - on postprandial factor VII 
levels. It was found that both oils rich in saturated fatty acids resulted in lower postprandial factor VII 
concentrations. For oleic acid, no consistent effects on fasting coagulation or fibrinolytic factors or on 
platelet aggregation have been found (Thijssen and Mensink, 2005). 
5.3.4. Polyunsaturated fatty acids (PUFA) 
5.3.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
For linoleic acid, no consistent effects on fasting coagulation or fibrinolytic factors or on platelet 
aggregation have been found (Thijssen and Mensink, 2005). 
5.3.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
For fish oils, no consistent effects on fasting coagulation or fibrinolytic factors have been found 
(Thijssen and Mensink, 2005). For platelet aggregation, results are more consistent. Using various 
outcome parameters, such as ex vivo and in vitro platelet aggregation tests, it has been demonstrated 
that consumption of fish oils reduces the tendency of platelets to aggregate. Effects, however, are only 
consistent at fish oil intakes of more than 1 g per day (Knapp, 1997; Wensing et al., 1999; Thijssen 
and Mensink, 2005). For alpha-linolenic acid, no effects have been reported compared to linoleic acid, 
oleic acid or SFA (Thijssen and Mensink, 2005; Goyens and Mensink, 2006). 
5.3.5. Trans fatty acids (TFA) 
The effects of TFA from hydrogenated sources on haemostatic function have recently been reviewed 
(EFSA, 2004). It was concluded that intervention studies do not provide evidence that TFA from 
hydrogenated oils have an impact on haemostatic function. 
5.3.6. Conjugated linoleic acid (CLA) 
Effects of CLA on haemostatic function have hardly been studied. In one study with 17 healthy 
female volunteers, consumption for 63 days of a diet enriched with a mixture of 3.9 g of CLA isomers 
did not affect in vivo bleeding time, in vitro platelet aggregation, the prothrombin time, activated 
partial thromboplastin time, and the antithrombin III levels when compared with sunflower oil. The 
four major isomers in the mixture used were: cis-9, trans-11 CLA (17.5% of total CLA), trans-8, cis-
10 CLA (16.6%), cis-11, trans-13 CLA (23.5%), trans-10, cis-12 CLA (22.6%) (Benito et al., 2001). 
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5.3.7. Conclusion 
No consistent picture has emerged of the effects of SFA, MUFA, TFA, and n-6 PUFA on haemostatic 
function. An exception may be the n-3 LCPUFA, which may decrease platelet aggregation in 
particular at daily intakes above 1 g. Dose-response relationships, however, cannot be ascertained. 
5.4. Inflammation and immune function  
Like haemostatic function, inflammation and immune function include numerous processes and many 
different cell types, which make it impossible to identify one single marker that describes the 
inflammatory or immune status of the human body. 
5.4.1. Saturated fatty acids (SFA), cis-monounsaturated fatty acids (cis-MUFA), n-6 
polyunsaturated fatty acids (n-6 PUFA) 
Based on prospective cohort studies and intervention studies, Kontogianni et al. (2006) concluded that 
SFA might increase plasma concentrations of inflammatory markers, but that results are far from 
consistent. For cis-MUFA, results were also not consistent. 
5.4.1.1. n-3 polyunsaturated fatty acids (n-3 PUFA) 
The effects of n-3 PUFA on blood markers of low-grade systemic inflammation and immune function 
have been the focus of many reviews. Balk et al. (2006) concluded that the evidence regarding the 
effects of n-3 PUFA from both animal and vegetable origin on high-sensitivity C-reactive protein (hs-
CRP) are inconclusive. Calder (2006) also concluded that ALA did not exert anti-inflammatory 
effects at realistic dietary intakes (up to 10g/day) in contrast to Giugliano et al. (2006). For fish oil it 
was concluded that n-3 LCPUFA are potentially potent anti-inflammatory agents. Many studies 
however have been carried out at intakes exceeding >1 up to 2 g per day, which limits the practical 
implications of these findings. Also, it was emphasised that larger trials are required to assess the 
therapeutic potential of n-3 LCPUFA in inflammatory diseases. Finally, Fritsche (2006) concluded 
that most studies – possibly because they were underpowered - failed to demonstrate an effect of n-3 
LCPUFA on the production of pro-inflammatory cytokines.  
5.4.2. Trans fatty acids (TFA) 
Reviews of epidemiologic studies have suggested that adverse effects of TFA from hydrogenated 
sources were related with some - but not all - inflammatory markers (Mozaffarian et al., 2006; 
Gebauer et al., 2007). Results from dietary intervention studies have inconsistently revealed similar 
effects (Lichtenstein et al., 2003).  
5.4.3. Conjugated linoleic acid (CLA) 
There is no evidence from human studies that at habitual intakes CLA has beneficial or detrimental 
effects on inflammation or immune function. At extreme high intakes (>3 g per day), trans-10, cis-12 
CLA may have unwanted effects in obese men on plasma pro-inflammatory markers (Risérus et al., 
2002). 
5.4.4. Conclusion 
No consistent picture has emerged on the effects SFA, MUFA, CLA and n-6 PUFA on parameters 
related to inflammation and immune function. There are indications that n-3 LCPUFA from fish oil 
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may have beneficial effects, but results between studies are not consistent. In contrast, TFA from 
hydrogenated sources may have adverse effects on the inflammatory profile. Clear dose-response 
relationships have, however, not been established. 
5.5. Blood pressure 
5.5.1. Total fat 
According to a meta-analysis of studies carried out in subjects with a body mass index of at least 
25 kg/m
2
, it appeared that after 12 months total fat intake did not affect blood pressure (Nordmann et 
al., 2006).  
5.5.2. Saturated fatty acids (SFA) 
Effects of SFA on blood pressure have been mainly studied in comparison with those of linoleic acid. 
In these studies, however, no specific effects of linoleic acidwere identified (Pietinen, 1994). 
5.5.3. Cis-monounsaturated fatty acids (cis-MUFA) 
Shah et al. (2007) published the results of a meta-analysis of ten intervention studies comparing high-
carbohydrate and high-cis-MUFA diets on blood pressure. It was reported that the diets rich in 
carbohydrate resulted in significantly higher systolic blood pressure (2.6 mm Hg, 95% CI: 0.4, 
4.7 mm Hg) and diastolic blood pressure (1.8 mm Hg, 95% CI: 0.0, 3.6 mm Hg). When the analysis 
was limited to the six randomised crossover studies, differences between the diets no longer reached 
statistical significance. It was, therefore, concluded that diets rich in carbohydrate might be associated 
with slightly higher blood pressure than diets rich in cis-monounsaturated fat. However, the difference 
– if any – is small and does not justify recommendations to increase the intake of cis-MUFA at the 
expense of carbohydrates to manage blood pressure. 
5.5.4. Polyunsaturated fatty acids 
5.5.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)  
There is no convincing evidence that linoleic acid positively influences blood pressure (see also SFA). 
5.5.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA)  
In a recent meta-analysis (Geleijnse et al., 2002), the effects of fish oil on reducing blood pressure 
were estimated from randomised trials. The median intake of fish oil (mainly EPA and DHA) was 
3.7 g per day. It was found that fish oil reduced systolic blood pressure on average by 2.1 mmHg and 
diastolic blood pressure by 1.6 mmHg. When the analyses were limited to double-blind trials, 
reductions of 1.7 mmHg and 1.5 mmHg were reported. Effects appeared to be larger in populations 
that were older (> 45 years) or hypertensive, while no dose response relationship of fish oil intake 
with change in blood pressure was observed. It was further mentioned that the antihypertensive effect 
of lower doses of fish oil (< 0.5 g per day) remained to be established. 
5.5.5. Trans fatty acids (TFA) 
Effects of TFA from hydrogenated oils on blood pressure have been examined in only a few trials 
with normotensive, healthy subjects. When compared with SFA, oleic acid or linoleic acid, no effects 
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of trans-MUFA on systolic or diastolic blood pressure were found (EFSA, 2004). Recently, it was 
also reported that a daily intake of 3.6 g of TFA from milk fat for 5 weeks did not change blood 
pressure and isobaric arterial elasticity (Raff et al., 2006). 
5.5.6. Conjugated linoleic acid (CLA) 
Effects of CLA on blood pressure have hardly been studied. In one study with healthy young men, it 
was however shown that a daily intake of 4.7 g of a mixture containing equal amounts of cis-9, trans-
11- and trans-10, cis-12 CLA isomers for 5 weeks did not affect blood pressure and isobaric arterial 
elasticity (Raff et al., 2006). 
5.5.7. Conclusion 
n-3 LCPUFA from fish oil and other sources may have a slight beneficial effect on blood pressure, 
especially at higher intakes (>0.5 g per day). For other fatty acids, there is no convincing evidence 
that they affect blood pressure. 
5.6. Glucose tolerance and insulin sensitivity 
5.6.1. Total fat 
There is some evidence that high-fat diets decrease insulin sensitivity, although the available data are 
not consistent (IoM, 2005). In the KANWU-study, for example, the adverse effect of SFA on insulin 
sensitivity was not evident when total fat intake exceeded 37 E% (Vessby et al., 2001). This may 
suggest that at these intakes total fat intake overruled effects of SFA on insulin sensitivity. 
Westerbacka et al. (2005) found in 10 obese women that increasing total fat intake from 16 to 56 E% 
for 2 weeks decreased insulin sensitivity.  
5.6.2. Saturated fatty acids (SFA), cis-monounsaturated fatty acids (cis-MUFA), n-6 
polyunsaturated fatty acids (n-6 PUFA) 
In 2004, Riccardi et al. (2004) have published a review on the effects of dietary fatty acids in relation 
to insulin sensitivity. It was concluded that in most intervention studies no effects were found of SFA 
versus unsaturated fatty acids. It was emphasised, however, that most studies were performed in very 
small groups of subjects and for a short period of time. In fact, in one of the largest trials in this field 
(the KANWU study), it was found that SFA might impair insulin-sensitivity when compared with cis-
MUFA, but only when total fat intake was below 37 E% (Vessby et al., 2001). Noteworthy, 
Lichtenstein et al. (2003) did not observe a consistent pattern between fatty acid intake with fasting 
glucose or insulin concentrations or with the HOMA-index, a marker for insulin resistance. 
5.6.3. n-3 polyunsaturated fatty acids (n-3 PUFA)  
In the KANWU study, fish oil had no effect on insulin-sensitivity (Vessby et al., 2001). Griffin et al. 
(2006) also found no effects of four different diets providing 6% of energy as PUFAs with an n-6:n-3 
ratio between 5:1 and 3:1 as compared with a control diet with a n-6:n-3 ratio of 10:1. The diets were 
enriched with alpha-linolenic acid, EPA, or DHA, or all three fatty acids. The diets were provided for 
six months. Insulin sensitivity was assessed with the homeostatic model assessment of insulin 
resistance and the revised quantitative insulin sensitivity test. Brady et al. (2004) did also not observe 
any effects of a daily supplement of 4 g of fish oil for six weeks on insulin sensitivity in Indian 
Asians. Insulin sensitivity was assessed by using the frequently sampled intravenous glucose tolerance 
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test with minimal model analyses. In contrast, another study suggested that in overweight women a 
daily supplement of 5 g of fish oil for 12 weeks improved insulin sensitivity as measured by an 
OGTT, but only in females with a high inflammatory status at baseline (Browning et al., 2007).  
5.6.4. Trans fatty acids (TFA) 
Effects of TFA from hydrogenated sources on insulin-sensitivity have been recently reviewed. It was 
concluded that intervention studies may suggest that - at extreme high intakes - TFA may have the 
same effects on postprandial insulinaemia in obese subject with type 2 diabetes as do SFA. At lower 
intakes, TFA did not adversely affect insulin sensitivity of healthy volunteers (EFSA, 2004; Risérus, 
2008). 
5.6.5. Conjugated linoleic acid (CLA) 
Several studies have examined the effects of CLA on plasma glucose and insulin concentrations. In 
only a few studies, insulin resistance was measured using the gold standard euglycaemic-
hyperinsulinaemic clamp technique.  
Using a euglycaemic-hyperinsulinaemic clamp, Risérus et al. (2002) concluded that a daily 
supplement of 3.4 g trans-10, cis-12 CLA increased insulin-resistance by 19% in obese men with 
signs of the metabolic syndrome. In another study with abdominally obese men (Risérus et al., 2004), 
daily consumption of 3 g cis-9, trans-11 CLA increased insulin resistance by 15%. On the other hand, 
Syvertsen et al. (2007) reported no effects on insulin resistance in overweight and obese men and 
women of a daily consumption of 3.4 g of a mixture of CLA isomers, composed of 37.5% cis-9, trans-
11 and 38% trans-10, cis-12 CLA. Risérus et al. (2004) also found no effect on insulin resistance of a 
CLA mixture, composed of cis-9, trans-11 and trans-10, cis-12 CLA in similar proportions. Also, 
results of studies that measured fasting glucose and insulin concentrations or used an OGTT to assess 
insulin-sensitivity are conflicting. Tricon et al. (2004) found no effects of dairy products naturally 
enriched with cis-9, trans-11 CLA (1.4 g per day for six weeks) on fasting glucose and insulin 
concentrations. Naumann et al. (2006) also concluded that consumption for 13 weeks of 3 g per day of 
either cis-9, trans-11 or trans-10, cis-12 CLA did not affect fasting glucose or insulin concentration in 
volunteers with LDL phenotype B. In contrast, Lambert et al. (2007) recently reported that 
supplementation for 12 weeks of 3.9 g per day of a mixture of CLA isomers, mainly cis-9, trans-11 
and trans-10, cis-12 CLA in similar proportions, improved insulin sensitivity as measured with an 
OGTT in non-obese, regularly exercising women. A sunflower oil high in oleic acid was used as 
control.  
5.6.6. Conclusion 
The limited number of human intervention studies in non-diabetic subjects does not provide 
consistent evidence that fatty acids change insulin sensitivity. If anything, SFA intake may impair and 
n-3 PUFA intake may improve insulin sensitivity. In addition, total fat intake may decrease insulin 
sensitivity. Clear dose-response relationships have, however, not been established. 
5.7. Body weight control and energy balance 
5.7.1. Total fat 
The impact of manipulation of the macronutrient content on body weight in the context of weight 
management in overweight and obese subjects may be different from the effects on prevention of 
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weight gain in leaner persons and may depend on whether diets are administered ad libitum or under 
isocaloric conditions.  
In intervention trials with tightly controlled energy intakes and fat intakes ranging from 10 to 78 E%, 
energy expenditure, weight loss and weight maintenance are a function of energy intake rather than of 
the macronutrient composition of the diet (IoM, 2005; van Dam and Seidell, 2007; Nordman et al., 
2006; Sacks et al., 2009). However, even in such studies, reduced fat diets (<35 E%) tend to be 
hypocaloric when compared to reduced carbohydrate diets (<50 E%) and enhance compliance with 
energy restriction, leading to slightly greater weight loss (IoM, 2005; van Dam and Seidell, 2007).  
Several randomised intervention studies suggest that reduced-fat (< 25 to 30 E%) diets consumed ad 
libitum have the potential to prevent weight gain in normal weight subjects and produce weight loss in 
overweight (BMI >25kg/m
2
) individuals as compared to higher fat diets (> 35 E%) (IoM, 2005). In 
some long-term (>1 year) intervention studies, dietary modifications with a shift from a habitual 
Western-type, high fat (35 to 40 E%), to fat-reduced (<30 E%) diets consumed ad libitum were 
associated with a reduced risk of weight gain or a moderate weight loss in various population groups 
including normal, overweight and obese subjects (IoM, 2005; Howard et al., 2006a; Lanza et al., 
2001).  
Foods containing high amounts of fat tend to be energy dense, and evidence suggests that consuming 
diets of high energy density can undermine normal appetite regulation leading to increased overall 
energy intake through „passive overconsumption‟ of food and can result in weight gain (WHO/FAO, 
2003; IoM, 2005). 
Overall, diets with <35 E% fat may provide some advantages over diets with >35 E% fat in medium-
term weight reduction and long-term prevention of weight gain. 
5.7.2. Saturated fatty acids (SFA), cis-monounsaturated fatty acids (cis-MUFA), n-6 
polyunsaturated fatty acids (n-6 PUFA) 
Increasing the intake of oleic acid from 13.1 E% to 31.4 E% while decreasing the intake of palmitic 
acid from 8.4 E% to 1.7 E% for four weeks in a group of healthy non-obese adults resulted in a 
223 kcal higher daily energy expenditure than a change from 8.4 E% to 16.8 E% palmitic acid plus a 
change from 13.1 E% to 16.4 E% oleic acid in another group for the same duration (Kien et al., 2005). 
Piers et al. (2003) also concluded that increasing the intake of cis-MUFA and cis-PUFA by 13 E% at 
the expense of SFA for four weeks had a beneficial effect on body mass in overweight and obese men. 
Schirmer and Phinney (2007) reported that a daily intake of 890 mg per day of -linolenic acid 
(provided by 5 g borage oil) for 1 year reduced weight regain in formerly obese subject. Olive oil was 
used as control.  
5.7.3. n-3 polyunsaturated fatty acids (n-3 PUFA)  
Hill et al. (2007) have studied the individual and combined effects of n-3 PUFA supplements in 
addition to the usual diet and regular exercise on body composition. Overweight volunteers consumed 
daily for 12 weeks 6 g tuna oil (approximately 1.9 g n-3 LCPUFA) or 6 g sunflower oil, with or 
without an exercise intervention. It was concluded that fish oil reduced body fat mass when compared 
with sunflower oil. Couet et al. (1997) have reported similar results for lean subjects when daily fish 
oil intake was increased for three weeks by 6 g at the expense of visible fats in the usual diet. 
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5.7.4. Trans fatty acids (TFA) 
In a prospective cohort study in 16,587 men, Koh-Banerjee et al. (2003) found that each 2 E% 
increase in TFA intake was associated with a 0.77 cm waist gain over 9 years, when isocalorically 
substituted for either PUFA or carbohydrates. 
5.7.5. Conjugated linoleic acid (CLA) 
CLA isomers have been extensively studied as potential modulators of body composition and body fat 
mass. In a recent meta-analysis of 18 clinical studies, Whigham et al. (2007) reported that the effect of 
CLA supplementation on the loss of fat mass is modest. It was estimated that supplementation with 
3.2 g CLA reduced fat mass by 0.09 kg per week. In a 1-year study, it was found that a daily 
consumption of 3.5 g CLA isomers containing equal amounts of cis-9, trans-11- and trans-10, cis-12 
CLA isomers decreased fat mass by approximately 2 kg. This effect was already achieved after six 
months (Gaullier et al., 2004). The reduction in fat mass appears to be located mainly in the legs 
(Gaullier et al., 2007), which is not considered as the metabolically active fat region. Although animal 
studies have suggested that trans-10, cis-12 CLA is the most active CLA isomer, this conclusion 
cannot be drawn from the limited number of human studies that have been carried out with single 
isomers (Wigham et al., 2007). It needs to be emphasised that CLA intakes in these studies exceed by 
far those that can be achieved with normal diets. 
5.7.6. Conclusion 
Short to medium-term (up to 1 year) and long-term intervention studies provide evidence that a 
moderate fat intake (<35 E%) is associated with reduced energy intake and therefore moderate weight 
reduction or prevention of weight gain. 
Some studies may suggest that SFA decreases energy expenditure as compared with cis-unsaturated 
fatty acids, but more studies - especially at lower intakes – are needed to extend these observations. 
From human studies, there is no evidence that, at habitual intakes n-3 PUFA, TFA, and CLA have a 
discernable impact on energy balance.  
5.8. Cardiovascular disease 
5.8.1. Total fat, saturated fatty acids (SFA), cis-monounsaturated fatty acids (cis-MUFA), 
n-6 polyunsaturated fatty acids (n-6 PUFA) 
A review of three dietary intervention studies has shown that decreasing the intakes of products rich 
in SFA plus cholesterol at the expense of products rich in linoleic acid and alpha-linolenic acid, and 
low in cholesterol, decreased the number of cardiovascular deaths (Sacks and Katan, 2002). No such 
effects were seen in a fourth study. Overall, these intervention trials strongly suggest that diet-induced 
changes in blood total cholesterol concentrations are causally related to changes in cardiovascular 
risk. Noteworthy, in these studies, total fat intake was hardly changed. In three other intervention 
trials, the reduction of total fat intake, in particular of saturated fat, and the increase in the 
consumption of carbohydrate-rich foods, did not significantly reduce the risk of cardiovascular 
disease. However, it cannot be excluded that the duration, compliance, and sample sizes may have 
been insufficient to demonstrate a reduction in coronary events. In the Health Professional follow up 
study, no relationships between total fat intake or intake of SFA, cis-MUFA, and n-6 PUFA with risk 
of stroke have been reported (He et al., 2003). Also, in the Women's Health Initiative Dietary 
Modification Trial a dietary intervention that reduced total fat intake and increased intakes of 
vegetables, fruits, and grains did not significantly reduce the risk of cardiovascular disease (Howard et 
al., 2006b). 
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5.8.2. n-3 polyunsaturated fatty acids (n-3 PUFA)  
He et al. (2004a) carried out a meta-analysis of cohort studies to examine the association between fish 
intake and CHD mortality. Results indicated that fish consumption was inversely associated with fatal 
CHD. Compared with subjects who never consumed fish or consumed fish less than once per month, 
the multivariate relative risk (RR) for CHD mortality were 0.89 (95% CI, 0.79 to 1.01) for fish intake 
1 to 3 times per month, 0.85 (95% CI, 0.76 to 0.96) for once per week, 0.77 (95% CI, 0.66 to 0.89) for 
2 to 4 times per week, and 0.62 (95% CI, 0.46 to 0.82) for 5 or more times per week. Each daily 
increase in fish intake of 20 g was related to a 7% lower risk of CHD mortality. Comparable 
conclusions were drawn when stroke was considered as endpoint (He et al., 2004b). It should be noted 
that in these two studies, relationships with fish intake were examined and not with n-3 LCPUFA.  
Bucher et al. (2002) explored the relationship between the intake of dietary (from fish) and 
supplemental n-3 LCPUFA on CHD using data from randomised controlled trials. The risk ratio in 
patients who were on n-3 LCPUFA-enriched diets was 0.8 (95% CI, 0.5 to 1.2) for nonfatal 
myocardial infarction, 0.7 (95% CI, 0.6 to 0.8) for fatal myocardial infarction, 0.7 (95% CI, 0.6 to 0.9) 
for sudden death, and 0.8 (95% CI, 0.7 to 0.9) for overall mortality compared to those on control diets 
or placebo. Results did not differ between dietary and supplemental interventions. No dose-response 
relationships were reported.  
Based on a meta-analysis of randomised trials and large prospective studies, Mozaffarian and Rimm 
(2006) reported that the intake of EPA plus DHA is negatively related to cardiovascular risk in a dose-
dependent way. Intakes of 250 mg per day of EPA and DHA appeared to be sufficient for primary 
prevention in healthy adults. Recently, Harris et al. (2008) also conducted a meta-analysis based on 
six epidemiological studies in the United States. Results showed a continuous significant dose-
response relationship between the intake of EPA plus DHA up to 500 mg per day and the risk of death 
from CHD. In addition, observational studies, randomised clinical trials and experimental studies 
provide evidence that modest consumption of fish or fish oil (1–2 servings/wk of oily fish, or approx. 
250 mg per day of EPA plus DHA) reduces the risk of coronary heart disease and sudden cardiac 
death (Mozzafarian, 2008). 
Wang et al. (2006) also concluded from a systematic review of the literature that increased 
consumption of n-3 LCPUFA from fish or fish-oil supplements, but not of alpha-linolenic acid, 
reduces the rates of all-cause mortality, cardiac and sudden death, and possibly stroke. Effects 
appeared to be stronger in secondary than in primary prevention settings. Adverse effects were minor. 
In contrast, based on a meta-analysis that included both randomised controlled trials and cohort 
studies, Hooper et al. (2006) concluded that dietary or supplemental n-3 PUFA had no effect on 
cardiovascular events in subjects at risk or in the general population. For many reasons, however, 
their approach has been criticised by other authors (Twisselmann, 2006). Virtanen et al. (2008) also 
reported that fish consumption was associated with a lower risk of total cardiovascular disease, a 
relationship that was not modified by the intake of n-6 PUFA. 
Mozaffarian et al. (2005) reported that fish oil significantly reduced heart rate, particularly in those 
with higher baseline heart rate or longer intervention duration. This conclusion was based on a meta-
analysis of thirty randomised controlled trials in humans. No evidence was present for a dose-
response effect. Brouwer et al. (2006) did not observe any beneficial effects of a daily supplement of 
2 g of fish oil on ventricular tachyarrhythmia or death in patients with implantable cardioverter-
defibrillators and prior documented malignant ventricular tachycardia or ventricular fibrillation. 
Results for alpha-linolenic acid are less consistent. Brouwer et al. (2004) reported that increasing 
intake of alpha-linolenic acid by 1.2 g per day decreased the risk of fatal coronary heart disease by at 
least 20%. Wang et al. (2006), however, found no evidence that alpha-linolenic acid reduced the rates 
of all-cause mortality, cardiac and sudden death, and possibly stroke. 
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5.8.3. Trans fatty acids (TFA) 
As already reviewed (EFSA, 2004; Mozaffarian and Clarke, 2009), results from a number of 
prospective cohort studies consistently support the findings from intervention studies for an 
association between higher intakes of TFA and increased risk of CHD. The available evidence is 
insufficient to establish whether there is any difference between ruminant and industrially produced 
TFA consumed in equivalent amounts and risk of CHD.   
5.8.4. Cholesterol 
In 2003, Hu and Willett (2002) reviewed the literature and concluded that there was no strong 
evidence that dietary cholesterol and modest egg consumption (1 egg per day) were related with either 
CHD or stroke. However, it was estimated that the relative risk for cardiovascular disease for each 
increase in the intake of dietary cholesterol of 200 mg / 1000 kcal was 1.37 (95% CI: 1.12 to 1.68) 
(Tanasescu et al., 2004). Djousse and Gaziano (2008) reported that in the 21,275 participants from the 
Physicians' Health Study I, the hazard ratio for incident heart failure was 1.28 (95% CI: 1.02 to 1.61) 
for men who consumed daily one egg and 1.64 (95% CI: 1.08 to 2.49) for those who consumed 2 or 
more eggs a day. Below these intakes, no associations were reported. In the Nurses' Health Study 
cohort, however, cholesterol intake was not related to intraparenchymal hemorrhages (Iso et al., 
2001). For stroke, no relationship with cholesterol intake was found in male US healthcare 
professionals (He et al., 2003). 
5.8.5. Conclusion 
From intervention and epidemiological prospective cohort studies, it can be concluded that the fatty-
acid composition of the diet is an important determinant of cardiovascular risk. Decreasing the intake 
of SFA and TFA, and increasing the intake of fish oil, lower cardiovascular risk. Alpha-linolenic acid 
may also have a specific beneficial effect, but more intervention studies, specifically designed to look 
at the cardioprotective effects of this fatty acid, are needed. Available data on the relationship 
between cholesterol intake and risk of cardiovascular disease are inconsistent at current levels of 
intake. 
5.9. Type 2 diabetes mellitus  
5.9.1. Total fat, saturated fatty acids (SFA), cis-monounsaturated fatty acids (cis-MUFA), 
and n-6 polyunsaturated fatty acids (n-6 PUFA) 
In the Nurses Health Study, no effects were found of total fat, SFA, and cis-MUFA intakes vs. those 
of an isocaloric amount of energy from carbohydrates on the risk to develop type 2 diabetes mellitus. 
However, for a 5 E% increase of linoleic acid intake, the RR was 0.63 (95% CI, 0.53 to 0.76) 
(Salmerón et al., 2001). In contrast, the Iowa Women‟s Health Study only found some suggestions for 
an inverse relationship between PUFA and vegetable fat intake with the incidence of type 2 diabetes, 
but not with any type of fatty acids or with animal fat (Meyer et al., 2001). In the Health Professionals 
Follow-up Study, no relationships were observed for men between total fat or fatty acid intake and the 
risk of type 2 diabetes. Relationships with vegetable or animal fat intake were also not statistically 
significant (Van Dam et al., 2002). 
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5.9.2. n-3 polyunsaturated fatty acids (n-3 PUFA)  
Salmeron et al. (2001) reported that in the Nurses Health Study EPA plus DHA intake was inversely 
related to the risk to develop type 2 diabetes mellitus. In two other studies, however, no effects of n-3 
PUFA were reported (Meyer et al., 2001; Van Dam et al, 2002). 
5.9.3. Trans fatty acids (TFA) 
In the Nurses Health Study a positive relationship was observed between the intake of TFA and the 
risk of development of type 2 diabetes. These effects were primarily observed in obese women, which 
may be explained by the fact that these women were already more insulin resistant at the start of the 
study compared with non-obese women (Salmeron et al., 2001). In other studies, however, such 
relationships were not reported (Meyer et al., 2001; van Dam et al., 2002). 
5.9.4. Cholesterol 
Meyer et al. (2001) found a positive relationship between the intake of cholesterol and the incidence 
of type 2 diabetes mellitus. At a median daily intake of 382 mg, the RR was 1.17 (95% CI, 1.01 to 
1.37). Results were not corrected for intakes of fatty acids. Salmeron et al. (2001) reported that each 
increase of 100 mg dietary cholesterol/1000 kcal was associated with a 12% increased risk of type 2 
diabetes mellitus, when results were adjusted for differences in the intakes of fatty acids. 
5.9.5. Conclusion 
Epidemiological prospective cohort studies have not found consistent relationships between total fat 
intake, the intake of specific fatty acids or cholesterol with the risk to develop type 2 diabetes 
mellitus. 
5.10. Cancer  
A large number of studies have examined the link between total fat, SFA, MUFA, n-3 and n-6 
LCPUFA, TFA and other specific fatty acid intakes and the occurrence of cancers. In its last report, 
the World Cancer Research Foundation (WCRF/AICR, 2007) found however that only few suggestive 
relationships could be established between the intake of total fat and/or fat-containing foods and the 
risk of cancer.  
There is limited evidence suggesting that high total fat intakes may increase the risk of breast 
(postmenopausal) cancer. Schulz et al. (2008) confirmed the positive association between total fat 
intake and incidence of breast cancer in the EPIC-Potsdam study (HR 2.34, 95% CI 1.45-3.79, p for 
trend 0.0004 for the highest compared to the lowest tertile of a simplified food pattern score. This 
score is positively associated with total dietary fat and all fatty acid fractions. Total fat intake was 
31.15 E% for the first tertile and 39.2 E% for the highest tertile, after adjustment for confounders). 
Similar conclusions were reached in other studies (Prentice et al., 2006; Chlebowski et al., 2006; 
Borugian et al., 2004; McEligot et al., 2006). Total fat intake has also been associated with higher risk 
of lung cancer.  
Saturated fat intakes appear to be positively associated with breast cancer risk (Boyd et al., 2003; 
Bingham et al., 2003; Cho et al., 2003; Thiebaut et al., 2007; Sieri et al., 2008). Results from the EPIC 
cohort in Cambridge show that, using dietary data from diaries, a daily intake of around 35 g SFA 
doubles the risk of breast cancer in comparison to daily intakes of 10 g or less (Gonzalez, 2006). No 
significant association was found between the intake of either SFA, total fat or any subtype of fat and 
the risk of prostate cancer (Crowe et al., 2008). 
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Trans fatty acids (Maillard et al., 2002) and more specifically trans-MUFA (Chajès et al., 2008) have 
been also strongly associated with an increased risk of breast cancer.  
Finally, the consumption of certain food items has also been associated with cancer risk. For example, 
butter consumption is associated with an increased risk of lung cancer, whereas the consumption of 
foods containing animal fat has been associated with an increased risk of colorectal cancer 
(WCRF/AICR, 2007). Conversely, consumption of fish (WCRF/AICR, 2007; Geelen et al., 2007; Hall 
et al., 2008) and olive oil (Stoneham et al., 2000; Rouillier et al., 2005; Galeone et al., 2007) appear to 
decrease the risk of colorectal cancer. However, these associations cannot be attributed to specific 
fatty acids. 
5.10.1. Conclusion 
For many specific fatty acids, results from prospective cohort studies are still too limited, and 
sometimes contradictory, to conclude on clear associations between their intakes and the risk of a 
particular type of cancer. The Panel concludes that at present the evidence is not sufficient to define a 
DRVs for total fat or specific fatty acids based on cancer outcomes.  
5.11. Nervous system function 
In the first months of life, lipids, besides energy, also supply structural components for the anatomical 
and functional development of the brain and the nervous system. DHA in functional areas of the brain 
is higher in breastfed infants than in infants fed formulas devoid of DHA (Farquharson et al., 1992; 
Makrides et al., 1994). The DHA content of tissues and brain has been associated with higher 
developmental scores observed in breastfed compared to formula-fed infants and this effect may be 
modulated by the individual genetic polymorhisms leading to DHA synthesis (Caspi et al., 2007).  
Within breastfed infants, DHA status at birth and maternal DHA intake in pregnancy are inter-
connected and are associated with the infants‟ developmental performance (Helland et al., 2003; 
Dunstan et al., 2008; Innis, 2007). Results from trials in formula fed infants are more divergent, and 
could be partly related to un-investigated covariates such as infants‟ DHA status at birth and the 
individual genetic background (Simmer et al., 2008). 
DHA supplementation through the complementary feeding period seems still effective in improving 
the neuro-functional and visual performance (Birch et al., 2007; Agostoni et al., 2009). Section 5.1.2.2 
reports indications on the levels of preformed DHA in the diet of infants. While 20 mg per day seem 
to represent the lowest limit of intake in the first six months through human milk (Marangoni et al, 
2000) and may partly affect the timing of developmental milestones in the first 12 months (Agostoni 
et al., 2009), 50 to 100 mg per day have been found effective for the visual function during the 
subsequent complementary feeding period (Birch et al., 2007; EFSA 2009). 
5.12. Cognitive decline and dementia  
There is some evidence from cross-sectional and prospective observational studies for an inverse 
association between dietary and supplemental intake of n-3 LCPUFA and the risk of cognitive 
decline, dementia, and Alzheimer disease (Lim et al., 2006; Issa et al., 2006). Available observational 
studies are more consistent in reporting benefits of n-3 LCPUFA on cognitive decline in elderly 
individuals without dementia than in the incidence of dementia or Alzheimer disease (Fothui et al., 
2009). The few clinical trials available do not provide convincing evidence for an effect of n-3 
LCPUFA in the prevention or treatment of any form of dementia (Fothui et al., 2009) and most recent 
systematic reviews agree that available data are insufficient to draw firm conclusions on the role of n-
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3 LCPUFA on cognitive function in normal aging or on the incidence of dementia, including 
Alzheimer disease (Cederholm and Palmblad, 2010; Cole et al., 2009).  
The Panel concludes that the evidence available is not sufficient to define a DRV for n-3 LCPUFA 
based on cognitive decline or dementia outcomes. 
6. Key data on which to base Dietary Reference Values  
It should be emphasised that Dietary Reference Values for macronutrients - which are expressed as 
E% - are mutually dependent, because the sum of the separate recommendations is 100%. Thus, a 
change in the recommendation for one of the macronutrients is necessarily accompanied by a change 
in the recommendation of at least one of the other energy-providing macronutrients. Similarly, 
reference values for the separate classes of fatty acids are mutually dependent, as the sum equals total 
fat intake. An exception may be the n-3 LCPUFA and cholesterol for which reference intakes are 
usually expressed in mg per day. Recommendations for dietary cholesterol – if any – are also 
expressed in mg/MJ or mg per day. 
6.1. Total fat 
Fat is an important dense source of energy and facilitates the absorption of fat-soluble dietary 
components such as vitamins. Fats and oils are in themselves important sources of these components 
and of EFA. High-fat diets may decrease insulin-sensitivity. Also, fat intake is positively associated 
with changes in fasting and postprandial factor VII, which may increase cardiovascular risk. However, 
no unequivocal conclusions can be drawn and effects cannot be quantified. Short to medium-term (up 
to one year) and long-term intervention studies provide evidence that a moderate fat intake (<35 E%) 
is accompanied by a reduced energy intake and therefore moderate weight reduction or prevention of 
weight gain. The available data do not permit to establish dose-response relationships. The Panel, 
therefore, comes to the conclusion that only a Reference Intake range can be given for total fat intake, 
partly based on practical considerations (e.g. current levels of intake, achievable dietary patterns). At 
the lowest observed intake of total fat in European countries (20 E%) no overt signs of deficiencies 
have been observed neither adverse effects on blood lipids. Total fat intakes > 35 E% may be 
compatible with both good health and normal body weight depending on dietary patterns and the level 
of physical activity. The Panel proposes to set for adults a lower bound of the Reference Intake range 
of 20 E% and an upper bound of 35 E%.  
Fat intake in infants can gradually be reduced in the second half of the first year of life, from the start 
of the complementary feeding period up to three years of age: 40 E% in the 6 to 12 month period and 
35 to 40 E% in the 2
nd
 and 3
rd
 year of life. Fat intakes below 25 E% have been associated with low 
vitamin levels in some young children. For children above the age of three years the RI for adults 
applies. 
6.2. Saturated fatty acids (SFA) 
SFA are synthesised by the body and are not required in the diet. Therefore, no PRI, AR, LTI or AI is 
set. 
There is a positive, dose-dependent relationship between the intake of a mixture of SFA and blood 
LDL cholesterol concentrations when compared to carbohydrates. There is also evidence from dietary 
intervention studies that decreasing the intakes of products rich in SFA by replacement with products 
rich in n-6 PUFA (without changing total fat intake) decreases the number of cardiovascular events. 
As the relationship between SFA intake and the increase in blood LDL cholesterol concentrations is 
continuous, no threshold of SFA intake can be defined below which there is no adverse effect. Also 
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no UL can be set as any increase in the intake of a mixture of SFA adversely affects blood LDL 
cholesterol concentrations. 
The four major SFA in the diet (lauric acid, myristic acid, palmitic acid, and stearic acid) may have 
different effects on the blood lipoprotein profile. However, the data available are not sufficient for the 
establishment of DRVs for individual SFA.  
Dietary SFA are provided by all fats and oils, which are also important sources of essential fatty 
acids. Furthermore, a significant proportion of dietary SFA is obtained from animal foods that are 
important sources of vitamins and essential minerals. Thus, there is a limit to which the intake of SFA 
can be lowered without compromising adequacy of intake of essential nutrients and this will vary 
between populations depending on prevailing patterns of food intake. Therefore, the Panel concludes 
that SFA intake should be as low as possible within the context of a nutritionally adequate diet. 
Limiting the intake of SFA should be considered when establishing nutrient goals and 
recommendations. 
The Panel notes that a number of authorities have established nutrient recommendations of SFA for 
individuals below 8 to 10 E% (see Section 4). Typically, these nutrient recommendations reflect a 
judgement of what level of SFA intake is practically achievable within the context of a nutritionally 
adequate diet based on known patterns of intake of foods and nutrients in specific populations. It is 
also noted that the average intake of SFA in adults in many EU Member States exceeds these 
recommendations (see Section 3).  
6.3. Cis-monounsaturated fatty acids (cis-MUFA) 
Cis-MUFA are not nutritionally essential as they can be synthesised from other (saturated) fatty acids 
and from carbohydrates and have no known specific role in preventing or promoting diet-related 
diseases, and are, therefore, not required in the diet. The Panel proposes not to set any DRV for cis-
MUFA. 
6.4. Cis-polyunsaturated fatty acids (cis-PUFA) 
In view of the different metabolic effects of the various dietary cis-PUFA, the Panel proposes not to 
formulate a DRV for the intake of total cis-PUFA. Also, the Panel proposes not to set specific values 
for the n-3/n-6 ratio as there are insufficient data on clinical and biochemical endpoints in humans to 
recommend a ratio independent of absolute levels of intake. 
6.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA)  
Linoleic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is 
therefore an EFA. However, there are not sufficient scientific data to derive an AR, PRI or LTI.  
There is a negative (beneficial), dose-dependent relationship between the intake of linoleic acid and 
blood LDL cholesterol concentrations, while this relationship is positive for HDL cholesterol 
concentrations. In addition, linoleic acid lowers fasting blood triacylglycerol concentrations, when 
compared to carbohydrates. There is also evidence from dietary intervention studies that decreasing 
the intakes of products rich in SFA by a replacement of products rich in n-6 PUFA (without changing 
total fat intake) reduces the number of cardiovascular events. As the relationship between linoleic acid 
intake and the blood lipid profile is continuous, no threshold value of linoleic acid intake can be 
identified below which the risk for cardiovascular events increases.  
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The Panel proposes to set an AI for linoleic acid of 4 E%, based on the lowest estimated mean intakes 
of the various population groups from a number of European countries, where overt linoleic 
deficiency symptoms are not present.  
Arachidonic acid is synthesised by the body from linoleic acid and is therefore not an EFA. Though it 
plays an important role to maintain metabolic integrity, there is no need to define a DRV for 
preformed arachidonic acid. The Panel, therefore, proposes not to set any DRV for arachidonic acid. 
Finally, there is at present no consistent evidence that the intake of any of the n-6 PUFA has 
detrimental effects on health (e.g. in promoting diet-related diseases). The Panel therefore proposes 
not to set an UL for total or any of the n-6 PUFA. 
6.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
Alpha-linolenic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, 
and is therefore an EFA. However, there are not sufficient scientific data to derive an AR. The Panel 
therefore proposes to set an AI for alpha-linolenic acid of 0.5 E%, based on the lowest estimated mean 
intakes of the various population groups from a number of European countries, where overt alpha-
linolenic acid deficiency symptoms are not present. There is no convincing evidence for a further 
positive or negative unique role for alpha-linolenic acid in diet-related diseases. 
The human body can synthesise EPA and DHA from alpha-linolenic acid. Intervention studies have 
demonstrated beneficial effects of preformed n-3 LCPUFA on recognised cardiovascular risk factors, 
such as a reduction of plasma triacylglycerol concentrations, platelet aggregation, and blood pressure. 
These effects were mainly observed at intakes 1g per day, well above levels that were associated 
with lower CVD risk in epidemiological studies. With respect to cardiovascular diseases, prospective 
epidemiological and dietary intervention studies indicate that oily fish consumption or n-3 LCPUFA 
dietary supplements (equivalent to a range of 250 to 500 mg of EPA plus DHA daily) decrease the 
risk of mortality from CHD and sudden cardiac death. An intake of 250 mg per day of EPA plus DHA 
appears to be sufficient for primary prevention in healthy subjects. Therefore, and because available 
data are insufficient to derive an AR, the Panel proposes to set an AI of 250 mg for EPA plus DHA 
based on considerations of cardiovascular health.  
In infants, DHA intakes at levels of 50 to 100 mg per day have been found effective for visual 
function during the complementary feeding period. The Panel proposes an AI of 100 mg for the age 
>6 months to 24 months. 
The currently available data do not permit to define an age specific quantitative estimate of an 
adequate dietary intake of EPA and DHA for children aged 2 to 18 years. However dietary advice for 
children should be consistent with advice (food and nutrient based dietary guidelines, respectively) 
for the adult population (which is 1 to 2 fatty fish meals per wk or ~250 mg of EPA plus DHA per 
day). This intake should also be compatible with an adequate n-3 LCPUFA supply during pregnancy 
and lactation, when 100 to 200 mg additional preformed DHA should be added to the habitual diet to 
compensate for oxidative losses of maternal dietary DHA and accumulation of DHA in body fat of the 
foetus/infant. 
6.5. Trans fatty acids (TFA) 
TFA are not synthesised in the human body to a significant extent, but are also not required in the 
diet. Therefore, no PRI, AR, or AI is set. 
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Consumption of diets containing trans-MUFA, like diets containing mixtures of SFA, increases blood 
total and LDL cholesterol concentrations in a dose-dependent manner, compared with consumption of 
diets containing cis-MUFA or cis-PUFA. Consumption of diets containing trans-MUFA also results 
in reduced blood HDL cholesterol concentrations and increases the total cholesterol to HDL 
cholesterol ratio. The available evidence indicates that TFA from ruminant sources have adverse 
effects on blood lipids and lipoproteins similar to those from industrial sources. Prospective cohort 
studies show a consistent relationship between higher intakes of TFA and increased risk of CHD. The 
available evidence is insufficient to establish whether there is a difference between equivalent 
amounts of ruminant and industrially produced TFA on the risk of CHD. 
Dietary TFA are provided by several fats and oils that are also important sources of essential fatty 
acids and other nutrients. Thus, there is a limit to which the intake of TFA can be lowered without 
compromising the adequacy of intake of essential nutrients. Therefore, the Panel concludes that TFA 
intake should be as low as possible within the context of a nutritionally adequate diet. Limiting the 
intake of TFA should be considered when establishing nutrient goals and recommendations. 
The Panel notes that a number of authorities have established nutrient recommendations of TFA for 
individuals below 1 to 2 E% (see Section 4). Typically, these recommendations reflect a judgement of 
what maximum level of TFA intake is practically achievable within the context of a nutritionally 
adequate diet based on known patterns of intake of foods and nutrients in specific populations. The 
Panel also notes that the average intake of TFA in adults in the EU has decreased considerably over 
recent years (see Section 3).  
6.6. Conjugated linoleic acid (CLA) 
There is no convincing evidence that any of the CLA isomers in the diet play a role in prevention or 
promotion of diet-related diseases. The Panel, therefore, proposes not to set any DRV for CLA. 
6.7. Cholesterol 
Cholesterol is sufficiently synthesised by the body and is not required in the diet. Therefore, no PRI, 
AR, or AI is set. 
Although there is a positive dose-dependent relationship between the intake of dietary cholesterol and 
blood LDL cholesterol concentrations, the main dietary determinant of blood levels of LDL 
cholesterol is saturated fat intake. Furthermore, most dietary cholesterol is obtained from foods which 
are also significant sources of dietary SFA, e.g. dairy and meat products. Therefore the Panel decided 
not to propose a reference value for cholesterol intake beside its conclusion on the intake of SFA. 
CONCLUSIONS AND RECOMMENDATIONS 
Total fat 
Available data are insufficient to define a Lower Threshold Intake or Tolerable Upper Intake Level 
for total fat intake. The Panel concludes that only a Reference Intake range can be established for total 
fat intake, partly based on practical considerations (e.g. current levels of intake, achievable dietary 
patterns in healthy populations). At the lowest observed intake of total fat (20 E%), no overt signs of 
deficiencies have been observed neither adverse effects on blood lipids. Total fat intakes > 35 E% 
may be compatible with both good health and normal body weight depending on dietary patterns and 
the level of physical activity. 
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The Panel proposes to set a lower bound of the Reference Intake Range of 20 E% and an upper bound 
of 35 E% for adults. 
In the second half of the first year of life, from the start of the complementary feeding period up to 
three years of age fat intake in infants and young children can be, gradually reduced: 40 E% in the 6 
to 12 month period and 35 to 40 E% in the 2
nd
 and 3
rd
 year of life. For children above the age of three 
years the Reference Intake Range for adults applies. 
Fat intakes below 25 E% have been associated with low vitamin levels in some infants and young 
children. 
Saturated fatty acids 
Saturated fatty acids are synthesised by the body and are not required in the diet. Therefore, no 
Population Reference Intake, Average Requirement, or Adequate Intake is set. 
As the relationship between saturated fatty acids intake and the effects on the blood lipid profile is 
continuous, there is no threshold of saturated fatty acids intake below which no adverse effects are 
observed. Thus, no Tolerble Upper Intake Level can be set.  
The Panel concludes that saturated fatty acids intake should be as low as possible within the context 
of a nutritionally adequate diet. Limiting the intake of saturated fatty acids should be considered when 
establishing nutrient goals and recommendations. 
Cis-monounsaturated fatty acids (cis-MUFA) 
Cis- monounsaturated fatty acids are not nutritionally essential, are synthesised by the body, have no 
known specific role in preventing or promoting diet-related diseases, and are not required in the diet. 
The Panel, therefore, proposes not to set any Dietary Reference Value for cis- monounsaturated fatty 
acids. 
Cis-polyunsaturated fatty acids (cis-PUFA) 
In view of the different metabolic effects of the various dietary cis- polyunsaturated fatty acids, the 
Panel proposes not to formulate any Dietary Reference Value for the intake of total cis- 
polyunsaturated fatty acids. Also, the Panel proposes not to set specific values for the n-3/n-6 ratio as 
available data are insufficient to recommend a ratio independent of absolute levels of intake which 
should be the subject of nutrient and/or food based dietary guidelines. 
n-6 polyunsaturated fatty acids (n-6 PUFA)  
Linoleic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, and is 
therefore an essential fatty acid. However, there is not sufficient scientific evidence to derive a Lower 
Threshold Intake, Average Requirement or Population Reference Intkae.  
As the relationship between linoleic acid intake and the blood lipid profile is continuous, there is no 
threshold of linoleic acid intake to establish a Lower Threshold Intake. 
The Panel proposes to set an Adequate Intake for linoleic acid of 4 E%, based on the lowest estimated 
mean intakes of the various population groups from various European countries, where overt linoleic 
acid deficiency symptoms are not present.  
Arachidonic acid is synthesised by the body from linoleic acid and is, therefore, not an essential fatty 
acid. The Panel proposes not to set any Dietary Reference Value for arachidonic acid. 
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Finally, there is at present no consistent evidence that intake of any of the n-6 polyunsaturated fatty 
acids has any detrimental effects on health (e.g. in promoting diet-related diseases). The Panel, 
therefore, proposes not to set an Tolerable Upper Intake Level for total or any of the n-6 
polyunsaturated fatty acids. 
n-3 polyunsaturated fatty acids (n-3 PUFA) 
Alpha-linolenic acid cannot be synthesised by the body, is required to maintain “metabolic integrity”, 
and is therefore an EFA. However, there are not sufficient scientific data to derive an Average 
Requirement, a Lower Threshold Intake or a Population Reference Intake.. The Panel proposes to set 
an AI for alpha-linolenic acid of 0.5 E%, based on the lowest estimated mean intakes of the various 
population groups from the various European countries, where overt alpha-linolenic acid deficiency 
symptoms are not present.  
The human body can synthesise eicosapentaenoic acid and docosahexaenoic acid from alpha-linolenic 
acid. Scientific evidence indicates that oily fish consumption or dietary supplements containing 
eicosapentaenoic acid plus docosahexaenoic acid decrease the risk of mortality from coronary heart 
disease. Taking into account that available data are insufficient to derive an Average Requirement, the 
Panel proposes to set an Adequate Intake for adults of 250 mg for eicosapentaenoic acid plus 
docosahexaenoic acid based on considerations of cardiovascular health.  
The Panel proposes an Adequate Intake of 100 mg docosahexaenoic acid for older infants (>6 months 
of age) and young children below the age of 24 months. 
For the age period 2 to 18 years, the Panel proposes no Adequate Intake for docosahexaenoic acid 
plus eicosapentaenoic acid. However dietary advice for children should be consistent with advice for 
the adult population. 
The Panel considers that during pregnancy and lactation an adequate n-3 long-chain polyunsaturated 
fatty acids supply consists of the Adequate Intake for adults (250 mg docosahexaenoic acid plus 
eicosapentaenoic acid) and 100 to 200 mg additional preformed docosahexaenoic acid. 
Trans fatty acids (TFA) 
Trans fatty acids are not synthesised by the human body, but are also not required in the diet. 
Therefore, no Population Reference Intake, Average Requirement, or Adequate Intake is set. 
Higher intakes of trans fatty acids have consistently been found to be associated with an increased 
risk of coronary heart disease.  
There is a limit to which the intake of trans fatty acids can be lowered without compromising the 
adequacy of intake of essential nutrients. Therefore, the Panel concludes that trans fatty acids intake 
should be as low as possible within the context of a nutritionally adequate diet. Limiting the intake of 
trans fatty acids should be considered when establishing nutrient goals and recommendations. 
Conjugated linoleic acids (CLA) 
There is no convincing evidence that any of the conjugated linoleic acids isomers in the diet play a 
role in prevention or promotion of diet-related diseases. The Panel therefore proposes not to set any 
Dietary Reference Value for conjugated linoleic acids. 
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Cholesterol 
Cholesterol is synthesised by the body and is not required in the diet. Therefore, no Population 
Reference Intake, Average Requirement, or Adequate Intake is set.  
Although there is a positive dose-dependent relationship between the intake of dietary cholesterol 
with blood LDL cholesterol concentrations, the main dietary determinant of blood LDL cholesterol 
concentrations is saturated fat intake.  
Therefore the Panel decided not to propose a reference value for cholesterol intake beside its 
conclusion on the intake of saturated fatty acids. 
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SUMMARY OF DRV FOR FATS 
 Adults Children 
1
 Pregnancy and lactation 
1
 
Total fat RI = 20-35E% 
 
>6-12 months, AI
2
 = 40 E% 
1-3 years, RI = 35-40 E% 
> 4 years, RI = 20-35 E% 
RI = 20-35E% 
 
SFA As low as possible As low as possible As low as possible 
Cis-MUFA No DRV No DRV No DRV 
Cis-PUFA No DRV No DRV No DRV 
.n-3/n-6 ratio No recommendation No recommendation No recommendation 
.n-6 PUFA No DRV No DRV No DRV 
..LA AI
3
 = 4 E%, AI
3
 = 4 E%, AI
3
 = 4 E%, 
..ARA No DRV No DRV No DRV 
.n-3 PUFA No DRV No DRV No DRV 
..ALA AI
3
 = 0.5 E% AI
3
 = 0.5 E% AI
3
 = 0.5 E% 
..EPA+DHA AI = 250mg per day AI 7-24 mths, 
DHA = 100 mg per day 
RI: DHA+EPA = 250mg per 
day plus 100-200mg per day 
DHA 
TFA As low as possible As low as possible As low as possible 
CLA No DRV No DRV No DRV 
Cholesterol No reference value besides 
the limitation on the intake 
of SFA 
No reference value besides 
the limitation on the intake 
of SFA 
No reference value besides 
the limitation on the intake 
of SFA 
 
1  Dietary Reference Values are as for adults unless otherwise noted. 
2  Based upon experimentally derived estimates of adquate nutrient intake/ consensus reports (Aggett et al., 1994, 
Agostoni et al., 2008) 
3  Based on lowest estimated mean intakes in EU where overt deficiency symptoms are not present 
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ANNEXES 
ANNEX 1A POPULATION, METHODS AND PERIOD OF DIETARY ASSESSMENT IN CHILDREN AND ADOLESCENTS IN EUROPEAN COUNTRIES. 
Country Population Dietary method Year of survey Reference 
AT Boys and girls aged 7-9 years 3-day record 2007 Elmadfa et al., 2009 
 Boys and girls aged 10-14 years 3-day record 2007 Elmadfa et al., 2009 
 Boys and girls aged 14-19 years 24-hour recall 2003-2004 Elmadfa et al., 2009 
     
BE Boys and girls aged 2.5-3 years 3-day record 2002-2003 Huybrechts and DeHenauw, 2007; Sioen et al., 2007 
 Boys and girls aged 4-6.5 years 3-day record 2002-2003 Huybrechts and DeHenauw, 2007; Sioen et al., 2007 
 Boys and girls aged 13-15 years 7-day record 1997 Matthys et al., 2003 
 Boys and girls aged 15-18 2x 24-hour recall 2004 De Vriese et al., 2006 
     
CZ Boys and girls aged 4-6 years 2x 24-hour recall n.a.
1 Tláskas, Hrstková. (unpublished data) (In: Elmadfa, 2009) 
 Boys and girls aged 7-9 years 2x 24-hour recall n.a. Tláskas, Hrstková. (unpublished data) (In: Elmadfa, 2009) 
     
DE Infants aged 12 months 3-day record 1989-2003 Hilbig and Kersting, 2006 
 Children aged 18 months 3-day record 1989-2003 Hilbig and Kersting, 2006 
 Children aged 2 years  3-day record 1989-2003 Hilbig and Kersting, 2006 
 Children aged 3 years 3-day record 1989-2003 Hilbig and Kersting, 2006 
 Boys and girls aged 6 years 3-day record 2006 Mensink et al., 2007 
 Boys and girls aged 7-9 years 3-day record 2006 Mensink et al., 2007 
 Boys and girls aged 10-11 years 3-day record 2006 Mensink et al., 2007 
 Boys and girls aged 12 years Dietary history (over the last 4 weeks)* 2006 Mensink et al.,2007 
 Boys and girls aged 13-14 years Dietary history (over the last 4 weeks)* 2006 Mensink et al.,2007 
 Boys and girls aged 15-17 years Dietary history (over the last 4 weeks)* 2006 Mensink et al.,2007 
     
DK Boys and girls aged 1-3 years 7-day record 1995 Andersen et al., 1996 
 Boys and girls aged 4-5 years 7-day record 2000-2002 Lyhne et al., 2005 
 Boys and girls aged 6-9 years 7-day record 2000-2002 Lyhne et al., 2005 
 Boys and girls aged 10-13 years 7-day record 2000-2002 Lyhne et al., 2005 
 Boys and girls aged 14-17 years 7-day record 2000-2002 Lyhne et al., 2005 
     
FI Infants aged 8 months 3-day record 1999 Lagstrom, 1999 
 Children aged 3 years 4-day record 1999 Lagstrom, 1999 
 Children aged 4 years 4 day record 1999 Lagstrom, 1999 
 Children aged 4 years 3-day record 2008 Kyttälä et al., 2008 
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Country Population Dietary method Year of survey Reference 
 Children aged 6 years 3-day record 2008 Kyttälä et al., 2008 
     
FR Boys and girls aged 4-6 years 3x 24-hour recall 2006-2007 Castetbon et al. 2009 (In: Elmadfa, 2009)  
 Boys and girls aged 7-9 years 3x 24-hour recall 2006-2007 Castetbon et al. 2009 (In: Elmadfa, 2009)  
 Boys and girls aged 10-14 years 3x 24-hour recall 2006-2007 Castetbon et al. 2009 (In: Elmadfa, 2009)  
 Boys and girls aged 15-18 years 3x 24-hour recall 2006-2007 Castetbon et al. 2009 (In: Elmadfa, 2009)  
     
GR Boys and girls aged 4-5 years  3-day record+24-hour recall / 3-day 
record 
2003-2004 Manios et al., 2006 
     
HU Boys and girls aged 11-14 years 3x 24-hour recall 2005-2006 Biro et al., 2007. (In: Elmadfa, 2009) 
     
IE Boys and girls 5-8 years 7-day record 2003-2004 Irish University Nutrition Alliance Irish National Children‟s Food Survey. 
www.iuna.net 
 Boys and girls 9-12 years 7-day record 2003-2004 Irish University Nutrition Alliance Irish National Children‟s Food Survey. 
www.iuna.net 
     
IT Boys and girls 4-6 years 7-day record n.a D‟Amicis, 2000 
 Boys and girls 7-9 years 7-day record n.a D‟Amicis, 2000 
 Boys and girls 10-14 years 7-day record n.a D‟Amicis, 2000 
 Boys and girls 15-18 years 7-day record n.a D‟Amicis, 2000 
     
NL Infants aged 9 month 2-day record (independent days)  2002 Boer et al., 2006 
 Infants aged 12 monts 2-day record (independent days)  2002 Boer et al., 2006 
 Children aged 18 months 2-day record (independent days)  2002 Boer et al., 2006 
 Boys and girls aged 2-3 years 2-day record (independent days) 2005-2006 Ocke et al., 2008 
 Boys and girls aged 4-6 years 2-day record (independent days) 2005-2006 Ocke et al., 2008 
 Boys and girls aged 7-9 years 2-day record 1997-1998 Hulshof et al., 2004 
 Boys and girls aged 9-13 years 2-day record 1997-1998 Hulshof et al., 2004 
 Boys and girls aged 14-18 years 2-day record 1997-1998 Hulshof et al., 2004 
     
NO Children aged 2 years Food Frequency Questionnaire 1998-1999 Lande and Anderson, 2005 
 Boys and girls aged 4 years 4-day record 2000 Øverby and Andersen, 2002 
 Boys and girls aged 9 years 4-day record 2000 Øverby and Andersen, 2002 
 Boys and girls aged 13 4-day record 2000 Øverby and Andersen, 2002 
 Boys and girls aged 16-19 years Food Frequency Questionnaire 1997 Johansson and Solvoll, 1999 
     
PL Boys and girls aged 4-6 years 24-hour recall 2000 Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009) 
 Boys and girls aged 7-9 years 24-hour recall 2000 Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009) 
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Country Population Dietary method Year of survey Reference 
 Boys and girls aged 10-14 years 24-hour recall 2000 Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009) 
 Boys and girls aged 15-18 years 24-hour recall 2000 Szponar et al, 2000 (unpublished data) (In: Elmadfa, 2009) 
     
PT Boys and girls aged 7-9 years 24-hour recall 2000-2002 Moreira et al., 2005 
 Boys and girls aged 13 years 24-hour recall 2000-2002 Moreira et al., 2005 
     
SI Boys and girls aged 14-17 years Food Frequency Questionnaire n.a. Fidler Mis et al. (unpublished data) (In: Elmadfa, 2009) 
     
ES Boys and girls aged 10-14 years 2x 24-hour recall 2002-2003 Serra Majem and Ribas, 2007; Serra Majem et al., 2006 and 2007 (In: Elmadfa, 
2009)  
 Boys and girls aged 15-18 years 2x 24-hour recall 2002-2003 Serra Majem and Ribas, 2007; Serra Majem et al., 2006 and 2007 (In: Elmadfa, 
2009)  
     
SE Boys and girls aged 4 years 4-day record 2003 Enghardt-Barbieri et al., 2006 
 Boys and girls aged 8-9 years 4-day record 2003 Enghardt-Barbieri et al., 2006 
 Boys and girls aged 11-12 years 4-day record 2003 Enghardt-Barbieri et al., 2006 
     
UK Boys and girls aged 4-6 years 7-day record 1997 Gregory et al., 2000 
 Boys and girls aged 7-10 years 7-day record 1997 Gregory et al., 2000 
 Boys and girls aged 11-14 years 7-day record 1997 Gregory et al., 2000 
 Boys and girls aged 15-18 years 7-day record 1997 Gregory et al., 2000 
 
1n.a. = not available 
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ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~1-3 YEARS IN EU COUNTRIES. 
 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Infants and Toddlers                   
DE 12 mo 432 34.3 5.2                 
 18 mo 478 36.2 6.0                 
   2 mo 458 37.0 5.9                 
   3 mo 427 36.7 5.8                 
FI   8 mo 215 28.8 4.1  12.6 2.3  8.7 1.5  4.9 0.8        
 13 mo 449 28 5.0  12.4 3.1  8.8 2.0  3.8 1.3        
   2 mo 398 33 4.8  14.5 3.0  10.8 2.0  4.4 1.4        
   3 mo 359 33 4.6  14.7 2.6  10.9 1.9  4.7 1.2        
NL    9 mo 333 25.6 3.7 25.0-34.21 11.5 1.5 9.7-13.51 10.9 1.7  8.7-12.91 5.3 1.3 3.8-7.01 0.1 0.1 0.0-0.21    
 12 mo 306 28.3 4.2 23.0-33.61 11.4 1.9 9.2-13.81 9.5 2.1 6.8-12.11 5.0 1.4 3.4-6.81 0.2 0.1 0.1-0.31    
 18 mo 302 27.1 3.8 22.3-32.11 11.8 1.8 6.4-98.0 4.5 1.3 2.9-6.21 3.5 1.3 2.1-5.21 0.3 0.1 0.2-0.51    
NO   2 mo 172 33.3 5.1  14.2 2.7  10.4 1.8  5.7 1.9        
                     
Pre-school children                    
Males                     
BE 2.5-3 102 29.2 3.8  13.0 2.7  10.4 1.3  4.4 1.3     159 32  
DK 1-3 129 36   17   10   5      207   
NL 2-3 313 29  22-37 11  8-15 15  10-20    0.8  0.5-1.0    
                     
Females                     
BE 2.5-3 95 30.3 5.0  13.8 2.6  10.8 2.0  4.3 1.1     165 37  
DK 1-3 149 36   17   10   4      221   
NL 2-3 313 29  23-35 11  9-14 15  11-19    0.7  0.5-1.1    
 
1P10-P90; 2 E; 3P2.5-97.5 
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ANNEX 1B  INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~4-6 YEARS IN EU COUNTRIES. 
 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
BE 4-6.5 236 30.1 3.9  13.4 2.0  10.8 1.4  4.5 1.2     171 36  
CZ 4-6 641 30.0 5.3              241 111  
DE 6 106 32.6 6.1 23.4-44.3  15.3 2.9  12.5 2.2  4.8 1.0     247 103 110-480 
DK 4-5 82 34.0 3.9 28-40 15.0 2.2 12-18 12.0 1.5 10-14 4.7 0.8 3.5-6.1 0.7 0.2 0.4-0.9    
FI 4 307 31.0   13.7   10.6   4.0      153 53  
 6 364 31.0   13.5   10.8   4.2      180 60  
FR 4-6 164 34.7 0.841  15.1               
GR 4-5 356 40.2 5.0  14.5 2.9              
IT 4-6 21 34.3 5.5  10.9 2.5  10.6 3.4  4.1 1.5     328 105  
NL 4-6 327 31.0  24-37 12.0  9-15 16.0  12-20    0.8  0.6-1.1    
NO 4 206 33.0 5.0  14.0 2.0  10.0 2.0  6.0 2.0     185 82  
PL 4-6 82 31.9 7.8  11.6 3.9  13.7 4.1  4.5 2.2     240 145  
SE 4 302 31.3 4.2 26.4-38.5 14.3 2.4 10.2-18.2 11.1 1.7 8.7-14.3 3.7 1.0 2.4-5.4 0.9 0.4 0.5-1.5 196 73 97-336 
UK  4-6 184 35.5 3.9 27.9-42.52 14.8 2.4 10.6-19.72 11.5 1.6 8.5-15.0 5.5 1.3 3.1-8.52 1.3 0.3 0.8-2.02 158 71 64-3302 
                     
Females                     
BE 4-6.5 228 29.7 3.2  13.5 1.7  10.6 1.5  4.4 1.0     145 30  
CZ 4-6 446 30.0 5.3                 
DE 6 102 32.2 4.6 24.4-38.7 15.2 2.0  12.1 1.6  4.9 1.1     201 89 95-453 
DK 4-5 77 35.0 4.5 29-42 16.0 3.1 12-18 12.0 1.7 10-14 4.8 0.8 3.6-6.3 0.6 0.2 0.4-0.9    
FI 4 307 31.0   13.7   10.6   4.0      139 51  
 6 349 31.0   1.8   10.7   4.1      156 56  
FR 4-6 162 36.3 0.51  15.8               
GR 4-5 389 40.5 5.0  14.4 2.9              
IT 4-6 17 33.8 3.5  10.8 2.0  9.7 2.3  4.0 1.2     327.1 107  
NL 4-6 312 31.0  25-36 12.0  10-15 15.0  12-19    0.8  0.6-1.1    
NO 4 185 32.0 5.0  14.2 3.0  10.0 2.0  6.0 2.0     174 65  
PL 4-6 84 32.5 7.0  12.0 3.3  13.6 3.9  4.7 2.2     245 176  
SE 4 288 32.1 4.6 24.6-39.5 14.6 2.5 10.9-18.7 11.5 1.9 8.5-14.5 3.7 0.9 2.5-5.3 0.9 0.3 0.5-1.6 187 68 93-312 
UK  4-6 171 35.9 4.4 26.2-44.82 15.3 2.5 10.4-21.22 11.5 1.7 8.2-15.12 5.4 1.4 3.2-8.42 1.3 0.3 0.8-2.02 156 60 62-2862 
 
1SE; 2 P2.5-P97.5 
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ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~7-9 YEARS IN EU COUNTRIES. 
 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
AT 7-9 146 34.1 5.3  14.4 2.7  11.7 2.4  6.1 2.0     259 111  
CZ 7-9 940 32.2 5.6                 
DE 7-9 321 32.4 5.5 23.6-40.8 15.1 2.5  12.5 2.0  4.8 1.0     247 99 118-453 
DK 6-9 174 34.0 3.9 27-40 15 2.2 12-19 12.0 1.5 9-14 4.7 0.7 3.4-6.0 0.6 0.2 0.4-0.9    
FR 7-9 160 36.0 0.41  15.1               
IE 5-8 145 33.5 4.3 25.9-40.8                
IT 7-9 29 34.8 5.9  9.4 2.2  10.9 3.1  4.6 3.1     375 193  
NL 7-9 104 33.8 6.1 24.8-44.6 13.4 2.8 9.2-17.6 11.8 2.7 8.1-16.7 6.4 1.8 3.7-10.3    155 63  
NO 9 402 32.8 5.0  14.0 3.0  10.0 2.0  6.0 2.0     225 103  
PL 7-9 101 32.0 7.5  12.0 3.8  13.3 3.6  4.6 1.9     315 220  
PT 7-9 1541 35.9 6.6  13.0 3.3  15.0 3.4  5.0 1.7        
SE 8-9 444 31.6 4.2 25.0-39.2 14.4 2.4 10.2-18.4 11.4 1.8 8.9-14.6 3.6 0.8 2.5-5.1 1.0 0.4 0.5-1.6 250 89 130-407 
UK  7-10 256 35.2 3.7 28.8-42.92 14.3 2.1 10.5-19.32 11.5 1.6 8.9-14.82 5.7 1.5 3.5-9.42 1.4 0.3 0.8-2.22 181 67 67-3352 
                     
Females                     
AT 7-9 134 34.2 5.7  14.3 3.0  11.5 2.3  6.5 2.3     262 304  
CZ 7-9 765 32.2 5.6                 
DE 7-9 308 31.3 5.8 22.2-41.8 14.9 2.6  11.8 2.2  4.5 1.1     227 105 86-411 
DK 6-9 157 33.0 4.3 26-40 15.0 2.3 11-18 11.0 1.7 8-14 4.6 0.7 3.7-5.7 0.6 0.2 0.4-0.9    
FR 7-9 14 36.5 0.61  15.5               
IE 5-8 151 34.4 3.9 27.9-41.0                
IT 7-9 21 34.9 4.7  10.9 2.4  9.9 1.8  4.3 1.8     309 119  
NL 7-9 134 34.4 6.6 24.2-45.7 13.6 2.9 9.0-19.1 11.9 2.9 7.7-17.0 6.6 2.1 3.5-10.5    147 72  
NO 9 408 31.0 5.0  14.0 3.0  10.0 2.0  6.0 2.0     200 105  
PL 7-9 103 33.2 7.6  11.8 3.6  14.2 3.8  5.1 2.6     281 194  
PT 7-9 1503 36.2 6.7  13.1 3.3  15.1 3.5  5.1 1.6        
SE 8-9 445 31.3 4.4 24.3-38.7 14.1 2.3 10.5-18.2 11.3 1.9 8.3-14.7 3.6 0.9 2.5-5.3 0.9 0.4 0.5-1.7 216 78 109-351 
UK  7-10 226 35.9 4.1 26.6-44.22 14.5 2.3 9.2-19.22 11.8 1.8 8.3-15.42 5.9 1.5 3.4-9.42 1.4 0.3 0.8-2.22 170 67 61-3292 
 
1SE; 2 P2.5-97.5 
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ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~10-14 YEARS IN EU COUNTRIES. 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
AT 10-14 248 34.5 6.2  14.5 3.3  12.0 2.5  6.1 1.9     271 146  
BE 13-15 74 36.1 4.5  15.7 2.5  14.4 2.2  6.1 1.6     265 72  
DE 10-11 199 32.1 5.8 22.9-41.6 15.1 2.6  12.4 2.2  4.6 1.0     261 118 101-493 
 12 114 33.7 5.2 25.6-44.1 15.6 2.3  12.7 2.3  5.3 1.0     343 142 162-616 
 13-14 214 33.5 5.5 24.4-41.1 15.5 2.4  12.7 2.0  5.2 1.2     382 165 188-709 
DK 10-13 145 33.0 4.4 26-40 15.1 2.3 11-19 11 1.7 9-14 4.5 0.8 3.3-6.0 0.6 0.2 0.3-0.9    
FR 10-14 160 36.3 0.41 15.1 14.0               
HU 11-14 124 35.0 4.9  10.9 2.1  10.8 2.1  8.2 2.1     347 116  
IE 9-12 148 33.3 4.5 26.2-40.8                
IT 10-14 52 35.8 5.3  10.8 2.4  11.9 2.9  5.1 1.5     370 101  
NL 9-13 197 35.0 6.0 26.1-44.8 13.1 2.7 9.0-18.3 10.1 2.3 6.5-14.0 7.5 2.3 4.0-11.9 1.4 1.0 0.4-3.3    
NO 13 590 31.0 6.0  13.0 3.0  10.0 2.0  5.0 2.0     241 134  
PL 10-14 202 34.6 7.7  12.1 3.8  14.7 3.9  5.5 2.9     408 323  
PT 13 987 32.0 4.5  10.9 1.8  13.1 2.5  5.3 1.1     378 148  
SE 11-12 517 31.7 4.6 24.3-38.8 14.1 2.4 10.4-18.1 11.6 2.1 8.5-15.3 3.7  2.5-5.4 1.0 0.5 1.0-1.8 233 92 109-406 
ES 10-14 66 40.8 4.1  14.3 1.8  16.7 2.5  5.7 0.9     362 34  
UK  11-14 237 35.2 4.3 26.0-43.62 13.8 2.2 9.8-18.62 11.7 1.8 8.4-15.22 6.1 1.4 3.8-9.52 1.3 0.3 0.7-2.02 201 80 78-4012 
                     
Females                     
AT 10-14 239 33.7 7.0  14.1 3.6  11.5 2.8  6.2 2.3     228 160  
BE 13-15 89 35.5 5.0  15.4 2.7  14.1 2.4  5.9 1.3     206 66  
DE 10-11 198 32.3 6.3 21.7-41.1 14.8 2.7  12.6 2.5  4.8 1.2     253 110 94-459 
 12 103 33.1 6.2 22.4-42.7 15.4 2.9  12.3 2.1  5.3 1.1     302 144 118-586 
 13-14 230 32.9 5.8 23.7-41.5 15.4 2.7  12.3 2.1  5.1 1.0     298 117 133-551 
DK 10-13 131 33.0 4.8 26-40 14.9 2.7 11-19 11.0 1.8 9-14 4.5 0.8 3.4-5.9 0.6 0.2 0.4-0.9    
FR 10-14 144 36.4 0.51 14.9 14.2               
HU 11-14 111 34.3 5.2  10.6 2.2  10.2 2.1  8.6 2.0     292 96  
IE 9-12 150 34.4 4.2 27.6-41.7                
IT 10-14 47 33.4 4.5  10.1 2.3  11.0 2.3  4.4 1.9     320 111  
NL 9-13 212 34.5 6.1 24.6-44.6 13.1 2.6 8.6-17.6 9.8 2.2 6.5-13.6 7.6 2.3 4.7-11.9 1.3 0.8 0.3-2.8    
NO 13 515 31.0 5.0  14.0 3.0  10.0 2.0  5.0 2.0     198 106  
PL 10-14 202 34.3 7.5  12.0 3.7  14.6 4.2  5.5 2.8     321 235  
PT 13 1053 32.0 4.7  10.9 1.9  13.0 2.6  5.3 1.2     360 146  
SE 11-12 499 31.3 4.6 23.4-39.4 14.0 2.3 10.4-17.9 11.4 2.1 8.1-14.7 3.7  2.5-5.4 0.9 0.4 0.5-1.7 204 87 96-375 
ES 10-14 53 39.7 2.9  13.6 1.2  16.6 1.2  5.4 0.4     313 50  
UK  11-14 238 36.1 5.0 23.3-45.22 14.0 2.5 9.3-18.72 12.0 2.2 8.0-17.12 6.4 1.7 3.8-10.22 1.3 0.4 0.7-2.22 169 72 61-3292 
1SE; 2 P2.5-P97.5 
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ANNEX 1B INTAKE OF FAT AND (CLUSTERS OF) FATTY ACIDS AND CHOLESTEROL AMONG CHILDREN AGED ~15-18 YEARS IN EU COUNTRIES. 
 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
AT 14->19 1527 36.5 8.9  18.3 6.2  11.1 3.4  4.7 2.6     375 204  
BE 15-18 405                   
DE 15-17 294 33.8 7.0 24.0-44.1             461 242 183-795 
DK 14-17 86 32 4.6 25-49 14 2.5 10-18 11 1.8 8-14 4.5 0.8 3.4-5.8 0.6 0.2 0.3-0.9    
FR 15-18 181 34.2 0.51 14.0                
IT 15-18 52 37.0 7.1  11.2 2.4  12.9 4.1  5.3 2.2     438 130  
NL 14-18 229 35.2 5.9 26.0-44.8 13.1 2.6 8.8-17.6 10.0 2.0 7.0-13.3 7.9 2.6 3.6-12.9 1.4 1.0 0.4-3.3 243 95 97-428 
NO 16-19 92 31.0   13.0   10.8   5.1      361   
PL 15-18 174 36.8 6.9  12.1 3.8  16.0 3.8  6.3 2.9     566 366  
SI 15-18 1010 28.0 7.0  13.0 3.0  10.3 3.0  5.0 2.0     300 188  
ES 15-18 61 40.4 3.8  13.8 1.8  16.7 2.3  5.7 0.9     382 48  
UK  15-18 179 35.9 4.7 26.3-45.32 13.9 2.1 9.4-17.62 12.0 2.1 8.2-.16.22 6.3 1.6 3.7-9.22 1.4 0.4 0.7-2.12 243 95 97-4282 
                     
Females                     
AT 14->19 1422 37.4 9.6  19.1 6.7  11.1 3.5  4.8 2.9     267 141  
BE 15-18 401                   
DE 15-17 317 31.4 6.7 21.8-41.3             288 152 120-572 
DK 14-17 117 31.0 4.7 23-38 14.0 2.5 10-18 11.0 1.8 8-13 4.4 0.7 3.3-5.9 0.6 0.2 0.3-0.8    
FR 15-18 222 36.4 0.31 14.2                
IT 15-18 47                   
NL 14-18 216 35.5 6.2 25.9-46.4 13.7 2.8 9.0-18.6 10.2 2.5 6.7-14.4 7.4 2.5 3.8-12.1 1.3 0.9 0.4-3.2    
NO 16-19 86 28.6   11.8   9.9   4.9      228   
PL 15-18 175 33.8 3.1  11.7 4.2  14.4 4.5  5.4 2.6     326 255  
SI 15-18 1214 29.0 7.0  13.0 3.0  10.0 3.0  6.0 2.0     218 139  
ES 15-18 57 41.9 3.7  13.7 1.3  17.7 1.9  6.0 1.0     314 46  
UK  15-18 210 35.9 5.4 22.7-45.62 13.8 2.5 8.8-19.32 11.7 2.2 6.6-15.62 6.7 1.9 3.7-10.62 1.3 0.4 0.7-2.22 177 80 53-3462 
 
1 SE; 2 P2.5-P97.5 
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ANNEX 1B INTAKE OF LINOLEIC ACID, CIS N-6 PUFA AND CIS N-3 PUFA AMONG CHILDREN IN EU COUNTRIES. 
 
Country Age 
yrs 
N Linoleic acid 
(g/d) 
Linoleic acid 
(E%) 
Cis n-6 PUFA 
(g/d) 
Cis n-6 PUFA 
(E%) 
Cis n-3 PUFA 
(g/d) 
Cis n-3 PUFA 
(E%) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males and Females                    
BE 2.5-3 197    4.0  3.2-4.7    4.05  3.2-4.75    0.53  0.43-0.62 
 4-6.5 464    4.3  3.5-4.9    4.25  3.55-4.86    0.58  0.48-0.66 
                     
Males                     
NL 9-13 197 16.5 7.11 6.9-30.6 6.4 2.1 3.3-10.6 16.6 7.1 6.9-31.0 6.5  3.3-10.7 1.5 0.7 0.7-3.1 0.6  0.3-1.0 
 14-18 229 21.0 10.2 7.6-41.3 6.8 2.5 3.1-11.5 21.2 10.3 7.7-41.7 6.9  3.2-11.6 1.9 0.9 0.8-3.8 0.6  0.3-1.0 
                     
SE 4  302 5.0 1.6 2.7-8.1    5.2 1.7 3.0-8.5 2.9  1.9-4.3 1.2 0.4 0.6-2.1 0.7 0.2 0.4-1.0 
 8-9  444 5.9 2.1 3.1-9.7 
 
  6.3 2.2 3.4-10.1 2.9  2.0-4.2 1.4 0.5 0.7-2.1 0.6 0.2 0.4-1.0 
 11-12  517 5.8 2.5 2.9-10.3    6.2 2.6 3.3-10.6 3.0  2.0-4.3 1.4 0.6 0.7-2.4 0.6 0.2 0.4-1.0 
                     
UK 4-6 184       8.0 2.6 3.6-13.41 4.8 1.2 2.7-7.41 1.3 0.6 0.5-2.91 0.8 0.3 0.4-1.81 
 7-10 256       9.7 3.3 4.7-18.81 4.9 1.4 4.0-8.41 1.6 0.7 0.6-3.581 1.4 0.3 0.8-2.21 
 11-14 237       11.4 3.7 6.2-19.31 5.2 1.2 3.3-8.41 2.0 1.2 0.8-4.11 0.9 0.5 0.4-1.91 
 15-18 179       13.3 4.6 6.1-24.81 5.2 1.4 3.0-7.91 2.2 0.9 0.6-3.81 0.9 0.3 0.5-1.61 
                     
Females                     
                     
NL 9-13 212 14.7 5.7 7.3-26.4 6.6 2.2 3.6-10.7 14.9 5.8 7.3-26.4 6.6  3.7-10.8 1.4 0.6 0.5-2.6 0.6  0.3-1.0 
 14-18 216 14.8 6.6 6.1-27.2 6.3 2.3 3.2-11.0 14.9 6.7 6.1-27.5 6.4  3.2-11.0 1.4 0.7 0.6-2.4 0.6  0.3-1.0 
                     
SE 4  288 5.0 1.6 2.7-8.1    4.9 1.6 2.7-7.9 3.0 0.7 2.0-4.2 1.1 0.5 0.6-1.9 0.7 0.3 0.4-1.1 
 8-9  445 5.9 2.1 3.1-9.7    5.7 2.0 3.0-9.4 2.9 0.8 2.0-4.4 1.3 0.5 0.6-2.1 0.9 0.2 0.5-1.7 
 11-12  399 5.8 2.5 2.9-10.3    5.6 2.5 2.7-10.2 3.0 0.9 1.9-4.5 1.2 0.5 0.5-2.3 0.7 0.2 0.4-1.1 
                     
UK 4-6 171       7.2 2.7 3.6-13.51 4.8 1.2 2.7-7.61 1.2 0.5 0.5-2.31 0.7 0.3 0.4-1.31 
 7-10 226       9.0 3.0 4.7-16.71 5.1 1.4 2.9-8.51 1.4 0.5 0.7-3.01 0.8 0.3 0.4-1.51 
 11-14 238       10.2 3.4 4.9-17.81 5.4 1.5 3.2-8.61 1.6 0.7 0.7-3.41 1.3 0.4 0.7-2.21 
 15-18 179       10.2 4.0 4.1-18.91 5.3 1.7 2.9-8.71 1.6 0.6 0.7-3.11 1.2 0.3 0.7-2.21 
 
1 P2.5-P97.5 
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ANNEX 1B DIETARY INTAKES OF ALA, EPA AND DHA BY CHILDREN IN DIFFERENT COUNTRIES. 
 
 ALA EPA DHA references 
 g/d E% g/d E% g/d E%  
Austria       Elmadfa, et al., 2009 
. 3-6 yr 0.8/0.7* 0.5/0.5 0.02 NA 0.08 NA  
. 7-10 yr 0.8/0.7 0.4/0.4 0.02 NA 0.07 NA  
 11-14 yr  1.2/1 0.6/0.5 0.03 NA 0.1/0.09 NA  
 15-18 yr 1.2/1 0.4/0.5 0.03 NA 0.09/1.0 NA  
Belgium       Sioen et al., 2007 
 2.5-3 yr 0.8 0.48 0.02 0.01 0.04 0.03  
 4-6.5 yr 0.9 0.54 0.03 0.02 0.05 0.03  
Sweden       Enghardt-Barbieri et al., 2006 
 4 yr 1.0 0.6 0.04 0.02 0.10 0.06  
 8-9 yr 1.1 0.5 0.04 0.02 0.13 0.06  
 11-12 yr 1.1 0.6 0.04 0.02 0.12 0.06  
* males/females 
NA Not Available 
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ANNEX 2A POPULATION, METHODS AND PERIOD OF DIETARY ASSESSMENT IN ADULTS IN EUROPEAN COUNTRIES. 
Country Population Dietary method Year of survey Reference 
AT Males and females aged 19-64 years 24-hour recall 2007 Elmadfa et al., 2009 
 Males and females aged 65 and over 3-day record 2007 Elmadfa et al., 2009 
     
BE Males and females aged 19-59 years 2x 24-hour recall 2004 De Vriese et al, 2006 
 Males and females aged 60-75 years 2x 24-hour recall 2004 De Vriese et al, 2006 
 Males and females aged 75+ years 2x 24-hour recall 2004 De Vriese et al, 2006 
     
CZ Males and females aged 19-64 years n..a. n.a.
1 Cífková and Skodova, 2004 
     
DE Males and females aged 35-64 years 24-hour recall 1996-1998 Linseisen et al., 2003 
 Males and females aged 19-64 years 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
  Males and females aged 19-24 years 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
  Males and females aged 25-34 years 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
  Males and females aged 35-50 years 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
  Males and females aged 51-64 years 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
  Males and females aged 65-80 years 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
 Males and Females aged 65 and over 24-hour recall + Dietary History 2005-2006 Anonymous, 2008 
     
DK Males and females aged 18-74 years 7-day record 2000-2002 Lyhne et al., 2005 
  Males and females aged 18-24 years 7-day record 2000-2002 Lyhne et al., 2005 
  Males and females aged 25-34 years 7-day record 2000-2002 Lyhne et al., 2005 
  Males and females aged 35-44 years 7-day record 2000-2002 Lyhne et al., 2005 
  Males and females aged 45-54 years 7-day record 2000-2002 Lyhne et al., 2005 
  Males and females aged 55-64 years 7-day record 2000-2002 Lyhne et al., 2005 
  Males and females aged 65-74 years 7-day record 2000-2002 Lyhne et al., 2005 
     
EE Males and females aged 19-65 years 24-hour recall 1997 Pomerleau et al., 2001 
  Males and females aged 19-34 years 24-hour recall 1997 Pomerleau et al., 2001 
  Males and females aged 35-49 years 24-hour recall 1997 Pomerleau et al., 2001 
  Males and females aged 50 and over 24-hour recall 1997 Pomerleau et al., 2001 
     
FI Males and females aged 25-64 years 3-day record 2002 Paturi et al., 2008 
 Males and females aged 65-74 years 4-day record 2002 Paturi et al., 2008 
     
FR Males and females aged 19-64 years 3x 24-hour recall 2006-2007 Castetbon et al. 2009. (In: Elmadfa, 2009)  
 Males and females aged 65-75 years 3x 24-hour recall 2006-2007 Castetbon et al. 2009. (In: Elmadfa, 2009)  
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Country Population Dietary method Year of survey Reference 
     
GR Males and females aged 19-64 years FFQ + 24-hour recall in sub group 1994-1999 Greek cohort EPIC study. (In: Elmadfa, 2009) 
 Males and females aged 65 and over FFQ 1994-1999 Greek cohort EPIC study. (In: Elmadfa, 2009) 
     
HU Males and females aged 11-14 years 3-day record 2003-2004 Rodler et al. 2007; Zajkás et al., 2007; Bíró et al., 2007 
(In: Elmadfa, 2009) 
 Males and females aged 18-59 3-day record 2003-2004 Rodler et al. 2007; Zajkás et al., 2007; Bíró et al., 2007 
(In: Elmadfa, 2009) 
 Males and females aged 60 and over 3-day record 2003-2004 Rodler et al. 2007; Zajkás et al., 2007; Bíró et al., 2007 
(In: Elmadfa, 2009) 
     
IE Males and females 18-64 years 7-day record 1997-1999 Irish Universities Nutrition Alliance North/South Ireland 
Food Consumption Survey. www.iuna.net  
  Males and females 18-35 years 7-day record 1997-1999 Irish Universities Nutrition Alliance North/South Ireland 
Food Consumption Survey. www.iuna.net  
  Males and females 36-50 years 7-day record 1997-1999 Irish Universities Nutrition Alliance North/South Ireland 
Food Consumption Survey. www.iuna.net  
  Males and females 51-64 years 7-day record 1997-1999 Irish Universities Nutrition Alliance North/South Ireland 
Food Consumption Survey. www.iuna.net  
     
IT Males and females 19-64 years 7-day record n.a. D‟Amicis, 2000 
 Males and females aged 65 and over 7-day record n.a. D‟Amicis, 2000 
     
LT Males and females 19-64 years 24-hour recall 2007 Unpublished data (In: Elmadfa, 2009) 
     
LV Males and females 19-64 years 24-hour recall 1997 Pomerleau et al., 2001 
  Males and females aged 19-34 years 24-hour recall 1997 Pomerleau et al., 2001 
  Males and females aged 35-49 years 24-hour recall 1997 Pomerleau et al., 2001 
  Males and females aged 50 and over 24-hour recall 1997 Pomerleau et al., 2001 
     
NL Males and Females aged 19-64 years 2-day record 1997-1998 Hulshof et al., 1998  
 Males and Females aged 65 and over 2-day record 1997-1998 Hulshof et al., 1998 
 Males and females aged 19-30 years  2x 24-hour recall  2003 Hulshof and Ocké, 2005; Kruizinga et al., 2007 
     
NO Males and females aged 19-64 years FFQ 1997 Johansson and Sovoll, 1999 
 Males and females aged 65 and over FFQ 1997 Johansson and Sovoll, 1999 
     
PL Males and females aged 19-64 years 24-hour recall 2000 Szponar et al., 2000 unpublished data (In: Elmadfa, 2009) 
 Males and females aged 65 and over 24-hour recall 2000 Szponar et al., 2000 unpublished data (In: Elmadfa., 2009) 
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Country Population Dietary method Year of survey Reference 
     
PT Males and females aged 18+ years FFQ n.a. EPIPorto study (In: Elmadfa, 2009)  
 Males and females aged 65 and over FFQ n.a. EPIPorto study (In: Elmadfa, 2009)  
     
RO Males and females aged 19-64 years personal interview 2006 National Synthesis 2006 (In: Elmadfa., 2009) 
 Males and females aged 65 and over personal interview 2006 National Synthesis 2006 (In: Elmadfa., 2009) 
     
ES Males and females aged 18-64 years 24-hour recall 2002-2003 Serra Majem et al., 2007  
 Males and females aged 65-75 years 24-hour recall 2002-2003 Serra Majem et al., 2007  
     
SE Males and females aged 18-74 years 7-day record 1997-1998 Becker and Pearson, 2002 
  Males and females aged 17-24 years 7-day record 1997-1998 Becker and Pearson, 2002 
  Males and females aged 25-34 years 7-day record 1997-1998 Becker and Pearson, 2002 
  Males and females aged 35-44 years 7-day record 1997-1998 Becker and Pearson, 2002 
  Males and females aged 45-54 years 7-day record 1997-1998 Becker and Pearson, 2002 
  Males and females aged 55-64 years 7-day record 1997-1998 Becker and Pearson, 2002 
  Males and females aged 65 and over 7-day record 1997-1998 Becker and Pearson, 2002 
     
UK Males and females aged 19-64 years 7-day record 2000-2001 Henderson et al., 2003 
  Males and females aged 19-24 years 7-day record 2000-2001 Henderson et al., 2003 
  Males and females aged 25-34 years 7-day record 2000-2001 Henderson et al., 2003 
  Males and females aged 35-49 years 7-day record 2000-2001 Henderson et al., 2003 
  Males and females aged 50-64 years 7-day record 2000-2001 Henderson et al., 2003 
  Males and females aged 65+ years 4-day record 1994-1995 Finch et al., 1998 
 
1n.a. = not available
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ANNEX 2B INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~19-64 YEARS (TOTAL POPULATION) IN EU  
COUNTRIES. 
 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
AT 19-64 778 37.4 8.9  14.3 4.3  13.0 3.8  7.9 3.7     352 227  
BE 19-59 413 38.7 5.6  15.6 3.0  14.1 2.1  7.1 2.1        
DE 19-64 4912 35.8 7.7              396 209  
CZ 19-64 1094 31.3 7.8              383 205  
DK 18-74 1467 33.0  26-401 14.0  11-181 12.0  9-141 4.7  3.7-5.91 0.6  0.4-0.91    
EE 19-65 900 36.5 12.6  14.1 5.8  13.9 5.9  5.6 3.0     348 275  
FI 25-64 730 33.1 7.9  12.9 4.1  12.0 3.5  5.9 2.2  0.4 0.2  27.7 13.02  
FR 19-64 852 35.5 0.33  14.4               
GR 19-64 8365 45.0 5.5  12.7 2.5  21.9 4.0  6.4 2.6     283 116  
HU >18 473 38.2 5.9  11.7 2.4  12.5 2.9  8.8 2.4     463 177  
IE 18-64 662 37.0 5.2 26.8-45.1                
IT 19-64 660 35.0 6.0  10.6 2.4  12.8 3.6  4.8 2.2     378 133  
LT 19-64 849 44.9 9.1  13.5 7.0  16.9 8.0  8.9 5.4     478 265  
LV 19-64 1065 42.7 11.7                 
NL 19-64 1836 36.5 6.4  14.3 3.2  12.8 2.8  7.0 2.3     250 150  
NO 19-64 1050 31.0 6.0  12.0 3.0  11.0 2.0  6.0 2.0     344 143  
PL 19-64 1106 36.7 7.9  12.3 3.9  16.2 4.3  5.7 2.4     553 382  
PT 19-64 917 28.4 4.7  8.8 2.0  12.3 2.3  4.8 0.9     324 106  
RO 19-64 177 38.9 9.0  26.3 5.0           800 430  
SE 18-74 589 34.0 5.0 26-43 15.0 3.0 10-19 13.0 2.0 9-16 4.6 1.4 3.0-7.2    349 126 185-570 
ES 18-64 718 41.1   12.7   18.1   6.1      376   
UK  19-64 833 35.8 5.6 24-46.64 13.4 2.9 7.8-19.04 12.1 2.3 7.5-16.54    1.2 0.4 0.5-2.14 304 128 95-6064 
                     
Females                     
AT 19-64 1345 37.3 9.3  14.9 4.6  12.3 3.6  8.1 4.0     283 176  
BE 19-59 460 36.4 6.4  15.2 3.0  13.3 2.3  6.9 2.7        
CZ 19-64 1094 31.2 8.4              277 157  
DE 19-64 6016 34.8 6.7              279 2.1  
DK 18-74 1684 32.0  25-381 14.0  10-171 11.0  8-141 4.7  3.7-4.71 0.6  0.4-0.81    
EE 19-64 1115 36.3 11.3                 
FI 25-64 846 31.2 7.4  12.0 3.9  10.9 3.2  5.7 2.2  0.4 0.2  26.6 13.82  
FR 19-64 1499 36.7 0.23  14.7               
GR 19-64 1203
4 
47.2 4.7  13.2 2.6  22.9 4.1  6.9 2.9     228 92  
HU >18 706 36.8 5.4  11.0 2.3  11.4 2.5  9.2 2.3     327 125  
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Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
IE 18-64 717 37.0 6.0 26.2-46.1                
IT 19-64 801 33.0 5.8  10.1 2.5  11.6 3.2  4.5 1.7     311 102  
LT 19-64 1132 41.9 9.5  12.9 7.0  15.7 7.6  8.7 5.4     319 209  
LV 19-64 1235 41.8 11.3                 
NL 19-64 2112 36.9 6.9  14.6 3.2  13.1 3.0  6.7 2.4     201 99  
NO 19-64 1146 31.0 6.0  12.0 3.0  11.0 2.0  5.0 2.0     260 101  
PL 19-64 1334 34.7 8.3  11.7 4.1  15.0 4.5  5.6 2.6     322 244  
PT 19-64 1472 29.9 4.5  9.4 2.0  13.0 2.9  4.9 0.9     302 103  
RO 19-64 341 39.7 7.7  24.8 3.8           680 340  
SE 18-74 626 34.0 5.0 26-41 14.0 2.0 10-18 12.0 2.0 9-16 4.7 1.4 3-7.3    291 98 149-487 
ES 18-64 895 40.7   12.6   18.1   5.8      286   
UK  19-64 891 34.9 6.5 22.0-47.94 13.2 3.3 7.2-20.04 11.5 2.6 6.7-16.74    1.2 0.4 0.4-2.14 213 95 60-4274 
 
1P10-P90; 2g/MJ; 3SE; 4P2.5-P97.5;  
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ANNEX 2B INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~19-34 YEARS IN EU COUNTRIES. 
Country Age 
Yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
DE 19-24 510 34.6 0.241 22.9-48.2             424 9.841 160-863 
 25-34 690 35.8 0.261 25.1-46.7             419 7.761 176-776 
DK 18-25 146 32.0 5.0 32-39 14.0 2.7 9-19 11.0 1.9 8-14 4.5 0.8 3.3-5.8 0.6 0.2 0.2-0.9    
 25-34 272 34.0 5.1 33-41 14.0 2.7 10-20 12.0 2.0 9-15 4.7 0.8 3.6-6.1 0.6 0.2 0.3-0.9    
EE 19-34 396 37.9 12.2                 
IE 18-35 253 37.7 4.9 29.2-45.1                
LV 19-34 337 44.2 11.0                 
NL 19-30 352 34.4 6.4 23.5-44.6 12.9 3.2 7.7-18.6 11.4 2.5 7.4-15.6 6.8 2.0 4.1-10.4 0.8 0.3 0.4-1.4    
SE 17-24 67 33.0 5.0 25-44 14.0 2 10-18 12.0 2 9-17 4.7 1.8 2.7-7.8    308 97 142-475 
 25-34 128 34.0 5.0 27-43 14.0 2 10-18 13.0 2 9-16 5.0 1.7 2.9-8.7    342 118 196-570 
UK 19-24 108 36.0 6.0 21.6-46.72 13.5 3.0 7.2-19.42       1.2 0.3 0.5-1.92 269 134 74-6272 
 25-34 219 35.8 5.4 26.0-47.22 13.2 2.6 8.5-18.32       1.2 0.4 0.6-2.02 298 120 120-6042 
                     
Females                    
DE 19-24 510 33.2 0.261 22.5-44.9             263 5.431 110-507 
 25-34 972 34.4 0.301 23.6-45.1             285 4.231 124-496 
DK 18-25 213 31.0 5.0 31-39 13.0 2.6 9-17 11.0 2.0 7-14 4.4 0.8 3.2-5.9 0.6 0.2 0.3-0.9    
 25-34 315 33.0 5.1 33-41 14.0 2.8 10-19 11.0 2.0 8-14 4.8 0.8 3.5-6.1 0.6 0.2 0.3-0.9    
EE 19-34 459 37.4 11.2                 
IE 18-35 269 38.0 56.4 28.4-46.1                
LV 19-34 342 41.8 11.4                 
NL 19-30 398 34.2 7.3 21.8-46.2 13.1 3.4 7.2-18.7 11.2 3.0 6.4-16.6 6.5 2.3 3.3-11.0 0.9 0.4 0.4-1.7    
SE 17-24 70 32.0 6 22-41 13.0 3 9-18 12.0 2 9-16 4.7 1.6 2.9-7.6    244 94 91-383 
 25-34 132 34.0 5 27-42 15.0 2 11-19 13.0 2 9-16 4.8 1.6 3.1-8.2    282 88 167-448 
UK 19-24 104 35.5 7.6 24.0-51.12 12.9 4.0 7.4-25.52 12.2 2.9 7.5-17.32    1.1 0.4 0.6-2.22 196 112 41-4652 
 25-34 210 35.4 5.9 22.3-46.12 13.2 2.9 7.5-18.62 11.7 2.4 7.5-16.92    1.1 0.4 0.4-2.12 188 83 59-3972 
 
1SE; 2 P2.5-P97.5 
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ANNEX 2B  INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~35-64 YEARS IN EU COUNTRIES. 
1Cohort Heidelberg; 2Cohort Potsdam; 3SE; 4P2.5-P97.5
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol 
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                    
DE 35-641 1013 36.0 9.4  15.1 5.0  12.6 4.0        371 266  
 35-642 1032 40.3 9.5  16.5 5.2  13.7 3.7        377 255  
 35-50 2079 36.2 0.163 24.7-48.3             398 4.163 164-776 
 51-64 1633 35.9 0.183 24.2-47.4             363 4.263 153-682 
DK 35-44 330 34.0 5.2 34-42 14.0 2.7 10-18 12.0 2.0 8-15 4.9 1.0 3.5-6.5 0.7 0.2 0.3-1.0    
 45-54 312 34.0 6.3 34-44 14.0 3.1 9-19 12.0 2.5 8-16 4.8 1.0 3.4-6.3 0.7 0.2 0.3-1.1    
 55-64 242 33.0 6.0 33-42 14.0 3.1 8-19 11.0 2.3 8-15 4.7 1.0 3.4-6.3 0.7 0.2 0.2-1.0    
EE 35-49 319 35.0 13.2                 
 50+ 185 35.8 12.2                 
IE 36-50 236 37.5 5.6 26.9-45.8                
 51-64 173 35.1 5.7 24.8-44.1                
 35-49 372 42.1 12.0                 
 50+ 356 41.8 11.9                 
SE 35-44 143 35.0 5.0 26-41 15.0 2.0 10-18 13.0 2.0 9-16 4.7 1.3 3.0-7.5    353 118 189-572 
 45-54 18 34.0 6.0 25-43 15.0 3.0 10-21 13.0 2.0 9-16 4.5 1.1 3.2-6.5    351 123 192-601 
 55-64 68 35.0 6.0 25-45 15.0 3.0 10-22 13.0 2.0 9-16 4.5 1.1 3.1-6.3    354 115 178-564 
UK 35-49 253 35.9 5.6 23.2-46.04 13.5 3.0 7.2-19.14       1.2 0.5 0.4-2.34 309 130 99-6044 
 50-64 253 35.6 5.7 23.9-46.14 13.4 3.1 7.7-20.34       1.2 0.4 0.5-2.14 319 127 108-6634 
Females                    
DE 35-641 1078 36.6 9.1  15.7 5.1  12.3 3.8        285 185  
 35-642 898 37.4 9.6  15.6 5.1  12.6 3.8        264 177  
 35-50 2694 35.4 0.224 24.4-46.7             285 2.474 113-508 
 51-64 1840 34.9 0.134 24.1-47.7             272 2.934 117-498 
DK 35-44 359 33.0 5.3 33-41 14.0 2.9 9-18 11.0 2.0 8-14 4.8 0.8 3.6-6.4 0.6 0.2 0.3-0.9    
 45-54 370 31.0 5.5 31-41 13.0 2.8 9-18 11.0 2.1 7-14 4.7 0.8 3.4-6.2 0.6 0.2 0.3-0.9    
 55-64 263 32.0 5.0 32-40 13.0 2.9 9-18 11.0 2.2 7-14 4.7 1.2 3.2-6.2 0.6 0.2 0.3-0.9    
EE 35-49 376 35.6 11.4                 
 50+ 280 35.3 11.3                 
IE 36-50 286 37.0 6.1 26.0-46.2                
 51-64 162 35.2 6.6 24.2-46.3                
LV 35-49 396 42.2 11.1                 
 50+ 496 39.8 11.4                 
SE 35-44 132 35.0 5.0 25-42 14.0 2.0 11-18 13.0 2.0 9-16 4.9 1.2 3.1-6.8    285 87 151-455 
 45-54 153 34.0 5.0 26-41 14.0 2.0 10-18 12.0 2.0 9-16 4.7 1.3 3.1-7.3    307 107 148-522 
 55-64 81 33.0 4.0 26-40 14.0 2.0 10-17 12.0 2.0 9-15 4.5 1.0 3.0-6.4    307 107 148-522 
UK 35-49 318 34.7 6.3 20.8-46.14 13.2 3.1 7.1-19.74 11.3 2.6 5.7-15.94    1.2 0.4 0.5-2.14 214 92 57-4234 
 50-64 259 34.5 6.8 22.4-47.84 13.3 3.7 6.6-21.14 11.1 2.6 6.4-17.34    1.2 0,5 0.4-2.14 239 93 100-4524 
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ANNEX 2B  INTAKE OF FAT AND (CLUSTERS) OF FATTY ACIDS AND CHOLESTEROL AMONG ADULTS AGED ~65 YEARS AND OVER IN EU COUNTRIES. 
 
Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
AT 65+ 147 37.6 5.8  15.6 3.1  12.7 3.4  7.4 2.2     330 136  
BE 60-74 416 40.0 6.8  16.4 4.1  14.5 3.0  7.2 2.5        
 >75 389 40.2 7.9  16.7 4.6  14.0 2.9  7.0 2.8        
DE 65-80 1469 36.0 0.181 24.8-48.0             330 3.681 146-585 
DK 65-75 165 34.0 5.5 23-43 14.0 3.0 9-19 12.0 2.1 8-15 4.3 1.0 2.9-5.9 0.7 0.2 0.4-1.1    
FI 65-74 229 31.4 7.9  12.0 4.5  11.1 3.5  5.7 2.0  0.4 0.2  27.7 13.02  
FR 65+ 130 33.7 0.71  13.6               
GR 65+ 2508 43.9 5.4  12.1 2.6  21.0 4.2  6.7 3.1     215 96  
HU 59+ 138 37.5 5.9  11.4 2.5  12.0 2.9  8.7 2.3     418 182  
IT 65+ 60 33.2 6.5  10.0 3.0  13.1 4.0  4.8 2.5     313 97  
NL 65+ 185 37.0 7.0  15.0 4.0  12.0 3.0  7.0 2.0     231 107  
NO 65+ 176 31.0 6.0  12.0 3.0  11.0 2.0  5.0 2.0     316 132  
PL 65+ 176 36.0 9.2  12.8 4.2  15.4 4.9  5.3 2.6     433 311  
PT 65+ 246 26.7 4.6  7.8 1.9  11.9 2.3  4.6 0.9     276 95  
RO 65+ 177 41.0 9.0  25.4 4.3  15.7 4.7        810 350  
 65+ 65 34.0 6.0 25-46 15.0 3 10-22 13.0 2 9-16 4.5 0.8 2.9-5.9    383 181 179-782 
ES 65-75 122 37.5   10.8   17.5   5.5      263   
UK 65+ 540 35.7 5.6 25.1-46.83 14.6 3.5 8.5-21.83 11.1 2.2 7.2-15.73 5.8 2.2 2.6-11.53 1.5 0.5 0.7-2.53    
                     
Females                     
AT 65+ 20 37.5 5.2  16.4 3.2  12.3 2.0  6.9 2.1     324 119  
BE 60-74 406 38.1 6.2  16.1 3.6  13.8 2.3  6.5 2.5        
 >75 355 39.6 6.9  17.7 4.8  14.0 2.9  5.9 2.0        
DE 65-80 1562 35.5 0.174 25.2-46.2             252 2.794 110-450 
DK 65-75 164 32.0 5.8 23-42 14.0 3.0 9-19 11.0 2.2 7-14 4.7 1.0 3.4-6.3 0.6 0.2 0.4-1.0    
FI 65-74 234 30.1 7.3  11.4 3.9  10.4 3.2  5.6 1.9  0.4 0.2  27.0 11.72  
FR 65+ 219 34.5 0.62  13.3               
GR 65+ 3600 45.3 5.0  12.3 2.5  21.8 4.4  7.0 3.3     173 76  
HU 59+ 235 36.3 5.5  10.9 2.0  11.3 2.5  9.1 2.2     297 113  
IT 65+  107 30.5 5.9  9.4 2.6  11.8 3.0  4.4 1.9     279 122  
NL 65+ 236 37.0 7.0  15.0 4.0  12.0 3.0  7.0 3.0     195 86  
NO 65+ 166 30.0 6.0  12.0 3.0  11.0 2.0  5.0 1.0     260 91  
PL 65+ 277 34.1 7.9  12.6 4.0  14.3 4.4  4.8 2.3     317 204  
PT 65+ 339 28.0 4.8  8.4 2.1  12.3 2.4  4.8 1.0     247 85  
RO 65+ 341 39.9 8.1  24.9 4.7  15.0 3.4        690 280  
SE 65+ 57 33.0 4.0 27-41 14.0 2.0 11-19 12.0 2.0 9-15 4.6 1.4 3.4-8.1    310 120 167-648 
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Country Age 
yrs 
N Total Fat  
(E%) 
Saturated Fatty Acids 
(E%) 
Monounsaturated Fatty 
Acids (E%) 
Polyunsaturated Fatty 
Acids (E%) 
Trans Fatty Acids  
(E%) 
Cholesterol  
(mg) 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
ES 65-75 122 38.1   11.0   17.7   5.4      209   
UK 65+ 735 36.1 6.1 22.6-47.73 15.3 4.0 7.7-23.83 10.9 2.2 6.4-15.53 5.6 2.3 1.4-11.03 1.6 0.5 0.7-2.73    
 
1SE; 2g/MJ; 3P2.5-P97.5 
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ANNEX 2B INTAKE OF LINOLEIC ACID, CIS N-6 PUFA AND CIS N-3 PUFA AMONG ADULTS IN EU COUNTRIES. 
 
Country Age 
yrs 
N Linoleic acid 
g/d 
Linoleic acid 
E% 
Cis n-6 PUFA 
g/d 
Cis n-6 PUFA 
E% 
Cis n-3 PUFA 
g/d 
Cis n-3 PUFA 
E% 
   mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 mean SD P5 - P95 
Males                     
FI 25-64 730    3.9 1.6     4.5 1.9     1.2 0.6  
 65-74 2339    3.8 1.5     4.3 1.7     1.3 0.7  
DE 35-641 1013 14.3 10.4     14.5 10.5  5.3 3.0  1.88 1.28  0.69 0.45  
 35-642 1032 18.6 12.8     18.8 12.8  6.5 3.5  2.59 1.96  0.91 0.58  
NL 19-35 352 17.8 7.3 7.5-32.1 5.8 1.9 3.2-9.0    5.85 1.87 3.12-9.06    0.70 0.28 0.33-1.25 
SE 18-74 589 9.7                  
UK 19-24 102       12.6 5.4 4.9-25.43 5.3 1.4 3.3-9.33 2.10 0.75 0.89-4.243 1.0 0.3 0.5-1.63 
 25-34 198       13.1 4.6 5.4-25.83 5.4 1.3 3.3-8.03 2.30 1.10 0.99-5.223 1.0 0.4 0.5-2.33 
 35-49 253       13.1 4.9 4.8-25.63 5.4 1.5 2.9-8.53 2.31 0.92 0.86-4.463 1.0 0.4 0.5-1.93 
 50-64 253       12.6 6.1 4.5-23.9
3 5.3 1.9 2.7-9.03 2.29 0.96 0.81-4.713 1.0 0.4 0.5-2.13 
 65+ 540       10.5 5.2 3.4-23.73 5.0 2.1 2.1-10.53 1.75 1.02 0.54-4.353 0.8 0.5 0.3-1.83 
                     
Females                     
FI 25-64 846    3.9 1.7     4.4 1.9     1.2 0.5  
 65-74 234    3.7 1.5     4.2 1.7     1.3 0.6  
DE 35-641 1078 10.9 9.3     10.1 11.0  5.3 3.3  1.53 1.08  0.74 045  
 35-642 898 11.6 7.6     11.7 7.6  5.8 3.1  1.72 1.07  0.88 0.52  
NL 19-35 398 12.0 6.0 4.2-23.6    5.5 2.0 12.3-9.8 5.52 2.07 2.61-9.79    0.66 0.33 0.29-1.28 
SE 18-74 626 7.8                  
UK 19-24 104       10.1 5.0 3.7-21.83 5.6 1.7 3.6-8.33 1.69 0.75 0.73-3.413 1.0 0.4 0.6-1.73 
 25-34 210       9.4 4.0 3.4-20.53 5.6 1.8 2.9-9.93 1.60 0.63 0.67-3.143 1.0 0.3 0.5-1.93 
 35-49 318       9.5 3.9 3.3-18.03 5.3 1.6 2.8-9.03 1.68 0.76 0.59-3.443 1.0 0.4 0.4-1.83 
 50-64 259       8.8 3.5 3.1-16.13 5.0 1.5 2.5-8.13 1.82 0.88 0.66-3.593 1.1 0.6 0.5-2.33 
 65+ 735       7.7 4.0 2.1-17.43 4.8 2.2 1.9-10.13 1.33 0.71 0.42-2.983 0.8 0.4 0.4-1.83 
 
1Cohort Heidelberg; 2Cohort Potsdam; 3 P2.5-P97.5 
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ANNEX 2B DIETARY INTAKES OF ALA, EPA AND DHA BY ADULTS IN DIFFERENT COUNTRIES 
 
 ALA EPA DHA references 
 men women men women men women  
g/d        
Austria 1.5 1.3 0.08 0.07 0.2 0.2 Elmadfa et al, 2009 
France 0.9 0.7 0.15 0.12 0.27 0.23 Astorg et al., 2004 
Germany * 1.59 1.32 0.10 0.07 0.19 0.14 Linseisen et al., 2003 
Germany** 2.25 1.51 0.13 0.08 0.21 0.14  
The Netherlands 1.95 1.26 0.03 0.03 0.07 0.05 Kruizinga et al., 2007 
Sweden 1.6 1.2 0.1 0.1 0.24 0.21 Becker and Pearson, 1998 
E%        
Austria 0.5 0.6 0.03 0.03 0.07 0.09 Elmadfa et al., 2009  
France 0.35 0.38 0.06 0.06 0.11 0.12 Astorg et al., 2004 
Germany* 0.6 0.6 0.04 0.03 0.07 0.07 Lineisen et al., 2003 
Germany** 0.8 0.8 0.05 0.04 0.07 0.07  
The Netherlands 0.6 0.6 0.01 0.02 0.02 0.03 Kruizinga et al., 2007 
Sweden 0.6 0.6 0.04 0.05 0.09 0.10 Becker and Pearson, 1998 
 
* German EPIC Cohort from center H and ** center P 
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ANNEX 3 OVERVIEW OF DIETARY RECOMMENDATIONS SET BY DIFFERENT  
  ORGANISATIONS  
Recommended intakes for Nordic Countries 2004 
The Nordic countries include Norway, Finland, Sweden, Denmark, and Iceland. 
Table 6:  Recommended fat and fatty acid intakes for Nordic Countries for adults and children 
from 2 years of age (NNR, 2004) 
 Recommended 
intake 
Remarks 
Total fat 25-35 E% - Intake < 30 E% is desirable for obese people, while 
for lean people intakes of 30-35 E% are acceptable 
- Intakes below 15 E% are not desirable, because it 
may be difficult to ensure adequate intake of fat-soluble 
vitamins and EFA 
SFA plus TFA < 10 E% - Lower levels may be desirable in people with 
hypercholesterolaemia 
- Intake of TFA from hydrogenated oils as low as 
possible 
Cis-MUFA 10-15 E%  
PUFA of which 
 n-3 fatty acids 
5-10 E% 
1 E% 
- Higher levels of PUFA are not recommended 
because of potentially harmful effects of very high intakes 
- The lower level of intake is 3 E%, including 0.5 E% 
from n-3 fatty acids. For pregnant and lactating women these 
values are 5 E% and 1 E% 
n-3 / n-6 ratio 1:3-9  
Cholesterol  - No reference value 
- A reduction in SFA intake is expected to decrease 
cholesterol intake 
 
Reference values for cholesterol were not included, because it was anticipated that guidelines that 
promote an increased consumption of fruit and vegetables and a decreased consumption of SFA will 
lead to a reduction in cholesterol intake. 
For children <6 months no guidelines have been formulated, as breastfeeding is recommended and 
because the the fat composition of infant formula and follow-on formla is regulated. For children 6-23 
months, however, separate guidelines have been formulated. 
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Table 7:  Recommended fat and fatty acids intakes for Nordic Countries for children 6-11 or 12-23 
months of age (NNR, 2004) 
 Age group Recommended 
intake 
Remarks 
Total fat 6-11 months 
 
11-23 months 
30-45 E% 
 
30-35 E% 
- A gradual decrease of fat intake with 
age from 12 to 23 months is recommended 
SFA plus TFA 6-11 months 
 
11-23 months 
 
 
10 E% 
- The intake of TFA should be as low 
as possible, because TFA may interfere with 
the metabolism of PUFA 
- No reference value for 6-11 months  
PUFA of which 
 n-3 fatty acids 
6-11 months 
 
 
11-23 months 
5-10 E% 
1 E% 
 
5-10 E% 
1 E% 
- The lower level of intake is 5 E%, 
including 1 E% from n-3 fatty acids 
 
- The lower level of intake is 4.5 E%, 
including 0.5 E% from n-3 fatty acids. 
n-3 / n-6 ratio 6-11 months 
 
11-23 months 
3-9 E% - It is mentioned that the optimum ratio 
is not known for the various age groups, but 
that the ratio of 5-15 as found in infant 
formulas should gradually approach the level 
for adults 
 
The recommendations are based on findings from epidemiological and clinical trials on the 
relationships between: 
 essential fatty acid deficiency and disease. 
 dietary fatty acids and dyslipoproteinaemia and atherosclerosis. 
 fat intake and control of body weight. 
 fat intake and insulin sensitivity. 
 dietary fat composition and effects on blood pressure (especially EPA and DHA), insulin 
sensitivity, blood coagulation and cancer. 
 energy requirements to sustain the rapid growth rate during infancy. 
 
Dietary Reference Values for the United Kingdom 
The Dietary Reference Values of fat and fatty acids for the United Kingdom were derived in 1991 
(DoH, 1991). Values are provided as an average value for the population. No information for age-
groups is given. 
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Table 8:  Dietary Reference Values of fat and fatty acids for the United Kingdom as an average 
value for the population (DoH, 1991). 
 DRV Remarks 
Total fat 33 E% - 35 E% when alcohol is not included 
SFA  10 E%  
TFA <2 E% or <5 g/d  
Cis-MUFA 12 E%  
PUFA 
.Linoleic acid 
. -linolenic acid 
6 E% 
>1 E% 
>0.2 E% 
- Although it was not concluded that high dietary intakes of 
PUFA may be harmful, intakes should not exceed 10 E% 
- A mixture of n-6 and n-3 PUFA 
Cholesterol  - No reference value 
 
The recommendations are based on findings from epidemiological and clinical trials on the 
relationships between: 
 essential fatty acid deficiency and disease 
 dietary fatty acids and dyslipoproteinaemia and atherosclerosis. 
 n-3 long-chain PUFA intake and thrombus formation 
There was insufficient evidence: 
 for a relationship between a high intake of PUFAs with any human disease. 
 for a relationship between a high intake of isomeric fatty acids with potential long term adverse 
effects on health. 
 for the recommendation to decrease fat intake to prevent cancer. It was stressed, however, that an 
increase in the consumption of any fatty acid was not encouraged. 
 to establish or to exclude a special role for dietary fat in the development of obesity 
 for a direct effect of dietary fat on the development of either type 1 or type 2 diabetes mellitus. 
The UK committee however supported recommendations that in diabetes fat intake should not 
exceed > 30-35 E% with not more than one third of energy from SFA. 
 
Recommended intakes for France 
The Dietary Reference Values of fat and fatty acids for France were derived in 2001 (AFSSA, 2001). 
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Table 9:  Recommended intakes of fat and fatty acids for France for adult men and women 
(AFSSA, 2001). 
 Recommended 
intake 
Remarks 
Total fat 30-35 E%  
SFA  8 E%  
TFA  - An upper consumption level for TFA is recommended for 
the future 
Cis-MUFA 20 E%  
PUFA of which 
.linoleic acid 
. -linolenic acid 
.LCPUFA 
.DHA 
 
4 E% 
0.8 E% 
0.20 E% 
0.05 E% 
 
n-3 / n-6 ratio 1:5 - Refers to -linolenic acid to linoleic acid ratio 
Cholesterol  - Recommendation only justified for hypercholesterolaemic 
people 
 
For pregnant and lactating women, separate guidelines have been formulated. 
Table 10:  Recommended intakes of fat and fatty acids for France for pregnant and lactating women 
(AFSSA, 2001).  
 Women 
.Pregnant  
.Lactating 
Recommended 
intake 
Remarks 
Total fat Both groups 30-35 E% 
 
 
SFA Both groups 8 E%  
TFA Both groups  - An upper consumption level for TFA 
is recommended for the future 
Cis-MUFA Both groups 20 E%  
PUFA of which 
.linoleic acid 
. -linolenic acid 
.LCPUFA 
.DHA 
Both groups  
4.4 E% 
0.9 E% 
0.4 E% 
0.1 E% 
 
 
The recommendations are based on findings from epidemiological and clinical trials on the 
relationships between: 
 essential fatty acid deficiency and disease. 
 dietary fatty acids and dyslipoproteinaemia and atherosclerosis. 
Further, 
 n-6 PUFAs producing ARA may promote tumor growth. 
 n-3 LCPUFAs may inhibit tumor growth. 
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 an -linolenic acid to linoleic acid ratio of 1:5 seems to prevent cancer development 
 
Dietary reference intakes of fat and fatty acids for the Netherlands 
The Dietary Reference Values of fat and fatty acids for the Netherlands were derived in 2001 (GR, 
2001).  
Table 11:  Dietary reference intakes of fat and fatty acids for the Netherlands (GR, 2001). 
 DRV Remarks 
Total fat 20-40 E% - Fat per se does not affect body weight, but may increase energy 
intake. For persons with undesirable weight gain, 30-35E% 
SAFA  < 10 E%  
TFA As low as possible  
Cis-MUFA   
PUFA of which 
.linoleic acid 
. -linolenic acid 
.EPA + DHA* 
<12 E% 
2.0 E% 
1.0 E% 
450 mg 
 
Cholesterol  - No reference value for cholesterol 
* Guidelines for a healthy diet 2006. 
 
For children and for pregnant and lactating women separate dietary reference intakes have been 
formulated. 
Table 12:  Dietary Reference Values of fat and fatty acids for the Netherlands for adolescents < 19 
years of age and for pregnant and lactating women (GR, 2001). 
 Age group DRV Remarks 
Total fat 0-6 months 
6-11 months 
1-3 years 
1-4 years 
4-7 years 
7-10 years 
10-13 years 
13-15 years 
 
 Women 
.Pregnant  
.Lactating 
45-50 E% 
35-40 E% 
30-35 E% 
30-35 E% 
30-35 E% 
30-35 E% 
30-35 E% 
30-35 E% 
 
 
30-35 E% 
30-35 E% 
- For children > 2 years, a gradual 
decrease in fat intake is recommended 
SFA All groups 
 
One third of fat 
energy 
- No reference values for pregnant and 
lactating women were given 
 
Dietary reference values for fats 
 
 
102 EFSA Journal 2010; 8(3):1461 
The recommendations are based on findings from epidemiological and clinical trials on the 
relationships between: 
 essential fatty acid deficiency and disease. 
 dietary fatty acids and dyslipoproteinaemia and atherosclerosis. 
 total fat intake and the risk to develop type 2 diabetes mellitus. 
There was insufficient evidence / data: 
 for a relationship between a high intake of saturated fatty acids, trans fatty acids, oleic acid, or 
linoleic acid and development of cancer. 
 for a relationship between a high intake of -linolenic acid and the development of prostate 
cancer. 
 for a relationship between a high intake of fish-oil fatty acids and the development of breast 
cancer and colorectal cancer. 
 to draw conclusions on the relationships between fatty acids and the risk to develop type 2 
diabetes mellitus. 
 to draw conclusions on the relationships between fatty acids and effects on the immune system. 
 to conclude that total fat intake itself causes obesity under isocaloric condition. It may, however, 
promote energy dysbalance 
 to draw conclusions on the relations between total fat intake and cancer 
 
Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland 
Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland were derived 
in 2000 and revised in 2008 (D-A-CH, 2008).  
Table 13:  Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland for 
adolescents and adults from 15 years of age D-A-CH (2008). 
 DRV Remarks 
Total fat 30 E% - Very heavy manual labourers may need more 
- 25 E% may be more favourable, because intake of plant 
foods will be higher 
SFA  < 10 E% - Limited to long-chain SFA 
TFA < 1 E%  
Cis-MUFA  - No reference value 
PUFA  
of which LA 
ALA 
 
< 7 E% 
2.5 E% 
0.5 E% 
- Up to 10 E% if SFA provide more than 10 E% 
 
n-3 / n-6 ratio 1:5 - Refers to -linolenic acid to linoleic acid ratio 
Cholesterol <300 mg per day - A reduction in SFA intake is expected to decrease 
cholesterol intake 
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For children <15 years and for pregnant and lactating women separate guidelines have been 
formulated. 
Table 14:  Dietary Reference Values of fat and fatty acids for Germany, Austria, and Switzerland for 
adolescents < 15 years of age and for pregnant and lactating women D-A-CH (2008). 
 Age group DRV Remarks 
Total fat 0-4 months 
1-4 years 
4-7 years 
7-10 years 
10-13 years 
13-15 years 
 
Women 
.Pregnant  
.Lactating 
45-50 E% 
35-40 E% 
30-35 E% 
30-35 E% 
30-35 E% 
30-35 E% 
 
 
30-35 E% 
30-35 E% 
- For children > 2 years, a gradual 
decrease in fat intake is recommended 
SFA All groups 
 
One third of 
energy 
fat 
 
The general recommendation to decrease total fat intake - and especially of fat rich in saturated fatty 
acids - was based on findings from epidemiological and clinical trials showing that a close 
relationship existed between high-fat diets and dyslipoproteinaemia, atherosclerosis, colon cancer, 
and body weight. 
 
Population nutrient intake goals from the WHO/FAO 
The population nutient intake goals to prevent diet-related chronic diseases as formulated by the 
WHO/FAO (2003) are based on relationships between intakes of total fat, fatty acids and cholesterol 
and the chronic diseases obesity, type 2 diabetes and cardiovascular disease.  
Table 15:  Population nutrient intake goals as formulated by the WHO/FAO (WHO, 2003). 
 Population nutrient 
intake goal 
Remarks 
Total fat 15-30 E% - Up to 35 E% is acceptable for highly active groups 
- For women of the reproducte age at least 20 E% may be 
recommended 
SFA  < 10 E%  
TFA < 1 E%  
Cis-MUFA By difference  
PUFA of which 
.n-6 PUFA 
.n-3 PUFA 
6-10 E% 
5-8 E% 
1-2 E% 
 
 
Cholesterol <300 mg per day  
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Acceptable macronutrient distribution ranges of fat, fatty acids and cholesterol for the United 
States and Canada  
For the US and Canada, Acceptable Macronutrient Distribution Ranges (AMDR) for fat and various 
fatty acids have been formulated (IoM, 2005). For adults the AMDR of total fat is 20 to 35E%, for 
children 1 to 3 years of age 30 to 40 E%, and for children 4 to 18 years of age 25 to 35 E%. The 
ADMR for n-6 polyunsaturated fatty acids (linoleic acid) is 5 to 10 E% and for n-3 polyunsaturated 
fatty acids (α-linolenic acid) 0.6 to 1.2 E%, of which 10% of total n-6 respectively n-3 
polyunsaturated fatty acids can come from their respective LCPUFA. 
No Adequate Intakes (AI), Estimated Average Requirements (EAR), and / or Recommended Daily 
Allowances (RDA) were formulated for SFA, TFA, cis-MUFA and cholesterol, because these 
(macro)nutrients are not essential and have no proven beneficial or independent role in the prevention 
of chronic diseases. 
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ANNEX 4  ESTIMATED CHANGES IN BLOOD LIPIDS AND LIPOPROTEINS FOR A GROUP OF SUBJECTS WHEN ONE PERCENT OF ENERGY IN THE DIET 
FROM CARBOHYDRATES IS REPLACED ISOCALORICALLY BY A PARTICULAR FATTY ACID OR WHEN DAILY CHOLESTEROL INTAKE IS INCREASED BY 
100 MG 
 
Fatty acid  
Total cholesterol 
(mmol/L) 
LDL cholesterol 
(mmol/L) 
HDL cholesterol 
(mmol/L) 
Total to HDL 
cholesterol ratio 
Triacylglycerol 
(mmol/L) 
Mixture of SFA Change 
95% CI 
+0.036 
0.029 to 0.043 
+0.032 
0.025 to 0.039 
+0.010 
0.007 to 0.013 
0.003 
-0.008 to 0.013 
-0.021 
-0.027 to -0.015 
.Lauric acid Change 
95% CI 
+0.069 
0.040 to 0.097 
+0.052 
0.026 to 0.078 
+0.027 
0.021 to 0.033 
-0.037 
-0.057 to -0.017 
-0.019 
-0.028 to -0.011 
.Myristic acid Change 
95% CI 
+0.059 
0.036 to 0.082 
+0.048 
0.027 to 0.069 
+0.018 
0.013 to 0.023 
-0.003 
-0.026 to 0.021 
-0.017 
-0.027 to -0.006 
.Palmitic acid Change 
95% CI 
+0.041 
0.028 to 0.054 
+0.039 
0.027 to 0.051 
+0.010 
0.007 to 0.013 
+0.005 
-0.008 to 0.019 
-0.017 
-0.023 to -0.011 
.Stearic acid Change 
95% CI 
-0.010 
-0.026 to 0.006 
-0.004 
-0.019 to 0.011 
+0.002 
-0.001 to 0.006 
-0.013 
-0.030 to 0.003 
-0.017 
-0.024 to -0.010 
Cis-MUFA 
(Oleic acid) 
Change 
95% CI 
-0.006 
-0.012 to 0.000 
-0.009 
-0.014 to -0.003 
+0.008 
0.005 to 0.011 
-0.026 
-0.035 to -0.017 
-0.019 
-0.024 to -0.014 
Cis-PUFA 
(Linoleic acid) 
Change 
95% CI 
-0.021 
-0.027 to -0.015 
-0.019 
-0.025 to -0.013 
+0.006 
0.003 to 0.009 
-0.032 
-0.042 to -0.022 
-0.026 
-0.031 to -0.020 
Trans-MUFA from 
hydrogenated sources 
Change 
95% CI 
+0.034 
0.022 to 0.045 
+0.041 
0.025 to 0.058 
-0.001 
-0.007 to 0.005 
+0.025 
0.010 to 0.040 
0.000 
-0.010 to 0.009 
Cholesterol Change 
95% CI 
+0.056 
0.046 to 0.065 
+0.050 
0.042 to 0.058 
0.008 
0.005 to 0.010 
0.020 
0.010 to 0.030 
 
Data are derived from (Mensink et al., 2003; Mozaffarian et al., 2006; Weggemans et al., 2001) 
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GLOSSARY / ABBREVIATIONS 
AI Adequate Intake 
ALA Alpha linolenic acid 
AMDR Acceptable Macronutrient Distribution Ranges 
AR Average Requirement 
ARA Arachidonic acid 
CHD Coronary heart disease 
CLA Conjugated linoleic acid 
DHA Docosahexaenoic acid 
DHGLA Dihomo-gamma-linolenic acid 
DRV Dietary Reference Value 
EAR Estimated Average Requirement 
EFA Essential fatty acid 
EFSA European Food Safety Authority 
EPA Eicosapentaenoic acid 
EPIC European Prospective Investigation into Cancer 
and Nutrition 
FFQ Food frequency questionnaire 
HOMA Homeostasis Model Assessment 
hs-CRP High-sensitivity C-reactive protein 
KANWU study A multicenter trial performed in Kuopio, Aarhus, 
Naples, Wollongong, and Upsala on the effects of 
substituting a SFA-rich
 
diet with a MUFA-rich 
diet on insulin sensitivity 
LA Linoleic acid 
LTI Lower Threshold Intake 
MUFA Monounsaturated fatty acids 
n-3 PUFA n-3 polyunsaturated fatty acids 
n-6 PUFA n-6 polyunsaturated fatty acids 
OGTT Oral glucose tolerance test 
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PRI Population Reference Intakes 
PUFA Polyunsaturated fatty acids 
RDA Recommended Daily Allowance 
RI Reference Intake ranges for macronutrients 
SFA Saturated fatty acids 
STRIP Special Turku Coronary Risk Factor Intervention 
Project 
TFA Trans fatty acids 
TG Triglycerides 
US United States 
VEP Visual evoked potential 
 
 
 
